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ABSTRACT 
 One of the greatest sources of biologically active compounds is natural products. Often 
these compounds serve as platforms for the design and development of novel drugs and 
therapeutics. The overwhelming amount of genomic information acquired in recent years has 
revealed that ribosomally synthesized and post-translationally modified natural products are 
much more widespread than originally anticipated. Identified in nearly all forms of life, these 
natural products display incredible structural diversity and possess a wide range of biological 
functions that include antimicrobial, antiviral, anti-inflammatory, antitumor, and antiallodynic 
activities. The unique pathways taken to biosynthesize these compounds offer exciting 
opportunities for the bioengineering of these complex molecules. 
 The studies described herein focus on both the mode of action and biosynthesis of 
antimicrobial peptides. In Chapter 2, it is demonstrated that haloduracin, a recently discovered 
two-peptide lantibiotic, possesses nanomolar antimicrobial activity against a panel of bacteria 
strains. The potency of haloduracin rivals that of nisin, an economically and therapeutically 
relevant lantibiotic, which can be attributed to a similar dual mode of action. Moreover, it was 
demonstrated that this lantibiotic of alkaliphile origin has better stability at physiological pH than 
nisin. The molecular target of haloduracin was identified as the cell wall peptidoglycan precursor 
lipid II. Through the in vitro biosynthesis of haloduracin, several analogues of Halα were 
prepared and evaluated for their ability to inhibit peptidoglycan biosynthesis as well as bacterial 
cell growth. 
 In an effort to overcome the limitations of in vitro biosynthesis strategies, a novel 
strategy was developed resulting in a constitutively active lantibiotic synthetase enzyme. This 
methodology, described in Chapter 3, enabled the production of fully-modified lacticin 481 
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products with proteinogenic and non-proteinogenic amino acid substitutions. A number of 
lacticin 481 analogues were prepared and their antimicrobial activity and ability to bind lipid II 
was assessed. Moreover, site-directed mutagenesis of the constitutively active synthetase resulted 
in a kinase-like enzyme with the ability to phosphorylate a number of peptide substrates. 
 The hunt for a lantibiotic synthetase enzyme responsible for installing the presumed 
dehydro amino acids and a thioether ring in the natural product sublancin, led to the 
identification and characterization of a unique post-translational modification. The studies 
described in Chapter 4, demonstrate that sublancin is not a lantibiotic, but rather an unusual S-
linked glycopeptide. Its structure was revised based on extensive chemical, biochemical, and 
spectroscopic characterization. In addition to structural investigation, bioinformatic analysis of 
the sublancin gene cluster led to the identification of an S-glycosyltransferase predicted to be 
responsible for the post-translational modification of the sublancin precursor peptide. The 
unprecedented glycosyltransferase was reconstituted in vitro and demonstrated remarkable 
substrate promiscuity for both the NDP-sugar co-substrate as well as the precursor peptide itself. 
An in vitro method was developed for the production of sublancin and analogues which were 
subsequently evaluated in bioactivity assays. Finally, a number of putative biosynthetic gene 
clusters were identified that appear to harbor the necessary genes for production of an S-
glycopeptide. An additional S-glycosyltransferase with more favorable intrinsic properties 
including better expression, stability, and solubility was reconstituted in vitro and demonstrated 
robust catalytic abilities. 
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CHAPTER 1: BIOSYNTHESIS AND MODE OF ACTION OF RIBOSOMALLY 
SYNTHESIZED AND POST-TRANSLATIONALLY MODIFIED NATURAL 
PRODUCTS1 
 
1.1. INTRODUCTION 
 The avalanche of genomic information acquired in the past decade has revealed that 
natural product biosynthesis using the ribosomal machinery is much more widespread than 
originally anticipated.1 Sequencing results have provided unparalleled new insights into the 
genetic capacity of organisms to generate secondary metabolites,2 including a rapid rise in the 
discovery of natural products that are ribosomally synthesized and extensively post-
translationally modified into mature, bioactive forms.3-14 These tailoring processes release the 
peptides from the structural and functional constraints imposed on natural ribosomal peptides, 
while at the same time restricting conformational flexibility to allow better target recognition and 
increase metabolic and chemical stability. The extent of modification is widely distributed across 
these natural products, ranging from the modification of just a single amino acid15 to the dense 
modification in which all but one amino acid is modified.11 
 There are a number of advantages for bioengineering molecules produced through these 
pathways. First, the enzymes involved in the post-translational modification process are often 
multi-functional and a single enzyme can execute a number of catalytic events. As a result, the 
biosynthetic pathways are relatively short. In addition, there is a direct link between gene 
sequence and the natural product, therefore non-silent, single nucleotide mutations are directly  
 
____________________________________________________ 
1 Reproduced in part with permission from: “Follow the leader: the use of leader peptides to guide natural product 
biosynthesis.” Nat. Chem. Biol. 2010, 6, 9-18. Copyright 2010 Nature Publishing Group. 
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translated to a mutated product. Furthermore, many of the biosynthetic enzymes have 
demonstrated remarkable substrate promiscuity, thus enabling the production of analogues for 
structure-activity relationship and additional studies. 
The number of ribosomally synthesized and post-translationally modified natural 
products has grown significantly in recent years with the discovery of the biosynthetic origin for 
many families including lantipeptides/lantibiotics, cytolysins, thiopeptides, amatoxins, 
cyanobactins, cyclotides, microviridins, and other bacteriocins.1,16 These natural products 
possess a wide variety of biological activities including antimicrobial, antiviral, anti-
inflammatory, antitumor, and antiallodynic activities.1,17-19 Many recent strategies have been 
explored in efforts to improve the production and pharmacological properties of bioactive 
peptides. These strategies, in combination with alternative routes of administration, have yielded 
a growing number of peptide-based drugs and drug candidates.20 Indeed, there are currently more 
than 60 therapeutic peptides used commercially and more than 150 in clinical trials.16,20,21 
In spite of the multitude of producing organisms and the diversity of biological activities, 
the key unifying theme shared among the ribosomally synthesized natural products is the general 
pathway by which they are biosynthesized (Figure 1.1). For the vast majority of natural products 
of ribosomal origin, the initial precursor peptide is much larger than the final product. These 
precursors typically contain N-terminal leader peptides, and in some cases, C-terminal 
extensions that are removed in the last step of the maturation process following post-translational 
modification. Interestingly, a recent comprehensive analysis of the structural motifs generated 
using these pathways concluded that the types of structures accessible through the ribosomal 
route are strikingly similar to those produced via nonribosomal biosynthesis (Figure 1.2).22,23 
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Figure 1.1. General biosynthetic scheme for ribosomally synthesized and post-translationally modified peptide 
natural products. Natural products prepared through this pathway have been identified in every domain of life and 
those identified display a remarkably wide range of biological activities. 
 
The continuing appearance of multi-drug resistant bacteria poses a significant threat to 
human health and presents an urgent need for the development of new antimicrobial drugs. 
Lantibiotics are a diverse and promising class of ribosomally synthesized and post-translationally 
modified antimicrobial peptides produced by a variety of Gram-positive bacteria and display a 
broad spectrum of activity.24,25 A multitude of members have been identified to date, with several 
displaying potent antimicrobial activity at nanomolar levels against nosocomial pathogens such 
as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci 
(VRE), and oxacillin-resistant Gram-positives.17,25 Importantly, development of significant levels 
of resistance has not been observed for nisin, the best-studied lantibiotic that has been used 
world-wide against food-borne pathogens for more than five decades.26 
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Figure 1.2. Examples of ribosomally synthesized and post-translationally modified peptide natural products 
highlighting the structural diversity observed in these molecules. 
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1.2. OVERVIEW OF LANTIBIOTICS 
 Lantibiotics are small (19-38 amino acids), low molecular weight (<5 kDa) cyclic 
peptides characterized by extensive post-translational modifications.17,23 The post-translational 
modifications common to all lantibiotics include 2,3-didehydroalanine (Dha) and (Z)-2,3-
didehydrobutyrine (Dhb) as well as the cyclized thioether amino acids meso-lanthionine (Lan) 
and (2S,3R,6R)-3-methyllanthionine (MeLan) (Figure 1.3). Any ribosomally synthesized peptide 
with lanthionine and/or methyllanthionine thioether cross-links can be classified as a 
lantipeptide; however, peptides with confirmed antimicrobial actively are further defined as a 
lantibiotic. The post-translational modifications are essential for the biological activities of the 
molecules. The thioether structures place conformational constraints on the otherwise flexible 
peptide backbones of these molecules, locking and aligning key interaction residues into optimal 
orientations to ensure high affinity binding with their specific biological targets. The unsaturated 
amino acids Dha and Dhb arise from the enzymatic dehydration of serine and threonine residues, 
respectively. Following dehydration, an enzyme-catalyzed, intramolecular Michael-type addition 
of cysteine thiols onto the unsaturated amino acids generates Lan and MeLan thioether rings 
(Figure 1.3).24 The meso stereochemistry resulting from thioether formation has been determined 
for a small subset of lantibiotics including nisin,27 subtilin,28 epidermin,29 Pep5,30,31 mersacidin,32 
and lactocin S.33 In addition, meso stereochemistry has been observed in prochlorosins, a family 
of lantipeptides (lanthionine-containing peptides) with currently unknown biological function.34 
For all other lantibiotics, meso stereochemistry is assumed. 
 In addition to the characteristic lantibiotic motifs, there are numerous, additional post-
translational modifications that introduce key functional groups that demonstrate importance in 
overall enhancement of metabolic stability and stronger molecular interactions with the 
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biological target. These post-translational modifications have enabled bacteria to explore greatly 
expanded chemical space beyond the side-chains of the 20 proteinogenic acids. They include 
lysinoalanine, β-hydroxy-aspartate, D-alanine, 5-chloro-tryptophan, S-aminovinyl-D-cysteine, 
3,4-dihydroxyproline, allo-isoleucine, and N-terminal modifications including 2-oxobutyryl, 2-
oxoproprionyl, and 2-hydroxypropionyl functionalities (Figure 1.3).17 Recently, additional 
unique modifications have been discovered that include labionin and N-acetylation.35 Currently 
there no fewer than 18 unique modifications identified in lantibiotics, although it is likely that 
additional post-translational modifications will be revealed as new lantibiotics are discovered.  
 Approximately 60 members of the lantibiotic family have been reported to date, although 
the number continues to expand as novel lantibiotics are discovered through genome mining 
efforts.16,24 There is remarkable diversity in the size, structure, extent of modification, and mode 
of action among the lantibiotics. A representative subset of family members highlighting the 
diversity of structural topologies and modifications is shown in Figure 1.4. The least modified 
lantibiotic is lactocin S with 24% modification,36 whereas microbisporicin is the most 
extensively modified (58%) and includes unusual modifications such as 5-chloro-tryptophan and 
both mono- and dihydroxylated proline.37 Several classification schemes have been proposed 
over recent decades to differentiate classes of lantibiotics. The first classification scheme was 
based on ring topology and biological activity.38 However, as lantibiotics with varied and novel 
structures and unique biological functions have been revealed, a new classification scheme has 
been adopted based on the biosynthetic pathway by which maturation of the peptide occurs and 
the presence or absence of biological activity (discussed in detail in section 1.4.1).17 
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Figure 1.3. Post-translational modifications found in lantibiotics. (a) A subset of post-translational modifications 
found in lantibiotics is shown. A shorthand notation commonly used for these modifications is shown in color below 
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the chemical structure. (b) The strategies by which lantibiotic synthetases introduce unsaturated amino acids and 
lanthionine rings in precursor peptides. Following the ribosomal synthesis of the LanA precursor peptide, LanB, 
LanM, RamC/LabKC, or LanL enzymes catalyze dehydration of Ser/Thr to afford Dha/Dhb. This modification 
proceeds through a two-step process, phosphorylation of Ser/Thr and subsequent β-elimination of the phosphate to 
generate Dha/Dhb for class II, III, and IV lantipeptides. LanC, LanM, or LanL enzymes then catalyze intramolecular 
Michael type addition of Cys thiols onto the unsaturated amino acids in a stereo- and regioselective manner to 
produce Lan and MeLan rings. It is currently not known how the RamC/LabKC proteins catalyze cyclization. 
Adapted from Ref. 39. 
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Figure 1.4. Structural diversity of lantibiotics represented by a subset of structures from classes I, II, and III. There 
are currently no class IV structures with full structural characterization. The same shorthand notation and color 
coding is used as in Figure 1.3.  
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1.3. LANTIBIOTIC MODES OF ACTION 
 The vast majority of known lanthionine-containing peptides demonstrate bacteriocidal 
activity17; however, lantipeptides can also act as signaling molecules40 or morphogenetic 
peptides.41 In addition, some lantibiotics are potent enzyme inhibitors.42 Much of the recent 
interest in lantibiotics stems from several members displaying nanomolar activity against a wide 
variety of pathogenic strains.43-45 Historically, it had been assumed that lantibiotics exert their 
antimicrobial activity through non-specific pore formation mediated by the interaction of the 
cationic peptide with the negatively charged phospholipids in the bacterial membrane—a mode 
of action shared among many antimicrobial peptides from a broad range of organisms.46 
However, much compelling evidence has accumulated over the past decade demonstrating that a 
subset of lantibiotics do in fact target a precise biomolecule. The first of many studies on the 
mode of action of nisin addressed the discrepancy in bactericidal activity between the lantibiotic 
and other pore-forming peptides such as magainin, ultimately leading to the identification of 
lipid II as the lantibiotic’s specific target.43 
 Lipid II is the monomeric precursor of cell wall peptidoglycan and consists of an 
undecaprenyl chain, a pyrophosphate group, a disaccharide moiety (MurNAc and GlcNAc), and 
a pentapeptide chain (Figure 1.5). Bacterial resistance to compounds that bind to lipid II has been 
slow to develop, possibly because in comparison to other resistance mechanisms such as efflux 
pumps and enzyme mutations, it is more challenging to change the structure of an advanced 
intermediate that is biosynthesized in 10 steps.47,48 Peptidoglycan synthesis involves both a 
cytoplasmic and an extracellular phase.49,50 The construction of the cell-wall subunit begins on 
the cytoplasmic side of the plasma membrane of the cell, where UDP-MurNAc- 
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Figure 1.5. Biosynthesis of cell wall peptidoglycan. Lipid II is polymerized into immature chains of peptidoglycan 
catalyzed by transglycosylase activity. Transpeptidases catalyze the cross-linking of nearby chains of peptidoglycan 
thus generating the mesh-like network of disaccharide-pentapeptide units. 
 
pentapeptide is assembled from basic building blocks via a multi-step process involving several 
enzymes. The pre-assembled UDP-MurNAc-pentapeptide, often referred to as the Park 
nucleotide, is then coupled to bactoprenyl-phosphate to yield lipid I. Next, a GlcNAc sugar is 
coupled by the peripherally membrane-associated protein, MurG, resulting in the final lipid II 
product. Finally, lipid II is then translocated to the periplasmic (Gram-negative) or exterior side 
of the plasma membrane (Gram-positive) via an unknown mechanism where it can serve as a 
substrate for peptidoglycan biosynthetic machinery.51 
 Peptidoglycan glycosyltransferases (PGTs) catalyze the processive polymerization of the 
C55 lipid-linked disaccharide to form peptidoglycan, a polymer of carbohydrate chains connected 
by peptide crosslinks that constitutes the main component of the bacterial cell wall. Layers of 
cell wall peptidoglycan act as an exoskeleton, forming the first line of defense against 
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environmental stresses and enabling the bacteria to withstand high internal osmotic pressures. 
Although the cell walls of different bacterial strains contain several structural differences, the 
composition of the peptidoglycan polymer is remarkably similar and the pathway to 
peptidoglycan biosynthesis is highly conserved. The cell wall in Gram-positive bacteria is 
approximately 20 layers thick, with each layer containing numerous peptidoglycan subunits. By 
contrast, a relatively small amount of bactoprenyl-phosphate molecules are present at around 
200,000 molecules per cell,52,53 so the amount of lipid II synthesized and available for 
incorporation is limited. As a result, it is a requirement that the lipid II cycle is an extremely 
dynamic and efficient process, with each lipid II molecule in the cell having a high turnover 
rate.54 The recycling process of lipid phosphate carrier molecule must be tightly controlled and 
efficient, and is thus regarded as the crux of bacterial cell-wall synthesis. Because an intact cell 
wall is absolutely essential for bacterial cell survival, peptidoglycan biosynthesis is a key target 
of many important classes of antibiotics, including penicillins, carbapenems, cephalosporins, the 
glycopeptides vancomycin55 and ramoplanin,56-59 host defense peptides,46,47 and an increasing 
number of lantibiotics described in further detail below. 
 Nisin is the oldest known and most extensively studied lantibiotic.60,61 This very potent 
and economically important class I lantibiotic exerts its antimicrobial activity through a dual 
mode of action, which involves binding and sequestering lipid II and pore formation in bacterial 
cell membranes.17 Binding studies have elucidated the precise interactions of nisin with lipid II.43 
A solution NMR structure of nisin bound to a truncated lipid II variant with only three isoprene 
units demonstrated that the N-terminal A and B rings of nisin form a cage surrounding the 
pyrophosphate linker region of lipid II.62 The remarkably high affinity interaction of nisin and 
lipid II (approximately 2 x 107 M-1)43 effectively sequesters the precursor and prevents 
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polymerization and integration of peptidoglycan units into the bacterial cell wall.63 In addition, 
this halting of peptidoglycan biosynthesis is particularly valuable for inhibitory activity by 
minimizing the availability of free bactoprenyl-phosphate molecules that must be recycled for 
further iterative processes in cell wall biogenesis. 
 In addition to lipid II binding, nisin is also capable of pore formation in the membranes of 
targeted bacteria. Nisin has been shown to permeabilize membranes by two distinct mechanisms. 
The first mechanism involves non-specific, electrostatic interactions of nisin with the anionic 
lipids in the membrane leading to the accumulation and aggregation of nisin monomers, 
ultimately resulting in the transient formation of pore-like structures. The affinity of nisin for 
membranes containing anionic lipids is much lower (about 1,800 M-1)64 compared to that for 
lipid II and as a result, this non-specific mechanism requires micromolar concentrations of the 
antimicrobial.  
 The second mechanism involves the specific docking of nisin to lipid II, which facilitates 
pore formation in the membranes of targeted bacteria. Mutational studies of nisin have shown 
that the hinge region between the C and D rings provides the required conformational flexibility 
that allows for the C-terminus to insert in the bacterial membrane.65 The C-terminus adopts a 
perpendicular transmembrane orientation relative to the lipid bilayer, producing pores of 
approximately 2 nm in diameter.66,67 Several studies have shown that pores formed by nisin in 
the presence of lipid II are much more stable than those formed in its absence.66-68 The 
stoichiometry of this pore complex has also been investigated, and it was demonstrated that each 
pore consists of 8 nisin molecules and 4 lipid II molecules.69  
 The first two rings of several other class I lantibiotics display high homology with those 
of nisin, suggesting that these peptides interact with lipid II as well. It has been experimentally 
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determined that epidermin,70,71 gallidermin,71 and mutacin 114072 also specifically target lipid II. 
However, epidermin and gallidermin lack the C-terminal tail and are shorter (~30 Å) compared 
with nisin (50 Å), and these differences in peptide lengths may explain why epidermin and 
gallidermin are not able to form pores in bacteria that are susceptible to pore formation by 
nisin.71 More recently, an additional class I lantibiotic, clausin, has been reported to bind lipid II 
in a manner similar to that of nisin.73 An additional activity for several lantibiotics including 
nisin, is the ability to prevent spore outgrowth of Gram-positive bacteria.74,75 A recent study 
suggested that inhibition of outgrowth is directly related to the ability of the lantibiotic to induce 
damage to the membrane of germinating spores thereby preventing the establishment of 
oxidative metabolism and a membrane potential.76 
 Several single component, class II lantibiotics including mersacidin,77 actagardine,70 
plantaricin C,78 and lacticin 481 also trigger bacterial cell death through interactions with lipid 
II.79 However, unlike nisin and other class I lantibiotics, these do not display the ability to form 
pores in bacterial cell membranes. Rather, they exert their antimicrobial activity by disrupting 
peptidoglycan biosynthesis through inhibition of transglycosylation.70,79 Studies on the 
interactions between lipid II and mersacidin revealed that the lipid binding site includes the 
terminal GlcNAc sugar moiety and that mersacidin does not bind to lipid I, suggesting a different 
binding mode compared with nisin and lipid II.77 It has been experimentally determined that this 
alternative binding mechanism results in an overall lower binding affinity between mersacidin 
and lipid II as compared to nisin’s affinity for this target molecule.80 Mersacidin, as well as many 
other class II lantibiotics, has an overall globular structure. NMR studies have also shown that 
mersacidin has considerable conformational flexibility and the small hinge region located 
between the two lanthionine rings at residues 12 and 13 enable this peptide to effectively bind 
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lipid II.80 Comparison of mersacidin with similar lantibiotics reveals a highly conserved thioether 
bridge pattern comprised of residues 12–18, which suggests that these residues form the core site 
for lipid II binding. Moreover, the majority of spectroscopic changes were observed in this 
conserved region upon binding of the antibiotic with lipid II, thus providing additional support of 
the importance of this motif in lipid II binding. Mutagenesis studies have demonstrated that 
Dha16 and Glu17 of this ring are required for antimicrobial activity.81 
 There are an increasing number of class II lantibiotics that consists of two-peptide 
systems. Each peptide of a two-peptide lantibiotic system contributes a unique role in the 
mechanism of antimicrobial activity. Whereas each of the component peptides displays either 
weak or no antimicrobial activity, the synergistic interaction of the two peptides often results in 
nanomolar activity against a wide range of Gram-positive bacteria. A small subset of two-peptide 
lantibiotics has been demonstrated to have the ability to specifically target lipid II and form pores 
in the membrane of target cells. These systems are remarkable because they seem to have split 
the lipid II-targeting and pore forming activities of nisin across two different peptides. A nisin-
like model for lacticin 3147 and staphylococcin C55 has been proposed,82,83 in which one peptide 
component (termed the α-peptide) binds to the peptidoglycan precursor to form a α-peptide:lipid 
II complex. This binding and sequestering of lipid II is often sufficient to provide modest 
antimicrobial activity through the inhibition of cell wall biosynthesis, much like the mode of 
action observed for the single component lantibiotic mersacidin. This α-peptide:lipid II complex 
serves as the docking site to allow for the recruitment of the second peptide (termed the β-
peptide) resulting in pore formation. For nearly all reported two-peptide lantibiotics, optimal 
activity is achieved when the two peptides are present in a 1:1 stoichiometry. In the case of 
lacticin 3147, it has been proposed that the peptide-lipid II complex consists of 1:1:1 
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stoichiometry (lipid II:Ltnα:Ltnβ) and a pore size of 0.6 nm.82 Haloduracin is a recently 
discovered two-peptide lantibiotic whose mode of action and lipid II targeting ability has been 
extensively characterized. These results are discussed in Chapter 2. 
 Binding to lipid II and pore formation are not the only mechanisms by which lantibiotics 
exert their activity. Cinnamycin and the related duramycins inhibit phospholipase A2 by 
sequestering its substrate, phosphatidylethanolamine (PE) with 1:1 stoichiometry.42,84 This 
binding activity prevents the phospholipase-A2-catalyzed release of arachidonic acid from the 
cell membrane and consequently affects the biosynthesis of leukotrienes and prostaglandins.24 
More recent studies have shown that cinnamycin accesses PE by causing transbilayer lipid 
movement.85 Some lantipeptides function as cell signaling molecules. For instance, the Class III 
lantipeptides SapB and SapT play essential morphological roles in the formation of aerial hyphae 
in streptomycetes.41,86,87 
 
1.4. BIOSYNTHESIS 
1.4.1. Classification of lantibiotics 
 Lantibiotics/lantipeptides are classified into four distinct classes based on their 
biosynthesis, with a particular focus on the steps of dehydration and cyclization (Figure 1.6). The 
nature and organization of the catalytic domains responsible for these post-translational 
modifications are unique for each class of lantibiotics. The biosynthesis of class I lantibiotics 
involves dedicated monofunctional enzymes that carry out distinct steps in lantibiotic maturation. 
A LanB dehydratase and a LanC cyclase catalyze dehydration and cyclization events, 
respectively, and secretion and leader peptide removal is performed by an ATP-binding cassette 
(ABC) transporter LanT and protease LanP, respectively.24 
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Figure 1.6. Composition of the catalytic domains of class I−IV lanthionine synthetases. The darker colors indicate 
positions of active site residues (in LanC) or conserved residues in LanM, RamC/LabKC, and LanL corresponding 
to the active site residues in structurally characterized homologous enzymes. Adapted from Ref. 39. 
 
 In contrast, the remaining three classes involve two multifunctional enzymes to install 
dehydrated amino acids and thioether cross-links, transport the modified peptide, and remove the 
leader peptide. Class II lantibiotics are produced by bifunctional LanM enzymes, which are 
responsible for both dehydration and cyclization steps.88 The modified precursor peptide is 
transported and proteolytically cleaved by bifunctional LanT enzymes. A number of class II 
lantibiotics, termed two-peptide lantibiotics, are composed of two different peptides, and each is 
synthesized by a dedicated LanM enzyme.89 Eight two-peptide lantibiotic systems have been 
reported to date and are further discussed in Chapter 2. 
 Class III and class IV lantibiotics are less well-characterized. However, additional 
members are being discovered and an increasing amount of information is becoming available 
regarding their biosynthesis through comparative genomics and biochemical characterization of 
the enzymes involved in these pathways. The dehydration and cyclization of class III lantibiotics 
are produced through the actions of RamC/LabKC multifunctional enzymes.35,90 The enzymes 
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responsible for the transport and leader peptide removal of class III lantibiotics are currently 
underexplored. However, for the few members that have been studied, two genes with sequence 
similarity to ABC transporters have been identified in each cluster which may encode for the 
enzymes responsible for the final steps in class III lantibiotic maturation.35,90 More recently, an 
additional class of lantibiotics was established following the discovery of a novel enzyme 
capable of installing the characteristic lanthionine post-translational modifications.91 This class 
IV subgroup has only a single member to date, but already much has been revealed regarding its 
biosynthesis mechanism.39,91 A multifunctional LanL enzyme catalyzes the dehydration and 
cyclization processes, and two genes adjacent to the precursor and synthetase genes appear to 
encode ATP-binding and membrane permease subunits, which may be involved in the export of 
the modified peptide. 
 
1.4.2. Gene organization 
 Lantibiotic biosynthetic genes are clustered and designated with the generic locus symbol 
lan. For each individual lantibiotic, a more specific genotypic designation is used (e.g. nis for 
nisin, hal for haloduracin). The clustered biosynthetic genes are found in a range of genetic 
scaffolds including conjugative transposable elements, on the chromosome of the host, or on 
plasmid replicons (Figure 1.7). Many genes and clusters have been sequenced, and these studies 
show similar gene organization for the production of various lantibiotics.24,92,93 Recent advances 
in high-throughput sequencing has lead to the exponential identification of lantibiotic 
biosynthetic gene clusters, revealing a more widespread distribution of organisms harboring the 
capacity to produce these complex molecules.16 In all cases, the cluster includes genes encoding 
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Figure 1.7. Organization of representative lantibiotic biosynthetic gene clusters. (a) The biosynthetic gene cluster 
for the production of nisin in Lactococcus lactis. The precursor peptide is colored in black, dehydratase in green, 
cyclase in yellow, transporter in red, protease in orange, and immunity protein in blue. (b) The biosynthetic gene 
cluster for the production of haloduracin in Bacillus halodurans C-125. The precursor peptide is colored in 
black,bifunctional synthetases in violet, and bifunctional transporter in red. 
  
for one or more precursor peptides (lanA) and the modification enzymes responsible for 
catalyzing the dehydration and cyclization events including lanB and lanC (class I), lanM (class 
II), ramC/labKC (class III), or lanL (class IV) genes. In addition, the transporter responsible for 
excretion of the mature lantibiotic is encoded by genes designated lanT. Class I lantibiotics 
require a dedicated protease encoded by a lanP gene in addition to the transporter. Some 
lantibiotics undergo more extensive post-translational modification and the genes encoding for 
the required enzymes are also typically found within the cluster.17 Additional genes, such as 
those that encode for regulation and immunity, may also be found within these clusters or they 
may be located on closely linked operons.17 
 
1.4.3. Precursor peptides 
 The lanA genes encode precursor peptides (LanA) that contain a core peptide region that 
will eventually become the mature lantibiotic, as well as an N-terminal leader peptide extension 
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that varies in length from 23 to 59 residues.24 While both the leader and core peptide sequences 
contain dehydratable serine and threonine residues, only those residues found in the core peptide 
undergo modification, giving rise to the structural features (Dha, Dhb, Lan, MeLan) shown in 
Figure 1.3. The role of the leader peptide has been investigated for both class I and class II 
lantibiotics using in vivo mutagenesis studies and in vitro reconstitution of the post-translational 
modification reactions. Much of class I and class II research has focused on the important 
features of leader peptides required for modification of the core peptide; however, due to their 
relatively recent discoveries, not much is known regarding leader peptide requirements for class 
III and class IV lantibiotics. Leader sequences are also present in the precursors of many other 
ribosomal peptide natural products such as those described in section 1.1., all of which appear to 
utilize the leader peptide to direct the maturation process.1 
Several roles have been suggested for the leader peptides of lantibiotics. The role most 
commonly proposed for the leader peptides is that of a secretion signal. However, the vast 
majority of leader peptides of natural product biosynthesis have no homology with the peptides 
of the typical Sec and twin-arginine translocation pathways that are used in bacteria, archaea and 
plants to transport proteins across membranes. A second role that is frequently postulated is that 
of a recognition motif for the post-translational modification enzymes. It is this role that is most 
enticing from a natural product engineering perspective as it may allow generation of analogs by 
attachment of core peptide variants or even very different peptides to the leader peptides. A 
related proposed task is that of a cis-acting chaperone in which the leader peptide actively assists 
during the PTM process. Taking clues from the roles of leader peptides attached to enzymes,94 
they may also assist in folding of the precursor peptide, stabilizing the precursor against 
degradation, or keeping the precursor peptide inactive during biosynthesis inside the host until 
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the appropriate time for secretion and proteolysis. Indeed, many of the proteases involved in 
ribosomal natural product biosynthesis in the lantibiotics are localized on the outside of the 
producing cells and in some cases the protease is part of the transporter. Further delineating the 
function of these peptide sequences will offer exciting insights into basic biological processes as 
well as provide improved opportunities to reprogram natural product structures by utilizing the 
leader peptide directed biosynthetic enzymes. 
 
1.4.3.1. Leader peptides of class I lantibiotics 
The leader peptides of class I lantibiotics are about 25 amino acids in length and are rich 
in Asp residues (Figure 1.8). The leader peptide portion often contains a common “FNLD” 
sequence between −20 to −15 residues (negative numbers for the leader peptide result from 
counting backwards from the cleavage site, i.e. the first residue N-terminal to the start of the core 
peptide is −1). Individual mutation of residues of this motif (F−18L, L−16K, D−15A) in the nisin 
precursor, NisA, resulted in no detection of nisin or its precursors.95 Moreover, the NisA mutants 
R−1Q and A−4D were still able to be modified and secreted, but the leader peptide was no 
longer removed. A similar result was observed for Arg−1 mutants of EpiA, the precursor of 
epidermin.96 Remarkably, mutations of conserved residues Pro−2 and Asp−7 of NisA did not 
affect the production of nisin.95 More recent studies on substitutions within or outside the FNLD 
box and with truncated forms of the NisA leader peptide have strongly supported the importance 
of the leader peptide for efficient processing of the peptide by the nisin biosynthetic machinery.97 
 NMR studies on fully processed nisin attached to its leader peptide did not reveal any 
interactions between the leader and the nisin molecule, both in solution and in micelles.98 
Moreover, none of the investigated lantibiotic leader peptides displayed secondary structure in 
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aqueous solution, although they attain α-helical conformations in trifluoroethanol99 and structure 
prediction tools anticipate helical character. These observations do not support the hypothesis 
that the leader peptide acts as a chaperone for folding. However, leader peptides attached to the 
mature lantibiotics greatly reduce or abolish their antimicrobial activity, consistent with a 
protective mechanism.95,100 In addition, ATP-binding cassette transporters clearly use the class I 
leader peptides for recognition because various engineered non-lantibiotic cargo attached to 
these leader sequences are secreted.101,102 Similarly, the leader peptide of nisin is also recognized 
by the dehydratase and cyclase enzymes as demonstrated by in vivo processing of non-lantibiotic 
therapeutic peptides attached to the nisin leader peptide,103,104 and by in vitro studies on the 
cyclase enzyme.100 The nisin cyclase, NisC, is made up of an α,α-barrel that contains the active 
site and a separate domain proposed to contain the leader peptide binding site.100 
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                                |------------leader peptide-------------|        
                                1                                               50 
           Nisin A P13068   (1) ----------------MSTKDFNLDLVSVSKK--DSGASPRITSISLCTP 
           Nisin Z P29559   (1) ----------------MSTKDFNLDLVSVSKK--DSGASPRITSISLCTP 
         Nisin Q BAD05046   (1) ----------------MSTKDFNLDLVSVSKT--DSGASTRITSISLCTP 
         Nisin F ABU45463   (1) ----------------MSTKDFNLDLVSVSKK--DSGASPRITSISLCTP 
           Nisin U Q2QBT0   (1) ----------------MNNEDFNLDLIKISKEN-NSGASPRITSKSLCTP 
                 Nisin U2   (1) ----------------MNNEDFNLDLIKISKEN-NSGASPRVTSKSLCTP 
    epilancin K7 AAA79236   (1) ----------------MNNSLFDLNLNKGVET-QKSDLSPQSASVLKTSI 
          Subtilin P10946   (1) ---------------MSKFDDFDLDVVKVSKQ--DSKITPQWKSESLCTP 
            Pep5 CAA90023   (1) --------------MKNNKNLFDLEIKKETSQNTDELEPQTAGPAIRASV 
        Ericin S AAL15569   (1) ---------------MSKFDDFDLDVVKVSKQ--DSKITPQWKSESVCTP 
        Ericin A AAL15567   (1) ------------MTNMSKFDDFDLDVVKVSKQ--DSKITPQVLSKSLCTP 
         Epidermin P08136   (1) -----------MEAVKEKNDLFNLDVKVNAKESNDSGAEPRIASKFICTP 
       Gallidermin P21838   (1) -----------MEAVKEKNELFDLDVKVNAKESNDSGAEPRIASKFLCTP 
Mutacin 1140 (III) O68586   (1) MSNTQLLEVLGTETFDVQEDLFAFDTTDTTIVASNDDPDTRFKSWSLCTP 
       Mutacin I AAG48564   (1) MSNTQLLEVLGTETFDVQEDLFAFDTTDTTIVASNDDPDTRFSSLSLCSL 
                Consensus   (1)                 M  DDF LDLV VSK   DSGASPRI S SLCTP 
 
                                51                     75 
           Nisin A P13068  (33) GCKTGALMGCNMKTATCHCSIHVSK 
           Nisin Z P29559  (33) GCKTGALMGCNMKTATCNCSIHVSK 
         Nisin Q BAD05046  (33) GCKTGVLMGCNLKTATCNCSVHVSK 
         Nisin F ABU45463  (33) GCKTGALMGCNMKTATCNCSVHVSK 
           Nisin U Q2QBT0  (34) GCKTGILMTCPLKTATCGCHFG--- 
                 Nisin U2  (34) GCKTGILMTCPLKTATCGCHFG--- 
    epilancin K7 AAA79236  (34) KVSKKYCKGVTLTCGCNITGGK--- 
          Subtilin P10946  (34) GCVTGALQTCFLQTLTCNCKISK-- 
            Pep5 CAA90023  (37) KQCQKTLKATRLFTVSCKGKNGCK- 
        Ericin S AAL15569  (34) GCVTGVLQTCFLQTITCNCHISK-- 
        Ericin A AAL15567  (37) GCITGPLQTCYLCFPTFAKC----- 
         Epidermin P08136  (40) GCAKTG--SFNSYCC---------- 
       Gallidermin P21838  (40) GCAKTG--SFNSYCC---------- 
Mutacin 1140 (III) O68586  (51) GCARTG--SFNSYCC---------- 
       Mutacin I AAG48564  (51) GCTGVKNPSFNSYCC---------- 
                Consensus  (51) GC TG L SCNL T TC C       
 
 
 
 
Figure 1.8. Leader sequence conservation among class I lantibiotics. (a) Sequence alignment of the precursor 
peptides for selected members of class I lantibiotics. (b) Weblogo representation of the data used in panel (a). The 
leader peptide is indicated by the blue line above the sequence and the highly conserved “FNLD” sequence is 
indicated by the orange box. 
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1.4.3.2. Leader peptides of class II lantibiotics 
 The leader peptides of class II lantibiotics are typically also rich in Asp and Glu residues, 
contain an ELXXBXG motif (B = V, L, or I), and usually end in a double Gly motif (Figure 1.9). 
Originally defined as consecutive Gly residues preceding the proteolytic cleavage site of non-
lantibiotic bacteriocins,105 this motif now also includes GlyAla and GlySer/Thr sequences. Like 
the leader peptides of class I lantibiotics, the double Gly leader peptides play several roles that 
include keeping the modified core peptide inactive when still attached to the leader peptide.88 In 
addition, in vitro studies on lacticin 481 have shown that the leader peptide is important for 
efficient dehydration and cyclization, but not essential. When the leader peptide and the core 
region of the lacticin 481 precursor peptide were presented in trans to lacticin 481 synthetase, 
dehydration still occurred, albeit with much decreased efficiency.106 Unexpectedly, even 
incubation of the synthetase with just the core peptide resulted in dehydration. Hence, the leader 
peptide is not a compulsory allosteric element for dehydratase activity. Instead, the enzyme has a 
low level basal activity in the absence of the leader peptide, suggesting that the leader peptide 
may influence the equilibrium between an inactive and an active form of the enzyme by binding 
to the latter.107 Upon binding, lacticin 481 synthetase processes its substrate peptide 
distributively and directionally, moving from N- to C-terminus,108 whereas in the absence of the 
leader peptide, no such directionality was observed.106 The unique role of the leader peptide in 
the biosynthesis of lacticin 481 was exploited in further engineering studies of LctM which are 
discussed in Chapter 3. 
 Site-directed mutagenesis studies have shown that the double Gly motif is essential for 
proteolytic processing,109,110 but not for installation of lanthionine rings.107 Hence, the  
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                                    |------leader peptide--------| 
                                    1                                               50 
Butyrivibriocin OR79 AAC19355   (1) -------MNKELNALTNPIDEKELEQILGGG---NGVIKTISHECHMNTW 
        Ruminococcin-A P83674   (1) -------MRNDVLTLTNPMEEKELEQILGGG---NGVLKTISHECNMNTW 
              Variacin A58711   (1) --------MTNAFQALDEVTDAELDAILGG---GSGVIPTISHECHMNSF 
          Lacticin 481 P36499   (1) ------MKEQNSFNLLQEVTESELDLILGAKG-GSGVIHTISHECNMNSW 
     Bacteriocin J46 CAA61674   (1) ------MKEQNSFNLLQEVTESELDLILGAKG-GSGVIHTISHEVIYNSW 
           Macedocin ABI30226   (1) -----MEKETTIIESIQEVSLEELDQIIGAGK--NGVFKTISHECHLNTW 
 Streptococcin A-M49 AAA62362   (1) -----MTKEHEIINSIQEVSLEELDQIIGAGK--NGVFKTISHECHLNTW 
Streptococcin A-FF22 AAB92600   (1) -----MEKNNEVINSIQEVSLEELDQIIGAGK--NGVFKTISHECHLNTW 
          Mutacin II AAC38144   (1) ----MNKLNSNAVVSLNEVSDSELDTILGGNRWWQGVVPTVSYECRMNSW 
               MukA1 ABK59354   (1) ----MKNTTNEMLELIQEVSLDELDQVIGGMG--KGAVGTISHECRYNSW 
               MukA2 ABK59355   (1) -----MKQSDEMLELIQEVSLDELDQVIGGAG--NGVIRTITQGCRMPNN 
               MukA3 ABK59356   (1) -----MKQSNEMLELIQEVSLDELDQVIGGMG--KGAVGTISHECRYNSW 
               MukA' ABK59357   (1) -MKKGTQLYLEALEALQEIKVEELDTFIGGG---GRASNTISSDCRWNSL 
         Salivaricin A P36500   (1) ----MKNSKDILNNAIEEVSEKELMEVAGGK-RGSGWIATITDDCPNSVF 
      Salivaricin A1 ABB05512   (1) ----MKNSKDVLNNAIEEVSEKELMEVAGGK-KGSGWFATITDDCPNSVF 
      Salivaricin A2 ABB05514   (1) ----MKNSKDILNNAIEEVSEKELMEVAGGK-RGTGWFATITDDCPNSVF 
      Salivaricin A3 ABB05511   (1) ----MKNSKDVLNNAIEEVSEKELMEVAGGK-KGPGWIATITDDCPNSIF 
      Salivaricin A4 ABB05509   (1) ----MKNSKDILNNAIEEVSEKELMEVAGGK-RGPGWIATITDDCPNSIF 
      Salivaricin A5 ABB05510   (1) ----MKNSKDILNNAIEEVSEKELMEVAGGK-RGPGWIATITDDCPNSVF 
       Bovicin HJ-50 AAP23217   (1) -----MMNATENQIFVETVSDQELEMLIGG--ADRGWIKTLTKDCPNVIS 
   Thermophilin 1277 BAF75720   (1) -----MMNATENQIFVETVSDQELEMLIGG--ADRGWIKTLTKDCPNVIS 
       Nukacin ISK-1 BAD01007   (1) MENSKVMKDIEVANLLEEVQEDELNEVLGAKK-KSGVIPTVSHDCHMNSF 
     Nukacin KQU-131 BAG70955   (1) MENSKIMKDIEVANLLEEVQEDELNEVLGAKK-KSGVIPTVSHDCHMNTF 
                    Consensus   (1)           EL NAIQEVSE ELD VIGG     GVI TISHDC  NSW 
 
                                    51           65 
Butyrivibriocin OR79 AAC19355  (41) QFIFTCCS------- 
        Ruminococcin-A P83674  (41) QFLFTCC-------- 
              Variacin A58711  (40) QFVFTCCS------- 
          Lacticin 481 P36499  (44) QFVFTCCS------- 
     Bacteriocin J46 CAA61674  (44) NFVFTCCS------- 
           Macedocin ABI30226  (44) AFLATCCS------- 
 Streptococcin A-M49 AAA62362  (44) AFLATCCS------- 
Streptococcin A-FF22 AAB92600  (44) AFLATCCS------- 
          Mutacin II AAC38144  (47) QHVFTCC-------- 
               MukA1 ABK59354  (45) AFLATCCS------- 
               MukA2 ABK59355  (44) MQVLFTC-------- 
               MukA3 ABK59356  (44) AFLATCCS------- 
               MukA' ABK59357  (47) QAIFSCC-------- 
         Salivaricin A P36500  (46) VCC------------ 
      Salivaricin A1 ABB05512  (46) VCC------------ 
      Salivaricin A2 ABB05514  (46) VCC------------ 
      Salivaricin A3 ABB05511  (46) VCC------------ 
      Salivaricin A4 ABB05509  (46) VCC------------ 
      Salivaricin A5 ABB05510  (46) VCC------------ 
       Bovicin HJ-50 AAP23217  (44) SICAGTIITACKNCA 
   Thermophilin 1277 BAF75720  (44) SICAGTIITACKNCA 
       Nukacin ISK-1 BAD01007  (50) QFVFTCCS------- 
     Nukacin KQU-131 BAG70955  (50) QFMFTCCS------- 
                    Consensus  (51)  FL TCC         
 
Figure 1.9. (continued on next page) 
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                                 |------leader peptide------| 
                                 1                                               50 
     mundticin KS BAB88211   (1) ---------------------MSQVVGG-KYYGNGVSCNKKGCSVDWGKA 
        mundticin AAR26473   (1) -------------MKKLTAKEMSQVVGG-KYYGNGVSCNKKGCSVDWGKA 
      mundticin L ACQ77507   (1) -------------MKKLTSKEMAQVVGG-KYYGNGLSCNKKGCSVDWGKA 
carnobacteriocin B1 P38579   (1) ----------MKSVKELNKKEMQQINGGAISYGNGVYCNKEKCWVNKAEN 
carnobacteriocin B2 P38580   (1) ----------MNSVKELNVKEMKQLHGG-VNYGNGVSCSKTKCSVNWGQA 
         curvacin A P0A311   (1) ----------MNNVKELSMTELQTITGGARSYGNGVYCNNKKCWVNRGEA 
        sakacin P AAM88858   (1) ----------MEKFIELSLKEVTAITGG-KYYGNGVHCGKHSCTVDWGTA 
  sakacin G skgA1 AAM73713   (1) ----------MKNTRSLTIQEIKSITGG-KYYGNGVSCNSHGCSVNWGQA 
  sakacin G skgA2 AAM73712   (1) ----------MKNAKSLTIQEMKSITGG-KYYGNGVSCNSHGCSVNWGQA 
      pediocin PA-1 P29430   (1) ----------MKKIEKLTEKEMANIIGG-KYYGNGVTCGKHSCSVDWGKA 
  plantaricin 423 AAL09346   (1) ---------MMKKIEKLTEKEMANIIGG-KYYGNGVTCGKHSCSVNWGQA 
  enterocin SE-K4 EEI61656   (1) ---------MILGIVLLSVSTLGITVDAATYYGNGVYCNTQKCWVDWSRA 
      enterocin A BAA92138   (1) -----MKHLKILSIKETQLIYGGTTHSG-KYYGNGVYCTKNKCTVDWAKA 
         leucocin A P34034   (1) ----MMNMKPTESYEQLDNSALEQVVGG-KYYGNGVHCTKSGCSVNWGEA 
mesentericin Y105 AAP37395   (1) ----MTNMKSVEAYQQLDNQNLKKVVGG-KYYGNGVHCTKSGCSVNWGEA 
     divercin V41 CAA11804   (1) -----MKNLKEGSYTAVNTDELKSINGGTKYYGNGVYCNSKKCWVDWGQA 
      enterocin P AAC45870   (1) MRKKLFSLALIGIFGLVVTNFGTKVDAATRSYGNGVYCNNSKCWVNWGEA 
 listeriocin 743A AAK19401   (1) MKKAALKFIIVIAILGFSFSFFSIQSEA-KSYGNGVQCNKKKCWVDWGSA 
                 Consensus   (1)           M  I  LT  EM  I GG KYYGNGVYCNK  CSVNWG A 
 
                                 51                       77 
     mundticin KS BAB88211  (29) IGIIGNNSAANLATGGAAGWKS----- 
        mundticin AAR26473  (37) IGIIGNNSAANLATGGAAGWKS----- 
      mundticin L ACQ77507  (37) IGIIGNNSAANLATGGAAGWKS----- 
carnobacteriocin B1 P38579  (41) KQAITGIVIGGWASSLAGMGH------ 
carnobacteriocin B2 P38580  (40) FQERYTAGINSFVSGVASGAGSIGRRP 
         curvacin A P0A311  (41) TQSIIGGMISGWASGLAGM-------- 
        sakacin P AAM88858  (40) IGNIGNNAAANWATGGNAGWNK----- 
  sakacin G skgA1 AAM73713  (40) WTCGVN----HLANGGHGVC------- 
  sakacin G skgA2 AAM73712  (40) WTCGVN----HLANGGHGVC------- 
      pediocin PA-1 P29430  (40) TTCIINNGAMAWATGGHQGNHKC---- 
  plantaricin 423 AAL09346  (41) FSCSVS----HLANFGHGKC------- 
  enterocin SE-K4 EEI61656  (42) RSEIVDRGVKAYVNGFTKVLGGVGGR- 
      enterocin A BAA92138  (45) TTCIAGMSIGGFLGGAIPGKC------ 
         leucocin A P34034  (46) FSAGVH----RLANGGNGFW------- 
mesentericin Y105 AAP37395  (46) ASAGIH----RLANGGNGFW------- 
     divercin V41 CAA11804  (46) SGCIGQTVVGGWLGGAIPGKC------ 
      enterocin P AAC45870  (51) KENIAGIVISGWASGLAGMGH------ 
 listeriocin 743A AAK19401  (50) ISTIGNNSAANWATGGAAGWKS----- 
                 Consensus  (51)  S I N     WATGG GG         
 
Figure 1.9. Leader sequence conservation among class II lantibiotics. (a) Sequence alignment of the precursor 
peptides for selected members of class II lantibiotics. (b) Weblogo representation of the data used in panel (a). The 
leader peptide is indicated by the blue line above the sequence. The conserved double-glycine cleavage site and the 
ELXXBXG motif is indicated by the green and violet boxes, respectively. (c) Sequence alignment of the precursor 
peptides for bacteriocins that do not undergo post-translational modification. 
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recognition of the leader peptides is different for the protease and synthetase. It has proven 
difficult to delineate the exact factors that are essential for recognition by the synthetase as 
nearly all single point mutants of the lacticin 481 leader peptide were still processed.107 The only 
clear disruption of processing by the synthetase was observed with a series of mutants that 
introduced Pro residues, supporting the hypothesis that the leader peptide attains an α-helical 
conformation when bound to the synthetase.107 Interestingly, leader peptides of the double Gly 
type with clear homology with lantibiotic leader peptides are also found in many bacteriocins 
that do not undergo posttranslational modifications (Figure 1.9). Therefore, these leader peptides 
are thought to only be important for secretion and/or for reducing the biological activity of the 
bacteriocin.111 Hence, the leader peptides of class II lantibiotics may have evolved from a role in 
secretion to include additional roles in guiding the enzymes involved in lantibiotic biosynthesis. 
However, the hypothesis that non-conserved amino acids in these leader peptides would convey 
recognition by the PTM enzymes for each specific lantibiotic is not supported by mutagenesis 
studies.107 
 
1.4.4. Lantibiotic synthetases 
The formation of unsaturated amino acids and thioether bridges requires both LanB and 
LanC proteins for class I lantibiotics (Figure 1.6). LanB proteins are normally very large 
(approximately 120 kDa) and have no homology with any other known proteins. The sequence 
identity within the LanB protein family is only around 30%. In silico analysis of the primary 
sequence of LanB proteins reveals overall hydrophilic structures with hydrophobic patches. 
Early studies on the dehydration activity of LanB proteins initially demonstrated the ability to 
form dehydrated Pep5 peptide after inactivation of pepC in a Pep5-producing strain.112 A similar 
result was obtained in which dehydrated NisA was obtained through the in vivo activity of NisB 
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in a NisC deficient strain.113 More recently, non-producing L. lactis strains were able to 
heterologously produce dehydrated NisA through expression of nisABT.102 To date, many efforts 
to reconstitute enzymatic dehydration by a LanB protein in vitro with purified protein or cell-free 
extracts have not been successful. It was previously hypothesized that this lack of activity may 
be due to the formation of a membrane-associated multimeric complex with the LanC and LanT 
proteins.97,114-116 However, two independent studies focused on nis gene co-expression systems 
in L. lactis102,117 and E. coli118 have demonstrated that complex formation is not required for 
NisB activity.  
 LanC proteins catalyze the regio- and stereospecific intramolecular addition of cysteine 
thiols onto unsaturated amino acids to form the thioether rings found in class I lantibiotics. Initial 
experiments on Pep5112 and nisin113 biosynthesis verified the role of LanC proteins, where 
correctly cyclized products were not formed in engineered strains lacking functional LanC 
proteins. Recently, LanC enzymes involved in nisin and subtilin biosynthesis were cloned, 
expressed, and purified and were shown to be zinc containing metalloproteins.119 The Zn atom in 
these enzymes was proposed to serve a catalytic role in activating the thiol for nucleophilic 
addition onto the unsaturated residues during lanthionine formation. Through the spectroscopic 
analysis of SpaC, it was demonstrated that the ligand environment of the metal atom consisted of 
two Cys residues along with either two His residues or one His and one water molecule. Direct 
evidence for the identity of the Zn ligands was obtained in a crystal structure of NisC, which 
showed Cys284, Cys330, His331, and a water molecule serving as the four tetrahedral ligands.100 
Results from the same study demonstrated the in vitro reconstitution of NisC activity using 
dehydrated NisA obtained from an engineered L. lactis strain expressing nisABT genes. Later 
studies, focused on variants of NisC, demonstrated that site-directed mutagenesis of the Zn 
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binding residues abolished cyclization activity of NisC and decreased the amount of bound metal 
in the enzyme.120 
 The lanM genes encode for large proteins involved in class II lantibiotic biosynthesis 
(Figure 1.6). These enzymes consist of an N-terminal domain that displays no sequence 
homology with the LanB proteins and a C-terminal LanC-like domain.24 The first report of the 
proposed role of LanM proteins came from studies in which lacticin 481 production was halted 
when the gene encoding LctM was disrupted.121,122 Additional supporting evidence was revealed 
in a genetic study in which introduction of lctA, lctM, and lctT genes and the lctFEG immunity 
genes into a normally non-producing L. lactis strain resulted in heterologous production of 
lacticin 481.123 Direct evidence for the role of LanM proteins was provided following the first in 
vitro reconstitution of an active lantibiotic synthetase, LctM.88 In this study, treatment of the 
LctA precursor with LctM resulted in a four-fold dehydrated, fully-cyclized peptide. Following 
the removal of the leader peptide with a commercially available protease, LysC, bioactive 
lacticin 481 was obtained. Both Mg2+ and ATP were essential for modification by LctM to occur. 
Later experiments demonstrated that ATP is utilized to activate Ser and Thr hydroxyls as 
phosphorylated intermediates to facilitate the elimination process during Dha and Dhb 
formation.124,125 
 A second example of in vitro reconstitution of LanM proteins was reported concerning 
HalM1 and HalM2 involved in the biosynthesis of the two-peptide lantibiotic, haloduracin.4 It 
has been demonstrated that HalM1 and HalM2 can each modify their substrate HalA1 and HalA2 
in vitro to produce the bioactive forms of haloduracin α- and β-peptide. More recently, two 
additional examples of LanM in vitro reconstitution have been reported, including ProcM,34 
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which is involved in the biosynthesis of prochlorosins, and CinM, which post-translationally 
modifies the cinnamycin precursor.126 
 The synthetases responsible for post-translational modification of class III and IV 
lantibiotics/lantipeptides have not been as thoroughly studied as those involved in class I and II 
biosynthesis. Synthetases of both class III and IV possess a three domain architecture consisting 
of a putative phospho-serine/-threonine lyase-like domain, a kinase-like domain, and a cyclase 
domain (Figure 1.6). This domain composition, in combination with the recently reported in vitro 
reconstitution and analysis of deletion mutants of VenL, a LanL enzyme involved in biosynthesis 
of venezuelin, suggested a unique dehydration strategy in which two independent domains install 
Dha and Dhb via a kinase domain through the phosphorylation of Ser and Thr residues, 
respectively. The subsequent elimination of the phosphate from pSer and pThr is carried out by a 
putative pSer/pThr lyase domain.39,91 Class IV cyclase domains have been shown to possess 
sequence similarities with LanC enzymes and with the cyclase domain of LanM proteins, 
suggesting that class I, II, and IV share a similar cyclization strategy, whereby a zinc ion is 
utilized to activate the cysteines for nucleophilic attack onto Dha and Dhb.100,119,120 
 The in vitro reconstitution of LabKC, identified a class III synthetase with the unusual 
ability to catalyze C-C bond formation during labyrinthopeptin biosynthesis (Figure 1.6).35 This 
process required the unprecedented use of GTP and Mg2+ for the phosphorylation and 
dehydration of serine residues. Additional experiments have been performed that demonstrate the 
ability of LabKC to catalyze the consecutive, double Michael addition cyclization reactions 
required for the formation of lanthionine and labionin motifs. The precise mechanism of 
cyclization is currently unknown for the LabKC and RamC proteins. In contrast to class I, II, and 
IV synthetases, class III proteins lack the conserved zinc ligands found in the LanC-like domains 
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of the aforementioned classes.39 As of yet, there has been no experimental evidence identifying 
the use of a metal ion for cysteine thiol activation. 
 
1.4.5. Other modifications 
 In addition to the characteristic (methyl)lanthionine and dehydro-amino acids, many 
additional post-translational modifications have been observed in lantibiotics (Figure 1.3). These 
unique modifications bearing unusual functionalities include lysinoalanine, aminovinyl cysteine, 
D-alanine, mono- and di-hydroxylations, N-terminal modifications, and a number of rare post-
translational modifications.17 These modifications are not installed by the synthetase enzymes, 
but rather by enzymes often encoded within the same biosynthetic gene cluster.24 These 
additional post-translational modifications can contribute significantly to the biological activity 
of these lantibiotics. Importantly, they provide opportunities for the study of novel lantibiotic 
enzymes, which may reveal new insights into lantibiotic biosynthesis and result in novel tools for 
installing new functionalities into peptides and proteins. 
A lysinoalanine bridge has been discovered in cinnamycin,127 ancovenin,128 and the 
duramycin family129 of lantibiotics. A small protein encoded by cinorf7 found within the 
cinnamycin biosynthetic gene cluster has been proposed to be involved in the formation of the 
crosslink between the ε-amine of lysine 19 and dehydroalanine 6.126 In addition to the 
lysinoalanine modification, L-Asp hydroxylation at the β-carbon to produce erythro-3-hydroxyl-
L-aspartic acid has been identified in cinnamycin and the duramycins.129,130 The enzyme CinX 
has recently been identified as the Fe(II)/α-ketoglutarate-dependent hydroxylase responsible for 
the formation of this modification. The specific recognition unit required for this modification is 
unknown, as this hydroxylation does not require the leader sequence or a cyclized form of the 
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core peptide for modification to occur.126 Both lysinoalanine and β-hydroxylation are critical in 
mediating the interactions of cinnamycin with its biological target.42,126,127 
The post-translationally installed crosslinks aminovinyl cysteine (AviCys) and 
aminovinyl methyl cysteine (AviMeCys) have been found at the C-terminus of epidermin,29 
gallidermin,131 cypemycin,132 and mutacin III.133A group of decarboxylases, designated LanD 
proteins, are found within the lantibiotic gene clusters and are responsible for this modification. 
The aminovinyl cysteine residues found within mersacidin and epidermin result from oxidative 
decarboxylation of a C-terminal cysteine by MrsD and EpiD, respectively.134,135 Both enzyme 
activities have been reconstituted in vitro and the crystal structures of these two flavin-containing 
decarboxylases have been solved. Whereas EpiD displayed a broad substrate specificity with 
only a C-terminal Cys as a requirement, MrsD required a more definitive substrate 
sequence.136,137 
The presence of D-alanine has been observed in a small number of lantibiotics. Structural 
analysis of lactocin S revealed the presence of three D-Ala residues.138 In addition, this unique 
modification was also discovered in both peptides of the two-component lantibiotic lacticin 
3147.139,140 One D-Ala is found in the α-peptide and two D-Ala are found in the β-peptide. The 
mechanism for D-Ala formation has been shown to involve a two-step process in which an L-
serine is dehydrated, followed by the stereospecific hydrogenation of the transiently formed Dha 
to produce D-Ala. The protein LtnJ is encoded in the lacticin 3147 gene cluster and has been 
proposed to catalyze this hydrogenation activity based on sequence similarity with known zinc-
containing alcohol dehydrogenases.141 
A number of N-terminal modifications have been identified that are believed to increase 
peptide stability against bacterial aminopeptidases.142 The N-terminal modifications 2-
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oxopropionyl and 2-oxobutyryl are the products of non-enzymatic hydrolysis of N-terminal Dha 
and Dhb, respectively, that become exposed following the proteolytic removal of the leader 
peptide. The 2-oxopropionyl group has been identified in lactocin S,138 and the 2-oxobutyryl 
functionality is found at the N-terminus of Pep5.30 Through NMR spectroscopy, it has been 
identified that epilancin K7 contains an N-terminal 2-hydroxypropionyl group.143,144 In addition, 
epicidin 280 is believed to bear the same modification. The putative oxidoreductase EciO may be 
involved, but this has never been confirmed experimentally.145 This modification is also present 
on epilancin 15X, and only recently was the stereochemistry of this modification determined via 
biochemical methods. It was demonstrated that ElxO, an NADP(H)-dependent alcohol 
dehydrogenase, catalyzes the conversion of an N-terminal pyruvate to D-lactate.142 
There have been few reports of very rare post-translational modifications. During late 
stages of cell growth, subtilin can become N-succinylated resulting in a reduction of biological 
activity.146 The chlorination of tryptophan has been identified in the recently discovered 
lantibiotic microbisporicin37 which likely results from the activity of a flavin-dependent 
halogenase.147 An additional post-translational modification of 3,4-dihydroxyproline has also 
been discovered in the microbisporicin structure. The AviCys containing natural product 
cypemycin possesses methylations at hydrophobic side chains including a bis-methylation at 
Ala1 and an L-allo-isoleucine at position 13.132 The recent identification and characterization of a 
structurally related compound, grisemycin, suggests that these compounds are in fact not 
lantibiotics, but a new class of peptide natural products, the linaridins, which may function as 
signaling molecules.148 Finally, actagardine has been reported to contain a sulfoxide as the result 
of the oxidation of a C-terminal thioether bridge.149 It is hypothesized that two monooxygenases 
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identified by sequencing of the producing organisms, ActO and LigO, may catalyze the 
oxidation.150 
 
1.4.6. Proteolysis and export 
 Nearly all lantibiotic gene clusters code for proteins that are responsible for the 
enzymatic removal of the leader peptide following post-translational modification and 
extracellular transport of the mature lantibiotic. Class I and class II lantibiotics utilize different 
enzymes to catalyze these events. In class I lantibiotics, the proteolytic LanP enzymes vary in 
size and contain a conserved catalytic triad (Asp, His, and Ser) and an Asn that plays a role in 
oxyanion hole formation.151 These proteases display homology with subtilisin-like serine 
proteases.24 Peptidase localization is believed to vary widely among class I lantibiotics. These 
enzymes can be found intracellularly, extracellularly, or anchored to the outside of the cell wall. 
The protease responsible for leader peptide removal of nisin, NisP, is located outside the cell 
membrane and is anchored on the cell surface.151 A study on the in vivo activity of NisP and 
NisT have addressed the substrate specificity of the protease and transporter. On one hand, the 
leader peptide was only removed from modified NisA after the thioether rings were formed and 
no protease activity was observed with unprocessed or uncyclized and dehydrated peptides, thus 
suggesting that NisP is specific toward thioether-containing precursor peptide. On the other 
hand, the same study demonstrated that the transporter, NisT, is able to export both processed 
and unprocessed forms of NisA precursor and non-lantibiotic peptides attached to the leader 
peptide as well.102 The substrate promiscuity of these enzymes has been exploited in a variety of 
in vivo engineering strategies.103,104,152 Studies on the activity of EpiP, the protease involved in 
the biosynthesis of epidermin, demonstrated that this protein is extracellularly located.96 PepP,112 
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LasP,151 and ElkP,144 the proteases for Pep5, lactocin S, and epilancin K7, respectively, lack the 
N-terminal pro-sequence found in NisP and EpiP and the C-terminal cell wall anchor of NisP. As 
a result, they are believed to function intracellularly, possibly as part of a membrane-bound 
complex.112 The activity of ElxP involved in the biosynthesis of epilancin 15X was recently 
reconstituted in vitro.142 
 Class II lantibiotic gene clusters do not contain genes encoding for LanP, but rather for 
bifunctional LanT transporters. These enzymes consist of an N-terminal protease domain and a 
C-terminal ATP-binding cassette (ABC) transporter domain, which is composed of a six-helix 
transmembrane domain with a C-terminal ATP-binding motif. Of the known bifunctional 
lantibiotic transporters, only the predicted protease domain from LctT comprised of residues 1-
150 has been heterologously expressed and reconstituted in vitro using expressed LctA and 
modified LctA as substrates.110 The protease domain of Class II LanT proteins share sequence 
homology with papain-like cysteine proteases and are thought to utilize a conserved Cys and His 
for catalysis. Mutagenesis studies of LctT demonstrated that the Cys residue was important for 
proteolytic activity, whereas the His influences regioselectivity.110 LctT protease cleaved at the 
predicted double-glycine motif site, and the formation of lanthionine rings was not required for 
protease activity.  
 
1.5. ENGINEERING OF ANTIMICROBIAL PEPTIDES 
1.5.1. In vivo approaches 
 The unique mode of action of lantibiotics and the long-term use of nisin in commercial 
applications has led to increased interest in the preparation of lantibiotic analogues with 
improved therapeutic properties. The gene-encoded nature of lantibiotics has enabled in vivo 
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bioengineering and heterologous expression systems to be developed for a number of lantibiotics 
including mersacidin,81 subtilin,153 Pep5,154 lacticin 3147,155 nukacin ISK-1,156,157 actagardine,150 
and nisin.75,158-161 
 Mutagenesis has yielded enormous insight into the structure-activity relationships of nisin 
and revealed key portions of the molecule that contribute to antimicrobial activity. To date, six 
natural variants of nisin have been identified,162 highlighting the natural diversity and tolerance 
for mutagenesis of this family of peptides. Remarkably, even subtle changes can have major 
repercussions on bioactivity. The replacement of Dha5 by Dhb in nisin Z resulted in a 2-10 fold 
reduction in bioactivity against a panel of strains.158 In contrast, substitution of Dhb2 for Dha led 
to a mutant that was twice as active.159 
 Removal of residues that become dehydro amino acids often results in a loss of 
bioactivity. Mutants of nisin containing a single mutation (Dha33 to Ala) or a double mutation 
(Dha5 to Ala, Dha33 to Ala) reduced activity to just 1% of native nisin.160 Mutation or disruption 
of ring structures often leads to a strong reduction in antimicrobial activity. This effect was 
observed for the slight alteration of the A-ring via substitution of Ser3 for Thr, resulting in a 
MeLan instead of a Lan. 
 Mutagenesis has also been utilized to investigate the effect of alterations at positions not 
involved in post-translational modifications. The substitution of Asn27 and His31 for Lys 
residues resulted in a mutant with improved solubility.163 Mutation of residues within the hinge 
region of nisin, such as deletion of Asn20 and Met21 led to a dramatic loss in the ability to form 
pores.164 Introduction of Pro at these positions had a stronger effect on pore formation, 
suggesting that this portion of the molecule plays an integral role in providing flexibility that 
allows for the insertion of the C-terminus into bacterial membranes.164 
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 Nearly all in vivo mutagenesis studies have resulted in identification of mutants with 
weaker antimicrobial activity or poorer pharmacological properties. Only a few exceptions exist, 
such as a three- to four-fold increase of activity observed for subtilin when Glu4 was changed to 
Ile.153 A systematic study focused on the random mutagenesis of the A- and B-rings of nisin led 
to the identification of A-ring variants with improved bioactivity and a modulated spectrum of 
target cells.165 In a separate in vivo mutagenesis study, a large library of nisin analogues was 
prepared that included several derivatives such as Asn20Pro, Met21Val, and Lys22Ser which 
demonstrated improved bioactivity against many Gram-positive pathogens including Listeria 
monocytogenes and Staphylococcus aureus.162 Despite these examples of success, a number of 
problems can arise when using an in vivo mutagenesis approach for the production of novel 
lantibiotics. These include challenges of identifying the stage at which biosynthesis of a mutant 
was impaired, potential regulatory and immunity issues, and the limitation of using proteinogenic 
amino acids.166-168 
 A particularly exciting approach for the production of lantibiotics in vivo is that which 
involves the co-expression of a lantibiotic LanA precursor in addition to biosynthetic enzymes in 
E. coli. Originally reported for lanthionine formation in the biosynthesis of nukacin ISK-1,169 this 
methodology has now been extended for the production of lantibiotics including nisin, 
haloduracin α-peptide and β-peptide, cinnamycin,126 and several of the recently discovered 
lantipeptides, prochlorosins.118 This strategy displays remarkable tolerance for mutant precursor 
peptides and enables full modification of the core peptide. Following expression and purification 
via affinity chromatography, the leader peptide can be removed in vitro to yield bioactive core 
peptides. 
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1.5.2. In vitro approaches 
 The in vitro reconstitution of a number of lantibiotic synthetases has been reported in the 
last decade representing all four classes of biosynthetic enzymes. The cyclase, NisC, involved in 
nisin biosynthesis, is the only class I cyclase enzyme to demonstrate activity in vitro.100 Neither 
its dehydratase partner, NisB, nor any other LanB enzymes have been successfully reconstituted 
in vitro. The bifunctional, class II LanM enzymes involved in lacticin 481 (LctM),88 haloduracin 
(HalM1 and HalM2),4 prochlorosins (ProcM),34 and cinnamycin (CinM)126 biosynthesis have all 
been successfully reconstituted in vitro to produce fully-modified and bioactive products. A 
single class III enzyme, LabKC,35 and a single class IV enzyme, VenL,91 were recently reported 
to display activity in vitro. The reconstitution of the activities of these enzymes in vitro is a 
significant achievement for understanding lantibiotic biosynthesis and for use in peptide 
engineering applications. 
 Site-directed mutagenesis studies focused on alterations within the lantibiotic core 
peptides have identified key structural features of lacticin 481170 and haloduracin α and β171 that 
are important for bioactivity. Furthermore, in vitro assays of lacticin 481 synthetase has allowed 
for extensive mechanistic investigations,124,125,172-174 for engineering applications,175,176 and for 
identification of key structural elements required for substrate recognition.106,107 Recently, an in 
vitro mutasynthesis strategy was utilized to produce lacticin 481 analogues containing 
proteinogenic and non-proteinogenic substitutions resulting in improved bioactivity compared to 
a pre-selected lacticin mutant with improved solubility properties (N15R and F21H 
mutations).176 To date, this is the only report identifying improved variants using an in vitro 
approach; however, as more lantibiotic biosynthetic systems are reconstituted in vitro, so should 
the likelihood of producing and identifying mutants with improved biological activities increase. 
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1.6. SUMMARY AND OUTLOOK 
 We have only begun to uncover the remarkable potential that ribosomally synthesized 
and post-translationally modified peptides offer as novel therapeutics and tools for chemical 
biology research. Besides the worldwide usage of nisin as a food preservative, many other 
lantibiotics have relevant applications. The lantibiotics lacticin 3147,44 haloduracin,45 and 
microbisporicin37 display potent activity against a wide-range of pathogenic organisms. 
Mersacidin displays similar activity to vancomycin in treating methicillin-resistant S. aureus 
infections in murine models.177 Lacticin 3147,178 haloduracin,45 mutacin 1140,179 and nisin45 all 
display activity against S. mutans strains, the causative agents of dental caries. Therefore, these 
lantibiotics have potential as anti-cavity treatments. 
 Some therapeutic and beneficial applications go beyond antimicrobial activity. The 
binding of cinnamycin and duramycin to phosphatidylethanolamine prevents the phospholipase-
A2-catalyzed release of arachidonic acid from the cell membrane and consequently affects the 
biosynthesis of leukotrienes and prostaglandins.42 Arachidonic acid is a biosynthetic precursor 
for the prostaglandins, a major class of compounds involved in inflammatory responses, and 
therefore applications of cinnamycin and the duramycins in treating cardiovascular diseases have 
been suggested. Duramycin has been shown to increase chloride secretion in lung epithelium,180 
and is currently in clinical trials to evaluate its efficacy in clearing of mucus excretions in 
patients with cystic fibrosis.181,182 Recently, spermicidal activity has been demonstrated for 
lacticin 3147.183 Bioactivity assays revealed that the class III lantibiotic, labyrinthopeptin A2, has 
an excellent efficacy against neuropathic pain in an in vivo mouse model.35 
 Our current understanding of lantibiotic biosynthesis and mode of action is the result of 
synergistic contributions from all areas of chemistry and life science including biochemistry, 
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microbiology, chemical biology, and genetics. Efforts of the past thirty years have greatly 
advanced our knowledge and understanding of these complex molecules and as advances in 
technologies continue to fuel research in this field, we peer with great anticipation of what 
discoveries lay ahead. This thesis will describe efforts to understand haloduracin mode of action 
(Chapter 2), leader peptide utilization by LctM (Chapter 3), and investigations of the putative 
lantibiotic sublancin (Chapter 4). 
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CHAPTER 2: MODE OF ACTION STUDIES OF THE TWO-PEPTIDE LANTIBIOTIC 
HALODURACIN1,2 
 
2.1. INTRODUCTION 
 Two-peptide lantibiotics function through the synergistic activities of two peptides. To 
date, eight two-peptide  lantibiotics have been reported which include haloduracin,3-5 lacticin 
3147,6 staphylococcin C55,7 Smb,8 plantaricin W,9 BHT-A,10 cytolysin,11 and lichenicidin.12 In 
these systems, two prepeptides are ribosomally synthesized as inactive precursors (LanA1 and 
LanA2), which are both enzymatically modified to their mature, bioactive forms (Lanα and 
Lanβ) (Figure 2.1). For all currently known two-peptide lantibiotics, the dehydration of serine 
and threonine residues and subsequent cyclization to form (methyl)lanthionine residues results 
from the actions of a bifunctional modification enzyme termed LanM. In most two-peptide 
systems, the homology between the LanA1 and LanA2 precursor sequences is low—therefore 
two different bifunctional enzymes (LanM1 and LanM2) each act specifically on only one of the 
precursor peptides.4,13 The modified LanA1 and LanA2 prepeptides are further processed by a 
LanT protein, which removes the leader peptides and secretes the final products. The mature 
peptides of several two-peptide systems share structural and sequence homology with known 
single-peptide lantibiotics. The mature α-peptides resemble the globular lantibiotic mersacidin 
with several fused thioether rings, whereas the mature β-peptides are typically elongated and 
more flexible (see Figure 1.4).14,15  
____________________________________________________ 
Reproduced in part with permission from:  
1 “Insights into the mode of action of the two-peptide lantibiotic haloduracin.” ACS Chem. Biol. 2009, 4, 865-874. 
Copyright 2009 American Chemical Society.  
2 “Haloduracin α Binds the Peptidoglycan Precursor Lipid II with 2:1 Stoichiometry.” J. Am. Chem. Soc. 2011, 
ASAP (published online October 17, 2011). Copyright 2011 American Chemical Society.  
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Figure 2.1. The biosynthesis of the peptides of haloduracin. (a) Biosynthetic scheme for and structure of Halα 
peptide. (a) Biosynthetic scheme for and structure of Halβ peptide. 
 
 Haloduracin, a two-peptide lantibiotic recently discovered by genome mining, is 
produced by the Gram-positive alkaliphilic bacterium Bacillus halodurans C-125.4,5 The 
lantibiotic consists of two post-translationally modified peptides, Halα and Halβ. This chapter 
describes in vivo and in vitro studies designed to investigate the mode of action of haloduracin 
and compares it to nisin, the prototypical lantibiotic. Wild-type haloduracin peptides were 
isolated, purified to homogeneity, and their independent roles in target binding and antimicrobial 
activities were assessed. Haloduracin was shown to have high potency against a range of Gram-
positive bacteria including pathogens such as methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant Enterococcus. The lantibiotic also inhibits spore outgrowth of Bacillus 
anthracis. The two peptides display optimal activity in a 1:1 stoichiometry and have similar 
efficacy as the commercially used lantibiotic nisin. However, haloduracin is more stable at pH 7 
than nisin. The precise roles of the individual haloduracin peptides for interaction with their 
molecular target, lipid II, have been identified and are discussed. Despite significant structural 
differences between the two peptides of haloduracin and those of the two-peptide lantibiotic 
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lacticin 3147, these two systems show similarities in their mode of action. Like Ltnα,15 Halα 
binds to a target on the surface of Gram-positive bacteria, and like Ltnβ,15 the addition of Halβ 
results in pore formation and potassium efflux. Using Halα mutants, its B- and C-thioether rings 
are shown to be important but not required for bioactivity, and a similar observation was made 
with mutants of Glu22, a residue that is highly conserved amongst several lantibiotics. These 
results suggest a dual mode of action in which Halα binds to lipid II, consequently preventing 
peptidoglycan biosynthesis. The Halα:lipid II complex then serves as a docking site for Halβ and 
once recruited, Halβ facilitates pore formation in the bacterial membrane. 
 
2.2. RESULTS AND DISCUSSION 
2.2.1 Haloduracin peptides function synergistically at a 1:1 ratio 
 Prior to assessing the specific activity of haloduracin against a panel of bacterial strains, 
the ratio of Halα and Halβ that yields maximum bioactivity was established. For this purpose, 
the ability of Halα and Halβ to inhibit cell growth at varying concentrations and ratios was 
examined. As indicated by the resultant isobologram (Figure 2.2), haloduracin is active at 
nanomolar levels against the indicator strain Lactococcus lactis HP, and Halα and Halβ display 
optimal activity at a 1:1 ratio. This ratio was determined as the lowest concentration of individual 
Halα or Halβ peptide that when combined, caused essentially complete growth inhibition 
(defined as >90%). The optimal synergy of Halα and Halβ at a 1:1 ratio is shared with other two-
peptide lantibiotic systems such as staphylococcin C55,7 plantaricin W,9 and lacticin 3147.16 
Although the haloduracin peptides are most active in combination, at much higher 
concentrations both Halα and Halβ displayed independent activity against the highly susceptible 
L. lactis HP strain. Using liquid media growth assays, Halα and Halβ had independent IC50 
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Figure 2.2. Isobologram indicating the concentrations of Halα and Halβ required to inhibit the growth of the 
indicator strain Lactococcus lactis HP. 
 
values of 1031 ± 13 nM and 3146 ± 81 nM, respectively, corresponding to a 50- to 100-fold 
decrease in efficacy as compared when the peptides were used together (Table 2.1). Though 
further experiments will be necessary to fully identify how these peptides are able to possess 
bioactivity in the absence of their counterpart, I speculate based on the structural similarity of 
Halα with mersacidin, that Halα ability to bind lipid II prevents peptidoglycan biosynthesis (vide 
infra). Halβ may exert its independent activity through a mechanism similar to nisin in the 
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absence of lipid II, in which the cationic Halβ peptide binds to anionic lipids of the cell 
membrane and the mass aggregation of Halβ monomers causes the transient formation of pore-
like structures in the bacterial cell membrane.17 
 
2.2.2 Comparison of antimicrobial potency of haloduracin and nisin  
 Agar diffusion growth inhibition assays were performed against a panel of Gram-positive 
and Gram-negative bacteria to obtain qualitative information regarding their sensitivity to 
treatment with haloduracin and nisin. These preliminary studies provided a binary outcome of 
either cell growth inhibition or proliferation. Strains that showed susceptibility toward 
haloduracin and nisin were subjected to growth inhibition assays in liquid media from which 
quantitative IC50 values were determined. Haloduracin and nisin shared a similar spectrum of 
inhibitory activity against a wide range of Gram-positive organisms, but lacked potency against 
the Gram-negative bacteria tested (Table 2.1). The concentrations of haloduracin and nisin 
required to inhibit several strains revealed that the effectiveness of the antimicrobial peptides is 
target strain dependent. For example, L. lactis HP was quite sensitive to both lantibiotics with 
IC50 values in the low-nanomolar range (29 and 14 nM for haloduracin and nisin, respectively). 
Some strains were more sensitive to haloduracin than to nisin (vancomycin-resistant 
Enterococcus) and vice versa (Micrococcus luteus). However, in most cases, only a two- or 
three-fold difference was observed in the IC50 values of haloduracin and nisin against a particular 
strain and overall, haloduracin and nisin activity was roughly equivalent against the panel of 
strains examined in this study.  
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Specific Activity Assessed by Liquid Growth Inhibition Assay 
 Haloduracin Nisin 
Strain Source IC50 (nM) 
MIC 
(nM) IC50 (nM) 
MIC 
(nM) 
Lactococcus lactis HP ATCC 11602 29 ± 21 73.4 14 ± 5 32.2 
Lactococcus lactis 481 CNRZ 481 63 ± 24 195 68 ± 6 127 
Lactococcus lactis 11454 ATCC 11454 308 ± 13 625 1,759 ± 400 2,800 
vancomycin-resistant Enterococcus faecium C33105* 265 ± 15 781 4,953 ± 187 12,500 
Bacillus anthracis Sterne 7702 Gut et al.18 363 ± 54 677 311 ± 216 417 
Bacillus subtilis ATCC 6633 262 ± 54 469 414 ± 165 820 
methicillin-resistant Staphylococcus aureus C5* 2,616 ± 396 4,690 1,459 ± 7 1,560 
Staphylococcus aureus ATCC 12600 1,144 ± 290 1,560 2,205 ± 523 4,690 
Staphylococcus epidermidis 15X Ekkelenkamp et al.19 273 ± 23 313 368 ± 152 508 
Micrococcus luteus ATCC 4698 520 ± 17 1,250 266 ± 92 410 
Streptococcus mutans ATCC 25175 1,837 ± 417 2,500 5,394 ± 732 12,500 
Activity Assessed by Agar Diffusion Growth Inhibition Assay 
Lactococcus lactis 117 CNRZ 117 + + 
Bacillus subtilis DB104 Kawamura et al.20 + + 
Bacillus subtilis LH45 Liu et al.21 + + 
Bacillus cereus Z4222 INRA Z4222 + + 
Bacillus cereus TZ415 INRA TZ415 + + 
Enterobacter cloacae 10-19C ATCC 29893 - - 
Escherichia coli DH5α UIUC-CMF - - 
Notes: ATCC: American Type Culture Collection; CNRZ: National Centre for Zootechnical Research; INRA: Institut National de la 
Recherche Agronomique; UIUC-CMF: University of Illinois Urbana-Champaign Cell and Media Facility. An * denotes clinical isolates from 
Carle Foundation Hospital (Urbana, IL). 
 
Table 2.1. Haloduracin and nisin share a similar spectrum of activity. 
 
2.2.3 Enhanced stability of haloduracin as compared with nisin  
 Nisin shows promising activities in vitro and in mouse models against several clinically 
relevant bacterial strains,22 however its inherent chemical instability23,24 and poor solubility at 
physiological pH have prevented therapeutic development. Nisin is produced by acidophilic 
Lactococcus lactis strains that grow and produce the compound in highest quantities in an acidic 
environment. Accordingly, nisin has been shown to exhibit highest solubility and stability at low 
pH.25 A number of degradation products of nisin have been reported.23,24,26 In a previous study, 
nisin stability was systematically monitored in low buffer concentrations over a pH range of 2 – 
8. The results showed that nisin is most stable at pH 3, and its stability was drastically 
compromised at both lower and higher pH values. Moreover, at pH 7 and 8, essentially complete 
degradation was observed in 10 days.27 
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 Haloduracin was discovered during a search for alkaliphilic lantibiotic producing 
bacteria.4 Its producer, Bacillus halodurans C-125, flourishes in basic environments with a pH 
greater than 9.5. For this reason, haloduracin may have improved chemical stability compared to 
nisin at neutral pH. We monitored the stability of Halα, Halβ, and nisin in a solution of low 
buffer concentration at pH 7.5 using HPLC and MALDI-TOF MS analysis (Figure 2.3a). Halα 
displayed remarkable stability with >90% of intact peptide remaining after 36 days. The globular 
nature of this peptide, in addition to its low number of residues capable of undergoing oxidation 
may contribute to its overall stability. Halβ showed moderate stability as compared with Halα 
and the degradation of this linear peptide occurred gradually over the course of this assay. 
Analysis of the additional peaks that were observed by HPLC show that the products are mostly 
the result of oxidation (M+16); breakdown of the oligopeptide chain was not observed. Nisin 
displayed the poorest stability of the three with many oxidation products observed at early time 
points followed by significant degradation of the peptide chain. The increased susceptibility 
towards oxidation of both Halβ and nisin may be due to their high number of thioether bridges. 
Agar diffusion assays were utilized to evaluate the antimicrobial activities of haloduracin and 
nisin over time, using the same samples that were analyzed by HPLC. As shown in Figure 2.3b, 
oxidation and degradation of nisin appears to have a much stronger deleterious effect on its 
bioactivity than oxidation of Halβ has on the antimicrobial activity of haloduracin. The observed 
activity is not due to solo activity of Halα, because Halα has much weaker activity in the 
absence of Halβ. It appears, therefore, that the structural requirements for Halβ activity are not 
critically dependent on unoxidized thioether crosslinks. 
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Figure 2.3. (a) Assessment of relative stabilities of Halα, Halβ, and nisin at pH 7.5 using HPLC and MS analysis. 
(b) Bioassay against Lactococcus lactis HP using the same samples as analyzed by HPLC in panel (a). The day of 
incubation is denoted above each well. Haloduracin: upper left (blue), nisin: lower left (red), nisin standards: right 
(yellow).  
 
2.2.4 Halα and Halβ act sequentially to affect target cells  
 To address the potential roles of the individual peptides of haloduracin, the order of 
binding events required to observe cell growth inhibitory activity was examined. When L. lactis 
HP target cells were incubated with Halα, followed by stringent washing to remove unbound 
peptide and subsequent incubation with Halβ, growth inhibition was observed (Figure 2.4). 
When the order of addition was reversed and cells were first exposed to Halβ, washed, and then 
treated with Halα, growth inhibition was not observed. When Halα and Halβ peptides were 
added at the same time, growth inhibition was observed. The described outcome of sequential 
addition is similar to that observed for the two-peptide lantibiotic lacticin 3147 (Ref.16) and 
suggests a scenario in which Halα binds a target on the outer surface of the bacterial cell and that 
the resulting complex is required for Halβ to exert its synergistic effect. 
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Figure 2.4. Sequential activity of haloduracin peptides against L. lactis HP. Growth curves are shown for (a) Halα 
treatment, washing, and Halβ addition. (b) Halβ treatment, washing, and Halα addition. Haloduracin: 1 μM, 500 nM, 
250 nM, 100 nM, 10 nM, 0 nM control, and nisin: 1 μM. When errors bars are not visible, the error was smaller than 
the size of the symbol used. 
 
2.2.5 Identification of lipid II as the specific molecular target of Halα  
 Antimicrobial activity at nanomolar concentrations suggests the involvement of a specific 
target molecule to which haloduracin binds to exert its biological activity. Lipid II has been 
identified as the docking molecule for several Class I and II lantibiotics (Figure 2.5).28 Based on 
shared structural features and homology with other lipid II binding lantibiotics, it has been 
suggested that Halα may serve as the primary mediator of target binding, whereas Halβ plays its 
major role in pore formation.15 Halα is proposed to inhibit the transglycosylases that form the 
glycan chains of the peptidoglycan by binding to lipid II on the outer surface of the bacterial 
membrane. An assay to observe lipid II binding by peptide antibiotic compounds has been 
recently developed by Professor Suzanne Walker and coworkers.29 In the laboratory of Professor 
Suzanne Walker, I performed experiments to assess the ability of several lantibiotics and other 
antimicrobial peptide compounds to bind lipid II. Using the major synthetic transglycosylase in 
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E. coli, PBP1b, and chemo-enzymatically prepared heptaprenyl lipid II substrate, I demonstrated 
that the Halα peptide does, in fact, inhibit bacterial transglycosylases by binding to lipid II. As 
anticipated, only the Halα component displayed lipid II binding with an IC50 of 9.58 ± 0.39 μM 
in experiments conducted with 4 μM lipid II. The Halβ component did not show any binding to 
lipid II even at concentrations greater than 100 μM when analyzed using the same conditions 
(Figure 2.5).  
 
 
Figure 2.5. In vitro transglycosylase assays using PBP1b, lipid II, and peptide inhibitor. (a) Naturally occurring lipid 
II and [14C]-GlcNAc labeled heptaprenyl lipid II analogue used for in vitro transglycosylase assay. (b) Halα peptide 
binds lipid II with an IC50 of 9.58 ± 0.39 μM (measured with 4 μM lipid II). (c) Halβ does not demonstrate binding 
at concentrations as high as 100 μM. When errors bars are not visible, the error was smaller than the size of the 
symbol used. The horizontal axes indicate the concentrations of peptide inhibitor used in reaction. The vertical axes 
indicate the relative amount of peptidoglycan formed in each reaction. The % PG (relative) is defined by 
[polymerized peptidoglycan / (total free lipid II + polymerized peptidoglycan)] normalized to 100%. 
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 The set of kinetic curves (Figure 2.6) show velocity versus substrate (lipid II) 
concentration for the PBP1b enzymatic reaction in the presence of 0, 6, and 8 μM Halα. In the 
absence of Halα, PBP1b displayed typical Michaelis-Menten kinetics. In the presence of Halα at 
either 6 or 8 μM concentrations, the reaction rate is negligible at low substrate concentrations; 
however, as soon as the substrate concentration exceeds a critical value, the rate increases and 
inhibition is largely overcome. These sigmoidal curves are consistent with a mechanism where 
Halα binds lipid II, effectively sequestering it such that it cannot be processed by PBP1b.29 Two 
vital pieces of information regarding this mechanism can be deduced from these inhibition 
curves. First, the reaction rate rapidly increases when the lipid II concentration exceeds one-half 
the concentration of Halα, and this result strongly suggests that Halα binds to lipid II in a 2:1 
ratio. Second, the transglycosylase reaction at low substrate concentrations was not observable in 
the presence of Halα, indicating that there is essentially no free lipid II in solution. Therefore, the 
apparent Kd for the interaction of lipid II and Halα must be very low. A Kd of 14.7 nM for the 
Halα-lipid II complex was calculated based upon the curve fits (see Figure 2.6 caption for 
equation) to the kinetic data and assuming a 2:1 binding stoichiometry. The data could not be fit 
to a 1:1 binding model. 
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Figure 2.6. The kinetics of transglycosylase inhibition indicates that Halα binds to lipid II with high affinity and in a 
2:1 Halα:lipid II ratio. Equation used for fitting: rate = Vmax*(((0.5*[I]-[S]+Kd)2 + 4*Kd*[S])0.5 - (0.5*[I] - 
[S]+Kd))/2/(Km+(((0.5*[I]-[S]+Kd)2+ 4*Kd*[S])0.5-(0.5*[I]-[S]+Kd))/2). See reference.30 
 
2.2.6 Membrane depolarization by haloduracin  
 Given the known pore forming activity of several lantibiotics, we examined the effect of 
haloduracin on membrane potential via flow cytometry with DiOC2, a membrane potential-
sensitive dye. Under physiological conditions, bacteria with intact cytoplasmic membranes 
maintain a membrane potential on the order of 100 to 200 mV (interior negative with respect to 
exterior).31 As shown in Figure 2.7, haloduracin rapidly (within 10 min) dissipated the membrane 
potential of B. subtilis cells in a concentration-dependent manner and at levels comparable to or 
lower than nisin. The extensive dissipation of membrane potential likely reflects damage of the 
cell membrane. 
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Figure 2.7. Haloduracin and nisin display comparable membrane depolarization activities. (a) Mean fluorescence 
intensity (MFI) for treatment of B. subtilis 6633 cells with haloduracin (blue) or nisin (red) over a range of 
concentrations. (b) Representative histogram of cell count vs. DiOC2 fluorescence intensity for haloduracin. 
Populations shown are for 0 nM (control, black), 25 nM (red), 250 nM (blue), 2.5 μM (violet), and 25 μM 
haloduracin (green). 
 
2.2.7 Pore formation by haloduracin and efflux of potassium ions  
 The effects of haloduracin on membrane potential prompted the investigation of 
potassium efflux using a cell impermeable, potassium-sensitive dye (PBFI). Treatment of an M. 
luteus cell suspension with Halα and Halβ triggered rapid efflux of intracellular potassium 
(Figure 2.8). Nearly identical results were observed for other Gram-positive strains such as 
Bacillus subtilis ATCC 6633. Potassium ion release was detected after a short lag time followed 
by a rapid signal increase that reached a plateau within 4-5 min. The observed potassium release 
was dose-dependent and efflux was not detected in untreated samples. When cells were treated 
with Halα or Halβ alone at low micromolar concentrations, no leakage of potassium was 
observed. These findings, in addition to the results obtained from the sequential binding study 
described above, prompted us to further investigate the individual roles of the haloduracin 
peptides in pore formation. When Halα and Halβ were added either together or when cells were 
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Figure 2.8. Potassium ion release from Micrococcus luteus cells induced by haloduracin and nisin. Reponses to 10 
μM (blue), 5 μM (green), 1 μM (red), 0.25 μM (orange), and 0 μM (gray) haloduracin or nisin. 
 
pre-incubated with Halβ for 5 min followed by the addition of Halα, a short lag was observed for 
20-30 s followed by rapid K+ efflux (Figure 2.9). However, when cells were pre-incubated with 
Halα followed by the addition of Halβ, rapid onset of efflux was observed and the lag was 
essentially absent. The combined results of potassium efflux and sequential binding assays 
suggest that the biological role of Halα involves binding to its target, resulting in a complex that 
serves as a docking site for Halβ to bind and form pores. A similar mechanism has been 
proposed for lacticin 3147 (Ref.15), and it may be that this is a general mechanism for two-
peptide lantibiotics for which the α-peptide has structural homology with mersacidin. 
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Figure 2.9. The effects on potassium release by pre-incubating Micrococcus luteus cells with either Halα or Halβ 
prior to addition of its counterpeptide. Shown in blue, (A) 5 μM Halα pre-incubation followed by 5 μM Halβ 
addition; in green, (B) 5 μM Halβ pre-incubation followed by 5 μM Halα addition; in red, (C) simultaneous addition 
of 5 μM Halα and 5 μM Halβ; in orange, (D) addition of 5 μM nisin; in violet, (E) addition of 5 μM Halα; in pink, 
(F) addition of 5 μM Halβ; and in gray (G) a control without haloduracin. Vertical line (black) indicates time of 
antibiotic addition. 
 
2.2.8 Production and evaluation of Halα analogues  
 The Halα peptide possesses a conserved CTLTXEC thioether bridge motif (B-ring), 
which is believed to be important for lipid II binding.4,32 This sequence is found in several class 
II lantibiotics including the single-peptide lantibiotics mersacidin and actagardine, as well as the 
Ltnα peptide from the two-peptide lantibiotic lacticin 3147.6,33,34 Residing within this ring is a 
highly conserved glutamate residue, which has been shown for mersacidin to be essential for 
binding to lipid II.35 
 Haloduracin biosynthesis was recently reconstituted in vitro4 providing a method for the 
production of haloduracin mutants.32 The effects of individually disrupting the B- and C- 
thioether rings of Halα were probed by the mutation of Cys23 and Cys27 to alanines, 
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Figure 2.10. General method for the in vitro production of Halα mutant peptides. The HalA1-Xa wt peptide was 
mutated at specific residues of the core peptide. Treatment of expressed and purified peptide with HalM1, followed 
by treatment with Factor Xa to proteolytically remove the leader peptide and HPLC purification resulted in the Halα 
mutant peptides as indicated. Shaded circles of Halα peptides indicate residues that were mutated in this study. 
 
respectively. Additionally, the conserved glutamate residing in the conserved B-ring was 
mutated to the isosteric glutamine (Figure 2.10). It has been shown previously that these 
mutations do not affect the formation of the other ring structures.32  
 All Halα mutants retained the ability to inhibit L. lactis HP cell growth in liquid medium 
when incubated in the presence of wild type Halβ (Figure 2.11a). Quantitative IC50 values 
highlight the importance of the thioether rings of Halα in the antimicrobial activity of 
haloduracin with IC50 values of 335 ± 29 nM (10-fold loss) and 1180 ± 48 nM (30-fold loss) for 
wt Halβ combined with Halα C23A and C27A, respectively. The highly conserved glutamate 
residue residing in the B-ring of Halα also was important but not required for activity and 
displayed an IC50 of 964 ± 76 nM for Halα E22Q in combination with wt Halβ.  
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 Maintaining biological activity at all in spite of the absence of conserved thioether rings 
present in Halα was unanticipated as these motifs are generally considered to be the basis of 
lantibiotic bioactivity, and disruption of a ring has often resulted in abolished activity.36 The 
relatively modest reduction of bioactivity of the highly conserved B-ring mutant (10-fold) was 
therefore most unexpected. The retention of activity for the C27A and E22Q mutants were also 
unexpected as these mutants had no activity in agar diffusion assays.32 Increased activity of two-
peptide lantibiotics in liquid media compared to solid agar media has been previously observed.37 
Additional studies were used to investigate whether the reduced potency of Halα mutants in 
combination with wild type Halβ is reflective of the ability of Halα mutants to bind lipid II or to 
effectively recruit Halβ for synergistic activity, or both. 
 As a comparison to the above growth inhibition study, these mutants were also subjected 
to analysis using the described PBP1b transglycosylase assay. These peptides were analyzed 
using identical reaction conditions as used for evaluation of Halα and Halβ. Loss of lipid II 
binding ability corresponded well to the diminished activity observed for the cell-based growth 
inhibition assays. Overall, all mutants displayed weaker ability to prevent peptidoglycan 
formation (Figure 2.11b). Of the mutations investigated, the E22Q proved most impactful. Not 
only was antimicrobial activity significantly reduced, but lipid II binding was essentially 
abolished. This mutant did not display any binding to lipid II even at high concentrations up to 
100 μM, thus corroborating the critical role of this glutamate residue in lipid II binding. The IC50 
values for lipid II binding with C23A and C27A were 50.7 ± 1.7 μM and 29.5 ± 3.5 μM with 4 
μM lipid II, respectively, corresponding to approximately 5- and 3-fold weaker inhibitory 
activity as compared to the in vivo isolated Halα peptide (IC50 of 9.58 ± 0.39 μM). The IC50 
values for Halα C23A and C27A lipid II binding were surprisingly reversed as compared with 
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the observed growth inhibition values. This observation may be due to different degrees to which 
lipid II binding occurs and the ability to recruit Halβ peptide. Introduction of the C23A mutation 
opened the B-ring which resembles the highly conserved CTLTEXC lipid II binding motif, 
thereby greatly diminishing its ability to bind lipid II. However, the C-terminal C-ring remained 
intact and this mutant remained quite effective in antimicrobial activity when used in 
combination with Halβ. The C27A mutation opened the C-ring of the peptide resulting in a 
flexible C-terminal tail. This mutant was still quite effective in lipid II binding; however, of the 
three mutants evaluated, this peptide displayed the weakest antimicrobial activity. It is likely that 
the C-ring may serve as the critical surface for Halα-Halβ interactions and the disruption of C-
terminal structure rigidity may result in the inability to effectively recruit Halβ. Further 
experiments such as solution NMR, isothermal calorimetry, or other techniques to investigate 
peptide-peptide interactions would greatly enhance our understanding of how two-peptide 
lantibiotic interact with each other. 
 
 
Figure 2.11. Deleterious effects of disrupting conserved thioether bridges and mutating conserved residues of the 
Halα peptide. (a) Impacts on antimicrobial activity against L. lactis HP cells. Treatment included Halβ wt peptide at 
a 1:1 Halα mutant:Halβ ratio. (b) Effects on lipid II binding ability using in vitro transglycosylase assay. For both 
panels: Halα E22Q (red), Halα C23A (green), Halα C27A (blue). 
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2.2.9 Influence of the leader peptide on the biological activity of Halα  
 The Halα mutants used in this work were made using a previously described in vitro 
reconstituted biosynthesis.4,32 In this process, the lanthionine synthetase HalM1 carries out a 
series of post-translational modifications on the HalA1 precursor peptide that result in the 
thioether crosslinks shown in Figure 2.1. The precursor peptide has an additional N-terminal 
extension of 41 amino acids called the leader peptide that is important for recognition by HalM1. 
In addition, the leader peptides of lantibiotic precursor peptides are generally believed to keep 
their products inactive while they are synthesized in the cytoplasm.38-42 For haloduracin, the 
bifunctional protease/transporter HalT removes the leader peptide. HalT has not been 
investigated to date, but in a related system for the lantibiotic lacticin 481, the dedicated protease 
domain of the transporter LctT removes the leader peptide of modified LctA precursor peptide 
and secretes the final product.40,43 Given the common belief that lantibiotics with their leader 
peptide still attached are inactive, it was surprising to find that Halα with its leader peptide intact 
(Leader-Halα) displayed antimicrobial activity against L. lactis HP when combined with Halβ 
(Figure 2.12a). It may be possible that the indicator strain secretes a protease that removes all or 
part of the leader peptide from a small subset of Halα molecules, resulting in the observed 
activity. Alternatively, Halα with its leader peptide attached may still engage bind to lipid II. To 
test the latter explanation, the peptidoglycan polymerization assay was conducted in the presence 
of leader-Halα. Indeed, this peptide proved a potent inhibitor of lipid II polymerization (Figure 
2.12b) with an IC50 of 7.1 ± 0.2 μM (with 4 μM lipid II). This potency was similar to the activity 
of wt-Halα (compare Figure 2.5b). The weaker antimicrobial activity of leader-Halα with wt 
Halβ when compared to Halα combined with Halβ (Figure 2.12a) is likely the consequence of 
less optimal synergy between the two peptides when the leader peptide is still attached to Halα.   
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Figure 2.12. Evaluation of the antimicrobial activity and enzyme inhibitory activity of Halα with its leader peptide 
attached. (a) Agar diffusion growth inhibition assay against L. lactis HP. Inhibitory activity was assessed using 
individual peptides (50 μM Halα, 50 μM Leader-Halα, and 50 μM Halβ, upper row) and in combination (at 50 μM) 
with 50 μM Halβ (lower row left and center). Nisin was used as a control at a 50 μM concentration (lower right). (b) 
Inhibition of the PBP1b-catalyzed formation of peptidoglycan (PG) by leader-Halα. 
 
2.2.10 Inhibition of spore outgrowth  
 Nisin inhibits the outgrowth of spores from several pathogenic Gram-positive bacteria 
including Bacillus and Clostridium.18,44,45 To determine if haloduracin is capable of preventing 
spore outgrowth, Bacillis anthracis (Sterne 7702) was selected as a model. Spores were 
germinated in Brain Heart Infusion (BHI) medium in the presence of a range of haloduracin or 
nisin concentrations (Figure 2.13a and b). For cultures containing low amounts of haloduracin 
(0.1 μM), differential interference contrast (DIC) microscopy revealed chains of vegetative 
bacilli after 5 and 10 h. However, no bacilli were present within cultures supplemented with 1, 
10, or 100 μM haloduracin. This dose dependent response shows that haloduracin was equally 
effective as nisin in the inhibition of B. anthracis spore outgrowth. Halα and Halβ inhibited 
spore outgrowth only at 100 μM when incubated independently, whereas vegetative bacilli were 
observed in cultures containing 10 μM or less of either peptide (Figure 2.13c and d). Hence, the  
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Figure 2.13. Inhibition of Bacillus anthracis spore outgrowth by haloduracin peptides in combination and 
separately. (a) Spore outgrowth inhibition by haloduracin (Halα and Halβ in combination). (b)  Spore outgrowth 
inhibition by nisin (control). (c) Spore outgrowth inhibition by Halα. (d) Spore outgrowth inhibition by Halβ. White 
scale bars equal 5.0 μm for all images. 
 
spore outgrowth inhibition depicted in Figure 2.13a is the result of a synergistic mechanism of 
both peptides. 
 
2.3. SUMMARY 
 This study illustrates the potent antimicrobial activity displayed in a synergistic manner 
by the two peptides of haloduracin. The activity of this two-peptide lantibiotic rivals that of 
nisin, which has been used worldwide as an effective preservative against food-borne pathogens. 
Haloduracin displayed higher stability than nisin at pH 7, which bodes well for potential 
commercial use. Despite significant differences in the structures of both the α- and β-peptides of 
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lacticin 3147 and haloduracin, these two compounds appear to operate by a similar mechanism 
that involves recognition of lipid II by the α-peptides of a target at the cell surface, namely lipid 
II, and utilization of the β-peptides for membrane permeabilization. As such, these compounds 
combine the two activities of nisin into separate peptides.17  
 Lipid II plays an essential role in bacterial cell wall biosynthesis by serving as the 
substrate for the bacterial cell wall biosynthetic enzymes. The transport of the fundamental 
disaccharide-pentapeptide building blocks of peptidoglycan across the plasma membrane where 
they can be incorporated into the growing cell wall is necessary for bacterial viability. Due to its 
critical role in this process, lipid II is the target for several antibiotics which include 
glycopeptides (teicoplanin, ramoplanin, and vancomycin) and both class I and class II 
lantibiotics.28 Lipid II is utilized in at least two different modes of action by these lantibiotic 
classes.17 Class II lantibiotics bind to lipid II and thereby prevent its use by cell wall biosynthetic 
enzymes to effectively inhibit peptidoglycan formation. Class I lantibiotics have also been shown 
to bind lipid II to inhibit peptidoglycan biosynthesis and additionally use this molecule to form 
pores in the membrane of target cells.  
 Haloduracin is a member of the growing subclass of two-component lantibiotics which 
fall into the Class II family. The antimicrobial activity at nanomolar concentrations displayed by 
haloduracin implies the involvement of a specific target molecule, which was predicted to be 
lipid II based on previous studies with other lipid II-binding lantibiotics.3 Sequence alignment of 
both Halα and Halβ peptides with other known two-component systems that target lipid II reveal 
significant similarities in lanthionine bridging patterns.4 In addition to homologies in ring 
patterns, Halα contains a remarkably conserved CTLTXEC motif which is believed to be 
essential for lipid II binding. This sequence is shared between several Class II members 
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including the single-component lantibiotics mersacidin33 and actagardine,34 as well as the Ltnα 
peptide from the two-component lantibiotic lacticin 3147.6  
 Our initial bioactivity studies suggested that Halα and Halβ peptides play two very 
different roles in the antimicrobial activity of haloduracin. The isobolographic analysis and 
specific activity studies indicate that both peptides are absolutely required to exert optimal 
antibiotic activity against sensitive strains. Though this contributes to the understanding of the 
stoichiometry of the bioactive complex, no information regarding the order of binding events can 
be inferred. Several lines of evidence from the cell-based assays suggest that the initial contact 
between haloduracin and the cell involves the Halα peptide. The outcome of the sequential 
addition of haloduracin peptides suggests a situation in which Halα binds lipid II on the outer 
surface of the bacterial cell. Upon the subsequent addition of Halβ to cells pre-treated with Halα 
inhibition of cell growth was observed. This inhibitory effect was not observed when the order of 
peptide addition was reversed, thus the peptides appear to operate in a sequential manner, a 
conclusion that is strengthened by the lipid II polymerization assays. 
 Binding of lipid II by the Halα peptide was confirmed by in vitro analysis of enzymatic 
conversion of lipid II into immature peptidoglycan by PBP1b. Halα was shown to bind tightly to 
its target with a nanomolar dissociation constant, whereas Halβ displayed no binding to lipid II 
even at high micromolar levels. The disruption of conserved thioether rings and binding motifs 
of Halα resulted in loss of binding efficiency to its lipid II target. This loss in binding due to 
disruption of conserved features was particularly evident for the highly conserved Glu22 residue 
whereby mutation to Gln resulted in complete abolishment of binding ability. Trends observed in 
the diminished binding to lipid II correlated well with in vivo growth inhibition assays where 
Halα mutants displayed much poorer antimicrobial activities than the wild-type α-peptide. 
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 The results of in vivo and in vitro experiments have enabled the first proposal of the mode 
of action of a two-peptide lantibiotic that takes into consideration the stoichiometry of the event 
(Figure 2.13). This three-step model of antibiotic activity of haloduracin begins with the (i) Halα 
peptide associating with the cell membrane and binding lipid II. (ii) The binding of lipid II 
induces or stabilizes a specific conformation of Halα resulting in a lipid II-Halα complex that 
facilitates the recruitment of Halβ. (ii) When bound to the lipid II-Halα complex, Halβ is able to 
adopt a transmembrane conformation which enables the formation of a defined pore. 
Haloduracin is a two-component lantibiotic which has now been shown to function in a 1:1 
Halα:Halβ ratio and bind lipid II in a 2:1 Halα:lipid II ratio. Collectively, the proposed ratio of 
components in the pore structure is 2:2:1 Halα:Halβ:lipid II.  
 
 
Figure 2.14. Proposed dual mode of action of haloduracin.  
 
 This work provides additional insights into lipid II binding by the peptides of a two-
component lantibiotic and reveals the stoichiometry of the haloduracin-lipid II pore. These 
results open the door for future investigations of the haloduracin-lipid II interaction including 
characterization of the complex via solution NMR spectroscopy and further transglycosylase 
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experiments—both of which may lead to the discovery of key motifs of lipid II that are critical 
for recognition by Halα and determination of the residues important for Halα-Halβ interactions. 
 The widespread prevalence of antibiotic resistance and the paucity of recent efforts 
towards discovery and development of antibiotics by the pharmaceutical industry have resulted 
in a great need for new antimicrobials. Members of the lantibiotic family of bacteriocins, and 
particularly those such as haloduracin which display greater stability and solubility at 
physiological pH, hold promising potential to help alleviate this problem and by understanding 
how these unusual peptides work, we may be able to rationally design highly effective antibiotics 
for future use. 
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2.4. EXPERIMENTAL 
2.4.1. Materials, cultures, and conditions 
 All chemicals and HPLC grade solvents were purchased from Sigma-Aldrich, unless 
otherwise stated. Tris, MOPS, and HEPES buffers were obtained from Fisher and α-cyano-4-
hydroxy-cinnamic acid from Fluka. All media including Luria Bertoni (LB), Brain Heart 
Infusion (BHI), Todd Hewitt (TH), Mueller Hinton Broth (MHB), and M17 supplemented with 
0.5% glucose (w/v) (GM17) was purchased from BD Biosciences. Factor Xa was purchased 
from New England Biolabs. Table 2.2 describes the bacteria strains, source, and culture 
conditions for all bacteria used for this study. All Halα mutants were prepared as described 
previously.4,32 
 
Strain Source Media Conditions  
Bacillus halodurans C-125 ATCC BAA-125 LB 30 °C, aerobic 
Lactoccoccus lactis HP ATCC 11602 GM17 30 °C, anaerobic 
Lactoccoccus lactis 481 CNRZ 481 GM17 30 °C, anaerobic 
Lactoccoccus lactis 11454 ATCC 11454 GM17 30 °C, anaerobic 
Vancomycin-resistant Enterococcus faecium C33105* BHI 37 °C, aerobic 
Bacillus anthracis Sterne 7702 Gut, I. M. et al.18 BHI 30 °C, aerobic 
Bacillus subtilis ATCC 6633 LB 30 °C, aerobic 
Methicillin-resistant Staphylococcus aureus C5* BHI 37 °C, aerobic 
Staphylococcus aureus ATCC 12600 BHI 37 °C, aerobic 
Staphylococcus epidermidis 15X Ekkelenkamp. et al.19 MHB 37 °C, aerobic 
Micrococcus luteus ATCC 4698 LB 37 °C, aerobic 
Streptococcus mutans ATCC 25175 TH 37 °C, anaerobic 
Lactococcus lactis 117 CNRZ 117 GM17 30 °C, anaerobic 
Bacillus subtilis DB104 Kawamura, F. et al.20 LB 30 °C, aerobic 
Bacillus subtilis LH45 Liu, W. et al.21 LB 30 °C, aerobic 
Bacillus cereus Z4222 INRA Z4222 LB 30 °C, aerobic 
Bacillus cereus TZ415 INRA TZ415 LB 30 °C, aerobic 
Enterobacter cloacae 10-19C ATCC 29893 LB 37 °C, aerobic 
Escherichia coli DH5α UIUC-CMF LB 37 °C, aerobic 
 
Notes: ATCC: American Type Culture Collection, CNRZ: National Centre for Zootechnical Research, INRA: Institut National 
de la Recherche Agronomique, UIUC-CMF: University of Illinois Urbana-Champaign Cell and Media Facility. An * denotes 
clinical isolates from Carle Foundation Hospital (Urbana, IL). 
 
Table 2.2. Growth conditions for strains used in this study. 
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2.4.2. Purification of haloduracin 
 A culture of Bacillus halodurans C-125 was grown in LB under aerobic conditions for 15 
h at 37 °C. Aliquots of the culture (300 μL) were removed and plated on Brain Heart Infusion 
agar plates (15 x 150 mm) and bacteria were grown for 96 h at 30 °C. Agar plates were gently 
washed with 70% isopropanol in sterile deionized water (v/v) to harvest cells from plates. The 
cell suspension was incubated for 24 h at 30 °C with vigorous agitation. Cells and debris were 
removed by centrifugation at 10k x g for 30 min at 4 °C and the haloduracin containing 
supernatant was concentrated via rotary evaporation. The resultant preparation was filtered using 
a 0.45 μm syringe filter to remove any residual cells or spores. Haloduracin peptides were 
purified by preparative HPLC performed on a Waters Delta 600 instrument equipped with a 
Phenomenex Jupiter Proteo C12 column (10 μm, 90 Å, 250 mm x 15 mm) equilibrated in 10% B 
(A: 0.1% TFA in water, B: 0.0866% TFA in 80% ACN/20% water (v/v)). The crude material 
was applied to the column and haloduracin peptides were eluted by maintaining the mobile phase 
at 10% B for 5 min, followed by an increase to 100% B over 50 min with a flow rate of 10.0 mL 
min-1. Under these conditions, Halα and Halβ eluted at 30.5 and 32 min, respectively. Halα 
fractions containing trace amounts of Halβ were further purified by lyophilization, resuspension 
of the peptide mixture in 50 mM TCEP and incubating at room temperature for 3 h. This material 
was re-applied to the preparative HPLC column and further purified using the conditions 
described above. The reduced Halα peptide retention time shifted to 27 min whereas the Halβ 
retention time remained unchanged at 32 min. All fractions were analyzed by mass spectrometry 
performed on a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer 
(Applied Biosystems Voyager DE-STR). A 1 μL aliquot of sample was combined with 1 μL of 
matrix consisting of saturated α-cyano-4-hydroxy-cinnamic acid matrix  in 50% ACN/50% 
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water with 0.1% TFA, and the total volume was spotted onto a MALDI target and dried under 
ambient conditions prior to MS analysis. The purified peptides were lyophilized to dryness and 
stored under N2 at −80 °C until further use (Figure 2.14). Typical yields for the peptides were 2 – 
3 mg Halα and 1.5 – 2 mg Halβ per liter of agar.  
 
 
Figure 2.15. MALDI-TOF mass spectra for purified Halα (blue) and Halβ (red) peptides. Halα expected [M+H]: 
3047.61, observed: 3046.48. Halβ expected [M+H]: 2332.88, observed: 2332.27. 
 
2.4.3. Purification of Nisin 
 A 500 mg sample of Nisaplin (Danisco) was suspended in 5 mL of 25% acetonitrile with 
0.1% TFA and was sonicated for 30 min, followed by centrifugation at 15,000 x g for 10 min to 
remove insoluble material. Nisin was purified by preparative HPLC using a Waters Delta 600 
instrument equipped with a Waters Delta-Pak C4 column (15 μm, 100 Å, 100 mm x 25 mm) 
equilibrated in 2% B (A: 0.1% TFA in water, B: 0.0866% TFA in 80% ACN/20% water (v/v)). 
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The soluble material was applied to the column and nisin was eluted by increasing to 100% B 
over 45 min with a flow rate of 8.0 mL min-1. Nisin eluted at 28 min. All fractions were analyzed 
by MALDI-TOF mass spectrometry as described above. The purified peptide was lyophilized to 
dryness and stored under N2 at −80 °C until further use (Figure 2.15). 
 
 
Figure 2.16. MALDI-TOF mass spectra for purified nisin. Expected [M+H]: 3355.20, observed: 3355.09. 
 
2.4.4. Preparation of Halα mutants 
 Purified HalA1-Xa peptides32 were dissolved (final concentration 0.3 mg mL-1) in HalM1 
assay buffer (50 mM Tris, pH 8.3) containing 10 mM MgCl2, 2.5 mM ATP, and 1 mM TCEP. 
HalM1 enzyme was added (10 μM final concentration) and reactions were incubated at 25 °C for 
3.5 h. At 3.5 h, complete conversion to dehydrated and cyclized product was observed in the 
soluble fraction as determined by MALDI-TOF MS. Insoluble material (unmodified peptide) 
was pelleted via centrifugation, and to the supernatant was added NaCl, CaCl2, and Factor Xa 
protease (final concentrations of 100 mM, 2 mM, and 1.5 μg mL-1, respectively). Cleavage 
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reactions were incubated at 25 °C for 6 h and were quenched with 1% TFA. Reactions were 
lyophilized to dryness and resuspended in 10% acetonitrile in water (v/v). Halα mutant peptides 
were purified using preparative HPLC and analyzed by MALDI-TOF MS as described above 
(Figures 2.17 – 2.19). IC50 values for Halα mutants were determined against the L. lactis HP as 
described below in combination with wild type Halβ peptide obtained from the producing strain. 
Both Halα and Halβ wild type peptides (in combination) and nisin standards were used as 
controls. 
 Modified HalA1-Xa peptide was prepared by Xiao Yang (Wilfred van der Donk 
Laboratory) via co-expression strategy described previously (Figure 2.20).46  
 
 
 
Figure 2.17. MALDI-TOF mass spectra for purified Halα C23A analogue. Expected [M+H]: 3016.55, observed: 
3017.96. 
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Figure 2.18. MALDI-TOF mass spectra for purified Halα C27A analogue. Expected [M+H]: 3016.55, observed: 
3017.83. 
 
 
 
Figure 2.19. MALDI-TOF mass spectra for purified Halα E22Q analogue. Expected [M+H]: 3047.63, observed: 
3049.71. 
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Figure 2.20. MALDI-TOF mass spectra for modified and purified HalA1-Xa. Expected [M+H]: 9612.69, observed: 
9612.55. 
 
2.4.5. Construction of the isobologram 
 Individual peptides were incubated at the concentrations indicated in Figure 2.2 with the 
indicator strain L. lactis HP and nisin standards were used as controls. Ninety-six-well microtiter 
plates were used for analysis. Serial dilutions of Halα and Halβ peptides were prepared in sterile 
deionized water (SDW).  For assay plates, the total volume in each well was 200 μL; the 
experimental wells contained 50 µL of diluted Halα and Halβ peptides at defined concentrations 
and 150 μL of a 1-in-10 dilution (approximately 1 x 108 CFU mL-1) of a culture of indicator 
strain diluted in fresh growth medium. In addition, each plate contained several blank (150 μL 
fresh growth medium and 50 µL SDW) and control wells (150 µL of untreated 1-in-10 diluted 
culture and 50 μL SDW). The optical density at 600 nm (OD600) was recorded at hourly intervals 
from 0 to 5 h with an additional measurement at 18 h. Plates were incubated at 30 °C under 
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anaerobic conditions. The triplicate readings were averaged, and blanks (growth medium and 
SDW only) were subtracted from these readings. 
 
2.4.6. Agar diffusion growth inhibition assays 
 Solid agar diffusion assays were used to assess antimicrobial activity. An overnight 
culture of indicator strain was grown in appropriate media and under optimal conditions (Table 
2.2). Ninety-six well agar plates were prepared by combining 20 mL of molten media agar 
(cooled to 42 °C) with 200 μL of dense overnight culture (approx 108-109 CFU mL-1). The 
seeded agar was allowed to solidify at 25 °C in a sterile Nunc OmniTray. An additional 20 mL of 
cooled molten media was combined with 200 μL of culture and poured over the lower solidified 
agar layer. A sterile 96-well PCR plate was placed in the molten agar upper layer, which was 
allowed to solidify at 25 °C. After sufficient solidification, the 96-well PCR plate was removed, 
and 15 μL of peptide solutions at a range of concentrations (10 μM, 5 μM, 1 μM, 500 nM, and 0 
nM) were separately dispensed into the newly formed wells. For assays with haloduracin 
peptides, a 1:1 ratio of Halα:Halβ was used. Plates were left at optimal growth temperature 
(strain dependent) for 15 h and antibacterial activity was qualitatively determined by the 
presence or absence of growth inhibition.  
 
2.4.7. Specific activity determination 
 Microtiter plates were used to determine the IC50 values (the concentration at which 50% 
growth inhibition is observed) of indicator strains. For assays with haloduracin, a 1:1 ratio of 
Halα:Halβ was used. Serial dilutions of Halα and Halβ peptides were prepared in sterile 
deionized water (SDW). Ninety-six well and forty-eight well microtiter plates (Corning Costar) 
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were utilized for anaerobic and aerobic strains, respectively (see Materials, Cultures, and 
Conditions). For 96-well plates, the total volume of culture in each well was 200 μL; the 
experimental wells contained 50 μL of diluted Halα and Halβ peptides at defined concentrations 
and 150 μL of a 1-in-10 dilution (approximately 1 x 108 CFU mL-1) of a culture of indicator 
strain diluted in fresh growth medium. In addition, each plate contained several blank (150 μL 
fresh growth medium and 50 μL SDW) and control wells (150 μL of untreated 1-in-10 diluted 
culture and 50 μL SDW). For 48-well plates, the total volume in each well was 300 μL; the 
experimental wells contained 75 μL of diluted Halα and Halβ peptides at defined concentrations 
and 225 μL of a 1-in-10 dilution (approximately 1 x 108 CFU mL-1) of a culture of indicator 
strain diluted in fresh growth medium. In addition, each plate contained several blank (225 μL 
fresh growth medium and 75 µL SDW) and control wells (225 μL of untreated 1-in-10 diluted 
culture and 75 μL SDW). The optical density at 600 nm (OD600) was recorded at hourly intervals 
from 0 to 5 h with an additional measurement at 18 h using a BioTek Synergy 2 plate reader. 
Plates were incubated according to optimal growth conditions (see Materials, Cultures, and 
Conditions). The triplicate readings were averaged, and blanks (growth medium and SDW only) 
were subtracted from these readings. Growth curves were developed using control (culture and 
SDW only) readings to ensure sufficient OD changes for accurate inhibition assessment. Curve 
fits for IC50 determination were produced by fitting the data with Origin8 software using the 
dose-response curve with the equation: y = A1 + (A2 – A1) / (1 +10(Logx0 – x)p), with p = variable 
Hill slope. A 50% growth inhibition was determined as half the final OD600 ± 0.05 of control 
culture. Nisin IC50 values were determined using identical procedures as described above.  
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 Specific activities for individual peptides were determined essentially as described above, 
except that peptides were evaluated independently. Specific activity was assessed against the 
indicator strain L. lactis HP and nisin standards were used as controls. 
 
2.4.8. Stability tests 
 Stock solutions of nisin, Halα, and Halβ were prepared in 50 mM MOPS, 100 mM NaCl 
at pH 7.5 with final peptide concentrations of 25 μM. These stocks were divided into 1 mL 
aliquots in sterile microcentrifuge tubes and were incubated at 25 °C. At the times indicated, an 
aliquot was analyzed by reverse-phase HPLC (Beckman Coulter System Gold) and MALDI-
TOF MS (Applied Biosystems Voyager DE-STR). Peptide aliquots were applied to a 
Phenomenex Jupiter Proteo C12 column (10 μm, 90 Å, 250 mm x 4.6 mm) equilibrated in 10% 
B (A: 0.1% TFA in water, B: 0.0866% TFA in 80% ACN/20% water (v/v)). Separation of intact 
peptide from degradation products was achieved by maintaining the mobile phase at 10% B for 5 
min, followed by an increase to 100% B over 50 min with a flow rate of 1.0 mL min-1. Fractions 
were collected and analyzed by MALDI-TOF MS as described above. Peak area corresponding 
to the intact peptide was determined via integration and plotted as a percentage relative to the 
peak area of peptide of day 0 (peak area of intact peptide day n / peak area of intact peptide day 
0). Agar diffusion growth assays were performed against L. lactis HP as described above. For 
haloduracin samples, 7.5 μL of Halα (day n) was combined with 7.5 μL of Halβ (day n) and the 
total 15 μL was dispensed in the well. For nisin samples, 7.5 μL of nisin (day n) was combined 
with 7.5 μL of sterile 50 mM MOPS, 100 mM NaCl at pH 7.5 and the total 15 μL was dispensed 
in the well. Positive controls included 15 μL of nisin at 20 μM, 10 μM, 1 μM, and 100 nM in 
sterile buffer. 
 92 
2.4.9. Sequential binding assays with Halα and Halβ 
 Lactococcus lactis HP cultures (in triplicate) were diluted 1-in-10 (approximately 1 x 108 
CFU mL-1), and 150 μL of each culture was added to 0.6 mL sterile microcentrifuge tubes which 
contained 50 μL of Halα or Halβ alone (at concentrations of 1 μM, 500 nM, 250 nM, 100 nM, 
10 nM, or 0 nM). Tubes were incubated at 25 °C for 20 min prior to centrifugation at 13,000 x g 
for 1 min. The supernatants were removed from each tube and cell pellets were washed twice in 
fresh GM17 media. Following the second wash, cell pellets were resuspended in 150 μL of fresh 
GM17. Cells treated with Halα alone were added to microtiter wells, which contained 50 μL of 
Halβ, and cells treated with Halβ alone were added to microtiter wells that contained 50 μL of 
Halα (at concentrations of 1 μM, 500 nM, 250 nM, 100 nM, 10 nM, or 0 nM). As controls, Halα 
and Halβ were used in combination and nisin was used at 1 μM concentrations. The microtiter 
plates were incubated at 30 °C and the optical density at 600 nm was recorded at hourly intervals 
from 0 to 5 h with an additional measurement at 18 h using a BioTek Synergy 2.  The triplicate 
readings were averaged, and blanks (150 μL of GM17 media and 50 μL SDW) were subtracted 
from these readings.   
 
2.4.10. Transglycosylase assays for lipid II binding studies 
 The gene encoding E. coli PBP1b was previously PCR amplified from MG1655 genomic 
DNA and cloned into pET21b vector (Novagen) as a C-terminal hexa-histidine (His6) fusion 
gene.47 The enzyme was expressed and purified by Tsung-Shing Andrew Wang or Tania Lupoli 
(Dan Kahne and Suzanne Walker Laboratory, Harvard University) as previously published.47 
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[14C]GlcNAc-labeled heptaprenyl lipid II analogue was chemo-enzymatically prepared by Dr. 
Yuto Sumida and Dr. Hiro Tsukamoto (Dan Kahne Laboratory) as previously described.48 
 For IC50 determinations, assays were carried out by separately incubating [14C]GlcNAc-
labeled heptaprenyl lipid II analogue (final concentration = 4 μM, typical specific activity = 288 
μCi/μmol) and peptide inhibitors (concentrations are indicated in the figure legends) in low-
binding microcentrifuge tubes (VWR) containing 9 μL of buffer consisting of 50 mM HEPES 
(pH 7.5), 10 mM CaCl2, 1,000 units/mL penicillin G, 0.2 mM octaethylene glycol monodecyl 
ether (decyl-PEG; Anatrace, Maumee, OH), and 11% DMSO (v/v) for 30 min at room 
temperature prior to PBP1b addition (to allow binding to occur). Reactions were started by 
adding 1 μL of PBP1b (from a solution freshly prepared by diluting the 50% glycerol stock 20-
fold into PBP1b dilution buffer consisting of 5 mM Tris (pH 8.0), 8 mM decyl-PEG) to the 
reaction mixture (final PBP1b concentration = 20-100 nM). Reactions were typically stopped 
after 30-45 min by adding 10 μL of ice-cold 10 mM Tris (pH 8.0) containing 10% Triton X-100. 
Quenched reactions were stored on ice until they were spotted on cellulose chromatography 
paper strips (3MM Whatman chromatography paper #3030-861, cut 1 cm width x 20 cm height) 
Products and starting material were separated using chromatography (isobutyric acid/1 M 
NH4OH, 5:3). The lipid II starting material migrates on the strip, while polymerized product 
remains at the origin. The paper strips were removed from chromatography chambers, allowed to 
dry, cut, and added to separate scintillation vials containing EcoLite(+) liquid scintillation fluid 
(MP Biomedical). Samples were analyzed using a LS6500 scintillation counter (Beckman 
Coulter). The percent radioactivity of the polymer product was calculated by comparing the 
amount of radioactivity that remains at the origin (peptidoglycan) to the total amount of 
radioactivity on the strip.   
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 For kinetics assays, reactions were carried out by separately incubating various 
concentrations (indicated in the figure legends) of [14C]GlcNAc-labeled heptaprenyl lipid II 
analogue (typical specific activity = 273 cpm/pmol) and Halα inhibitor (at 0, 6, or 8 μM) in low-
binding microcentrifuge tubes (VWR) containing 9 μL of buffer consisting of 50 mM HEPES 
(pH 7.5), 10 mM CaCl2, 1,000 units/mL penicillin G, 0.2 mM decyl-PEG, and 11% DMSO (v/v) 
for 30 min at room temperature prior to PBP1b addition (to allow binding to occur). Reactions 
were started by adding 1 μL of PBP1b (from a solution freshly prepared by diluting the 50% 
glycerol stock 20-fold into PBP1b dilution buffer consisting of 5 mM Tris (pH 8.0), 8 mM decyl-
PEG) to the reaction mixture (final PBP1b concentration = 20-100 nM). Reactions were typically 
stopped after 15 min by adding 10 μL of ice-cold 10 mM Tris (pH 8.0) containing 10% Triton X-
100. Quenched reactions were stored on ice until analyzed using paper chromatography and 
scintillation counting as described above. Equation used for fitting: rate = Vmax*(((0.5*[I]-
[S]+Kd)2 + 4*Kd*[S])0.5 - (0.5*[I] - [S]+Kd))/2/(Km+(((0.5*[I]-[S]+Kd)2+ 4*Kd*[S])0.5-(0.5*[I]-
[S]+Kd))/2). See reference.30  
  
2.4.11. Membrane potential assays 
 Membrane potential was measured using the membrane potential-sensitive dye, 3-3’ 
diethyloxacarbocyanine iodide (DiOC2, Molecular Probes/Invitrogen). B. subtilis ATCC 6633 
cultures (in triplicate) were grown to a density of 4 x 106 cells mL-1 and aliquots were transferred 
to tubes containing DiOC2 (final concentration of 300 nM). Cells were incubated with the dye for 
20 min at 30 °C under aeration conditions prior to the addition of either haloduracin or nisin at 
25 μM, 2.5 μM, 250 nM, 25 nM, and 0 nM. Following addition of peptides, cultures were 
incubated at 30 °C with aeration for an additional 10 min prior to analysis. The membrane 
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potential was assessed by measuring the B. subtilis-associated DiOC2 fluorescence by flow 
cytometry (BD Biosciences LSR II flow cytometer) with excitation at 488 nm with an argon 
laser and measurement of emission through a band-pass filter at 530/30 nm. A minimum of 
50,000 events were detected for each sample and the data was analyzed using the FCS Express 
3.00.0311 V Lite Stand-alone software. The data were plotted as the geometric mean of the 
fluorescence intensity (MFI). 
 
2.4.12. Potassium ion release assays 
 Potassium efflux was measured using the K+-sensitive fluorescent dye 1,3-
benzenedicarboxylic acid, 4,4’-(1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diylbis(5-
methoxy-6,2-benzofurandiyl))bis (PBFI, Molecular Probes/Invitrogen). A culture of 
Micrococcus luteus was grown to an OD600 of 1.0 and washed five times with assay buffer (5 
mM HEPES, 5 mM glucose, pH 7.2). Washed cells were resuspended in one-fifth the volume of 
assay buffer containing PBFI (final concentration of 10 μM) and aliquots were added to UV-
transparent microtiter plates (Nunc). Sample fluorescence (excitation = 346 nm, emission = 505 
nm) background data was collected (BioTek Synergy 2 plate reader, excitation filter 360/40, 
emission filter 508/20) until baseline signal was achieved, followed by the addition of 
haloduracin (Halα and Halβ in a 1:1 ratio) or nisin at 10 μM, 5 μM, 1 μM, 250 nM, and 0 nM. 
For pre-incubation studies of the haloduracin peptides, baseline signal was achieved followed by 
the addition of either Halα or Halβ to wells at the concentrations indicated and incubated for 5 
min prior to the addition of Halβ or Halα, respectively. 
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2.4.13. Inhibition of Bacillus anthracis spore outgrowth 
 B. anthracis spores at a concentration of 4.0 x 106 spores mL-1 were incubated in Brain 
Heart Infusion (BHI) medium supplemented with haloduracin (0.1, 1, 10, 100 μM at a 
Halα:Halβ ratio of 1:1) or 0.1 M MOPS (pH 6.8) as a control. For assessment of Halα and Halβ 
used independently, spores were incubated in BHI medium supplemented with the peptide at 0.1, 
1, 10, 100 μM or with 0.1 M MOPS (pH 6.8) as a control. As a positive control, spores were 
treated with nisin under the same conditions and concentrations as used for Halα and Halβ. 
Cultures were incubated at 37 °C under aeration conditions and ambient CO2 (0.03% CO2). At 0, 
5, and 10 h, samples were removed from the B. anthracis cultures and fixed by incubation in 3% 
formaldehyde (v/v) for 30 min at 37 °C. Samples were mounted on glass microscope slides in 
20% glycerol (v/v). Differential interference contrast (DIC) microscopy images were collected 
with an Applied Precision assembled DeltaVision epifluorescence microscope equipped with an 
Olympus Plan Apo x100 oil objective with a numerical aperture of 1.42 and a working distance 
of 0.15 mm. Images were processed with SoftWoRX Explorer Suite.  
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CHAPTER 3: NOVEL METHODOLOGIES IN THE PREPARATION OF 
LANTIBIOTICS AND BIOACTIVE PEPTIDES 
 
3.1. INTRODUCTION 
 One of the greatest sources of biologically active compounds is natural products. Often 
these compounds serve as platforms for the design and development of novel drugs and 
therapeutics. Microbes unknowingly provide scientists with numerous compounds showing 
promising activities and raising an increased focus on the discovery of novel natural products 
from these microscopic sources. However, while these compounds often display potent activity 
toward specific biological targets, additional pharmacological properties including solubility, 
stability, bioavailability, toxicity, and metabolism often necessitate improvement. Whereas small 
molecule pharmacophores are amenable to modifications via synthetic approaches, the structural 
complexity and often chemical sensitivity of natural products often precludes them from 
synthetic alterations required for further investigations such as structure-activity relationship 
studies. To overcome this barrier, a number of biotechnological and semi-synthetic approaches 
have been utilized in natural product research. Using these approaches, entire biosynthetic 
pathways or individual enzymes involved in the natural product biosynthesis are manipulated 
and utilized to afford diversified natural products with desired properties. 
 Historically, most peptide-based natural products with therapeutic properties are 
biosynthetically assembled via non-ribosomal peptide synthetase (NRPS) pathways.1,2 However, 
in recent years, it has become evident that there is a rapidly expanding class of peptide-based 
natural products with a wide range of biological functions that are produced by the ribosomal 
machinery.3-9 These types of compounds are ribosomally synthesized and post-translationally 
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modified to become molecules with a variety of activities including antimicrobial, antiviral, anti-
inflammatory, antitumor, and antiallodynic activities.10 These post-translational modifications 
release the peptides from the structural and functional constraints imposed on natural ribosomal 
peptides, while at the same time restricting conformational flexibility to allow better target 
recognition and increase metabolic and chemical stability.  
 The potent activity of lantibiotics and their unique modes of action make them attractive 
candidates as antimicrobial therapeutics. This class of polycyclic peptide natural products exhibit 
activity against a variety of clinically relevant bacterial pathogens including methicillin-resistant 
Staphylococcus aureus, vancomycin-resistant Enterococci, Listeria monocytogenes, and 
Clostridium difficile.11,12 Some lantibiotics have been shown to antagonize Gram-negative 
gastrointestinal pathogens such as Helicobacter pylori and Neisseria strains.13,14 Most of the 
biological activity assays and potency evaluations have been conducted in vitro, and there is little 
information available regarding their efficacy in vivo. Despite the evident promise lantibiotics 
hold for the treatment of these types of infections in the clinic, much development and 
optimization is necessary for the compounds to reach their full potential. 
 Lantibiotics possess remarkable structural complexity (see Figure 1.4). The synthesis of 
lantibiotic analogues to improve the pharmacological qualities of naturally occurring lantibiotics 
is typically not feasible. There have been a few reports of efforts toward lantibiotic total 
synthesis. Although the structure of nisin was established in 1971,15 the first total synthesis of the 
peptide was finally completed over 15 years later.16 In this report, 5 peptide segments of nisin 
were first prepared via solution-phase synthesis followed by the condensation of the 
independently prepared segments to afford full-length nisin in less than 1% total yield. 
Nonetheless, this synthetic feat has inspired attempts toward lantibiotic total synthesis in the past 
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decade including lactocin S17 and lacticin 3147 β peptide.18 In addition, reports on the synthesis 
of lantibiotic fragments have focused on construction of preformed thioether rings and other 
post-translational building blocks.19-28   
 In spite of the advances in synthetic approaches, the majority of efforts for lantibiotic 
production have focused on in vivo and in vitro bioengineering. These strategies take advantage 
of the ability and tolerance of the biosynthetic machinery to perform their catalysis in a variety of 
backgrounds including within heterologous hosts and in buffered solutions. In addition, these 
approaches capitalize on the promiscuity of the enzymes and their acceptance of mutagenized 
precursor peptide substrates. The gene-encoded nature of the lantibiotic precursor offers a key 
advantage over synthetic manipulation strategies in that simple, non-silent changes at the 
nucleotide level have a direct impact on precursor sequence and ultimately, the final lantibiotic 
compound. Therefore, the design and construction of analogues with improved therapeutic 
potential or for potential use as biochemical tools is feasible through genetic strategies. 
Additionally, the biosynthetic enzyme catalysts themselves are genetic in origin and are 
amenable to engineering and evolution strategies to improve their efficiencies and range of 
acceptable substrates. 
 In vivo bioengineering approaches and heterologous expression systems for the 
production of analogues have been developed for a number of lantibiotics including 
mersacidin,29 subtilin,30 Pep5,31 and nisin,32-36 and are discussed in detail in Chapter 1. Despite 
its widespread use and success, only a handful of analogues produced through in vivo 
bioengineering have displayed improved biological activity (Figure 3.1). The in vitro 
reconstitution of lantibiotic biosynthetic enzymes offers several key advantages over in vivo 
techniques, including the capacity to prepare combinatorial libraries of mutant LanA precursor 
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peptides, the ability to produce bioactive peptides in a cell-free environment to avoid 
complications arising from producer (or host) regulation and immunity, and the additional 
benefit to incorporate non-proteinogenic amino acids into the lantibiotic product.  
 
Figure 3.1. Lantibiotic analogues with improved specific activity. The dashed arrows indicate increased activity 
arising from the substitution of a single amino acid residue (light blue spheres), a combination of amino acid 
substitutions (red spheres), or non-proteinogenic amino acids (light green spheres). Adapted from Ref. 37. 
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 To date, the activities of several lanthionine synthetase enzymes representing several 
lanthionine-producing enzyme classes have been reconstituted in vitro (described in detail in 
Chapter 1.4.2.). This list includes enzymes of the LanM class: lacticin 481 synthetase (LctM) 
involved in lacticin 481 biosynthesis,38 cinnamycin synthetase (CinM) involved in the 
modification of cinnamycin,39 and HalM1 and HalM2 synthetases involved in the biosynthesis of 
haloduracin α  and β peptides, respectively.40 ProcM synthetase is an additional member of the 
LanM family and is involved in the biosynthesis of prochlorosins, a class of lantipeptides with 
currently undefined biological functions.41 The activities of a single member of the LanL class, 
VenL involved in the biosynthesis of venezuelin,42 and the LanKC class, LabKC involved in the 
biosynthesis of labyrinthopeptin,43 have also been successfully reconstituted in vitro. Finally, a 
monofunctional LanC cyclase enzyme, NisC, involved in maturation of nisin has demonstrated 
activity in vitro;44 however, in vitro reconstitution of its dehydratase partner, NisB, or any other 
enzymes in the LanB class, has not been successful. 
 Lacticin 481 is a lantibiotic produced by Lactococcus lactis CNRZ 481 that contains 
three Me(Lan) rings and one Dhb residue (Figure 3.2).45 The lacticin 481 precursor, LctA, is a 
51-amino acid peptide consisting of a C-terminal structural peptide that undergoes post-
translational modification, as well as an N-terminal leader peptide that is required for efficient 
processing by LctM.46,47 LctM is a bifunctional enzyme that introduces the post-translational 
modifications found in lacticin 481 by catalyzing both dehydration and cyclization steps.38 LctM 
was the first lantibiotic synthetase to be reconstituted in vitro and has since served as a model 
system for in vitro characterization of lantibiotic biosynthesis. Although its activity was 
reconstituted nearly a decade ago, very little is understood regarding the biological activity and  
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Figure 3.2. Biosynthesis of lacticin 481, a class II lantibiotic. The lacticin 481 precursor peptide (LctA) containing 
an N-terminal leader and C-terminal core peptide is transformed into a polycyclic thioether product through the 
action of a bifunctional enzyme (LctM) that dehydrates Ser to dehydroalanine and Thr to dehydrobutyrine, and 
subsequently catalyzes the Michael-type addition of Cys residues to these unsaturated amino acids. The leader is 
proteolytically removed from the modified core peptide by a bifunctional protease/transporter enzyme (LctT). 
Although the process is drawn as complete dehydration before the commencement of cyclization, recent studies 
suggest the dehydration and cyclization events may be alternating.48,49 
 
chemical properties of lacticin 481. In the past several years, several reports on LctM have 
focused on the characterization of the promiscuous substrate specificity of the enzyme towards 
truncated LctA mutant substrates.50-52 
 Only in more recent years have studies focused on engineering of the full length lacticin 
481 product.53 A significant challenge for the introduction of non-proteinogenic amino acids into 
lacticin 481 is the preparation of full length LctA prepeptides. To overcome this obstacle, a 
strategy was recently devised where a triazole-linked LctA peptide analogue was prepared via 
Cu(I)-catalyzed 1,3-dipolar cycloaddition of an alkyne-functionalized LctA leader peptide and an 
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azide-modified LctA structural region.52,54 By employing this technology, triazole-linked LctA 
substrates were prepared that contained mutations in the structural peptide with several non-
proteinogenic amino acids, including β-amino acids, D-amino acids, and N-alkyl glycine 
(peptoid) residues. An additional two mutations, Asn15Arg and Phe21His, were introduced to 
improve solubility of the final product.52,54,55 Starting with this more soluble version of the LctA 
precursor, a number of additional analogues were produced via an in vitro mutagenesis strategy 
(Figure 3.3).54 The bioactivity of these analogues were evaluated and it was demonstrated that 
many of the analogues had increased bioactivity compared to the parent compound.54 These 
efforts represented the first preparation of lantibiotic analogues containing non-proteinogenic 
amino acids. 
 Despite the invaluable potential of this approach, several shortcomings exist. Synthesis of 
the precursor peptide involves multiple reaction and purification steps following completion of 
SPPS, limiting process throughput and overall yield. Most class II single component lantibiotic 
precursor peptides are hydrophobic in nature, especially the residues of the leader peptide.10 As 
such, solubility of the full-length lantibiotic precursor peptide whether the leader and core 
peptide is joined via an amide bond or a triazole moiety, is often a major issue, especially for 
LctA. Furthermore, the process of first appending and then removing the 23-residue leader 
peptide is poorly atom efficient, and challenges the scalability of the reactions. Finally, leader 
peptide cleavage by LysC commercial protease is very low yielding and comes with the 
additional expense of losing the N-terminal lysine found in the natural product, thus producing 
lacticin 481 Δ1.53,54 
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Figure 3.3. In vitro mutasynthesis of lacticin 481 analogues. Synthetic substrate analogues were prepared using 
copper-catalyzed [2+3] cycloaddition of the leader peptide and core peptide fragments. The resulting LctA analogue 
was treated with LctM, which dehydrated the underlined Ser and Thr residues and incorporated the thioether rings 
shown. Endoproteinase LysC was then used to remove the leader peptide, but it also removes the first residue of 
native lacticin 481, Lys1. Adapted from Ref. 54. 
 
 
 Despite the ubiquitous nature of leader sequences in directing post-translational 
modifications in precursor peptides, the precise role of the leader, as well as the nature of its 
interaction with modifying enzymes, is not well understood (see Chapter 1.2.2 for additional 
information).10 The leader peptide was previously thought to be a recognition sequence 
necessary for substrate processing; however, studies on LctM have demonstrated that the core 
peptide is modified (albeit only one of four expected dehydrations) when the leader is absent.47 
Interestingly, providing the leader peptide in trans allowed for further modification of the core 
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peptide substrate in a distributive and directional fashion including dehydration and cyclization, 
though the extent of processing was still lower than the naturally occurring reactions with full-
length LctA substrate.47 Prolonged incubation times or higher concentrations of LctM did not 
afford fully-modified product. These data fit a previously proposed model in which an 
equilibrium population of LctM containing mostly inactive species in the absence of leader 
binding is shifted towards a population consisting more of an active conformation when the 
leader peptide binds (Figure 3.4).46 
 
 
Figure 3.4. The proposed role of the leader peptide in LctM activity based on several studies involving lacticin 481 
biosynthesis. It is proposed that the leader peptide shifts the equilibrium between inactive and active enzyme 
towards the active enzyme species. Adapted from Ref.46. 
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 This chapter is focused on the design, development, and implementation of a novel 
strategy for the production of lantibiotics and lantibiotic analogues. This strategy capitalizes on 
the substrate promiscuity of the LanM synthetases enzyme, LctM, and its ability to catalyze 
dehydration and cyclization events in vitro. By the generation of a “constitutively active” 
enzyme, a number of analogues of lacticin 481 were prepared and the mutations to this single 
component lantibiotic were evaluated in live cell and in vitro assays. This novel fusion enzyme 
displays overall better enzymatic properties with core peptide alone than wild-type LctM when 
provided with leader peptide and core peptide in trans. Single amino acid mutations were 
identified that resulted in improved bioactivity and inhibition of peptidoglycan biogenesis. In 
addition, the introduction of a single point mutation in the constitutively active LctM enzyme 
resulted in generation of a kinase-like enzyme with the potential to phosphorylate biologically 
relevant peptides at select serine or threonine residues, thus demonstrating potential for use in the 
preparation of a phosphopeptide library. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Design and development of constitutively-active fusion enzymes 
 The unanticipated ability of LctM to partially process the lacticin 481 core peptide in the 
absence of the leader peptide prompted additional studies of the unique role of the leader peptide 
during lantibiotic biosynthesis. The enhanced processing of the core peptide facilitated by the 
addition of leader peptide in trans suggested that the presence of the leader peptide conduces a 
shift in the equilibrium population from inactive to active enzyme species, thus leading to 
further, albeit incomplete, processing of the core peptide. An in trans approach for in vitro 
production of lantibiotics is advantageous from multiple aspects. As previously demonstrated, 
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non-proteinogenic amino acids could be incorporated into the core peptide for use in the 
production of unnatural amino-acid containing lantibiotic analogues.54 However, these studies 
required a triazole linkage to physically join the core and leader peptide together, whereas the in 
trans approach renders the challenging click chemistry unnecessary. An additional key benefit 
using the in trans strategy is that leader peptide removal via proteolysis would be avoided; 
thereby reducing the overall steps reported in traditional38-43,53 (i.e. reactions involving cloned 
heterologously expressed and purified full-length precursor and synthetase) and more recent54 
(i.e. reactions involving synthetically prepared precursor and cloned and heterologously 
expressed synthetase) methods of in vitro lantibiotic production. Unfortunately, LctM was only 
capable of dehydrating the core peptide at 3 of 4 possible sites under in trans reaction conditions 
and was not able to fully process the core peptide to generate bioactive material. Attempts at 
reaction optimization including longer incubation times or higher concentrations of LctM did not 
result in fully-processed, bioactive product. 
 The importance of the leader peptide for promoting efficient core peptide processing 
demonstrates its essential role as a vital element in the in trans synthetase reaction. As such, a 
novel strategy was developed to provide the leader peptide to the reaction without having to 
synthetically prepare and exogenously introduce it to the reaction. Rather than chemical 
synthesis and exogenous supplementation, the leader peptide would be provided to the reaction 
through genetic manipulation of the synthetase enzyme. The LctA leader peptide would be 
ribosomally synthesized as a fusion with the LctM synthetase enzyme joined together by a 
flexible linker. This effort to develop a constitutively active synthetase enzyme would take 
advantage of the demonstrated effects of the leader peptide on shifting the equilibrium 
population toward greater concentrations of active synthetase species. This approach would 
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enable the leader peptide to be provided in a “one-to-one” stoichiometry with the synthetase and 
promote a high local concentration of the leader peptide due to its physical connection with the 
enzyme. Additionally, this tethered approach would greatly simplify the components of the 
reaction as the leader peptide would not have to be exogenously added to or purified from the 
reaction mixture. 
 It has been demonstrated in previous studies that modification of a lantibiotic precursor 
by its LanM synthetase enzyme is possible regardless of the presence of additional amino acid 
sequences at the N-termini of both the precursor substrate and the enzyme. These sequences 
include many peptides, such as affinity tags utilized for purification, and it has been 
demonstrated that these terminal appendages are generally well-tolerated and do not adversely 
affect catalytic activity in either in vivo and in vitro backgrounds.38-42,53,56 Taking these results 
into consideration, a constitutively-active fusion enzyme, herein referred to as “ConFusion 
enzyme”, was designed with the LctA leader peptide fused at the N-terminal end of the LctM 
synthetase enzyme, joined by a small, flexible proteogenic linker consisting of glycine-serine 
repeating units (Figure 3.5a-b). The gene sequence encoding for the ConFusion enzyme was 
designed and constructed from naturally occurring  nucleotide sequences (LctA leader and LctM 
synthetase portions) as well as codon-optimized, synthetic sequences (linker portion). The newly 
constructed hybrid gene, lctCE-GSG, was subcloned into pET28b vector (Figure 3.5c). With 
anticipation that the length of the linker between leader peptide and the synthetase enzyme would 
have an effect on the constitutively active properties of the designed enzyme, the gene encoding 
this fusion was constructed with unique restriction sites that would allow for the excision of the 
sequence encoding for the linker and subsequent replacement with longer encoding sequences to 
produce progressively longer glycine-serine repeat linkers (Figure 3.5c). 
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 The lctCE-GSG gene, encoding for His6-LctCE-GSG was overexpressed in E. coli and 
purified via IMAC affinity chromatography. Synthetically prepared LctA(1-27) N15R F21H core 
peptide (prepared by Patrick Knerr) was incubated with purified His6-LctCE-GSG in the 
presence of Mg2+, ATP, and BSA in a Tris buffer (pH 7.5) and modification of the core peptide 
was observed (Figure 3.6). A fully modified product with four dehydrations was observed as a 
minor product. As observed with the previously published in trans assays,47 intermediates that 
underwent 1, 2, and 3 dehydrations were also present in the mixture, providing further evidence 
of a distributive mechanism by which lacticin 481 synthetase processes its substrate. The major 
product as determined by mass spectrometry was an intermediate with 3 dehydrations and one 
phosphorylation. Importantly, the mixture of material contained fully-modified −4 H2O product 
that demonstrated inhibitory activity against Lactococcus lactis HP indicator strain (Figure 3.6b). 
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Figure 3.5. The design and construction of a constitutively active lacticin 481 synthetase enzyme, “LctCE-GSn”. (a) 
Current model by which the modification enzyme LctM interacts with the full-length LctA precursor. It is proposed 
that the leader peptide shifts the equilibrium between inactive and active enzyme toward the active enzyme species 
thereby facilitating the post-translational modification of LctA core peptide. (b) The proposed model of a 
constitutively active lacticin 481 synthetase enzyme. LctA leader peptide is physically fused to the synthetase via a 
flexible proteinogenic linker. As with the model in panel a, it is proposed that the leader peptide shifts the 
equilibrium population toward the active enzyme species thereby enabling the modification of LctA core peptide 
without the need of leader peptide and core peptide being physically attached. (c) The genetic strategy for increasing 
the linker length between leader peptide and synthetase enzyme. 
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Figure 3.6. In vitro reconstitution of LctCE-GSG ConFusion enzyme. (a) MALDI-TOF mass spectra of LctA(1-27) 
N15R F21H core peptide before (black) and after (red) treatment with LctCE-GSG enzyme in the presence of Mg2+ 
and ATP. (b) Agar growth inhibition assay against the indicator strain, L. lactis HP, demonstrated that full-modifed 
bioactive material was present in the LctCE-GSG enzyme catalyzed reaction. Numbers above the peaks indicate the 
number of dehydrations. 
 
3.2.2 Effects of linker length on substrate processing 
 In an effort to create a better and more active lacticin 481 ConFusion enzyme, the linker 
region between the two components was expanded and the resulting enzymes were evaluated. 
Expansion of the linker was made possible via restriction endonuclease excision of the 
nucleotide sequence encoding for the GSG linker followed by ligation of a synthetically prepared 
double-stranded DNA (dsDNA) insert. The dsDNA insert consisted of oligonucleotides designed 
to self-hybridize with “preformed” overhangs for ligation at the vector restriction sites between 
the sequences encoding for the leader peptide and the synthetase (Figure 3.5c). The newly 
formed and expanded fusion genes were independently expressed in E. coli, purified, and utilized 
for modification of LctA (1-27) core peptide using the previously described assay conditions. 
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The products of the reactions and the relative activity of the enzymes were analyzed by MALDI-
TOF mass spectrometry (Figure 3.7). An enzyme with a linker encoding for 30 amino acids was 
able to convert the material to include a −4 H2O product as the dominant peak with a low amount 
of intermediates. As the linker length was decreased, so was the extent of processing of the core 
peptide. With enzymes possessing shorter linkers, a lower amount of −4 H2O product was 
observed and products of intermediate processing were present. Collectively, the results 
demonstrate that linker length has a positive correlation with the extent of processing. That is, as 
the linker length was extended, the enzyme was able to more completely modify the core 
peptide. 
 
  
Figure 3.7. Effects of linker length extension on the in vitro processing of LctA(1-27) N15R F21H core peptide by a 
series of lacticin 481 ConFusion enzymes. Shown are MALDI-TOF mass spectra of LctA(1-27) N15R F21H core 
following the termination of in vitro reactions after 1 h. Indicated to the right of the spectra is the enzyme utilized 
for the reaction. The final concentrations of substrate and enzyme was 20 µM and 2 µM, respectively. Numbers 
above the peaks indicate the number of dehydrations. *Asterisk indicates presence of phosphorylation. 
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 In each reaction, a −3 H2O + PO32- product was detected as a highly abundant 
intermediate species. It is not known why this intermediate is present in such high amounts, but it 
may reflect an overall low affinity of LctCE-GS30 for the nearly fully modified core peptide, 
thus leading to an incompletely modified product. It is evident in an LctCE-GS30 time course 
assay monitored by mass spectrometry, that the initial dehydration events occur more rapidly 
compared to the final event (Figure 3.8). It has been previously demonstrated that HalM2 
synthetase also displays an overall faster rate of reaction for early dehydration events and a 
slower rate as the modification of its substrate approaches completeness.48 It is necessary to point 
out that this apparent change in the rate of processing was observed even in a case with the use 
of full length substrate (leader attached to core). The C-terminal end of lacticin 481 core peptide 
is remarkably complex, with several overlapping thioether rings. The final dehydration of 
lacticin 481 core peptide is Thr24 which is adjacent to Cys25 and Cys26—two residues involved 
in the overlapping B and C-rings.48 As observed with HalM2 synthetase, it is likely that 
dehydration and cyclization events catalyzed by LctCE-GS30 also occur at the same time. In the 
ConFusion reaction, there is the additional hurdle of a leader-less substrate. It is has been 
proposed that the physical attachment of the leader peptide and core peptide is important for 
anchoring the core peptide near the synthetase active site during the modification process. 
Therefore, it is not surprising that the ConFusion enzyme system, with a leader-less substrate 
may have a challenged ability to catalyze the final dehydration event. Importantly, the 
unsaturated amino acid arising from Thr24 is not involved in a thioether ring––a modification 
that is generally essential for effective antimicrobial activity.8,11,57,58 
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Figure 3.8. Time course assay of LctA(1-27) N15R F21H core peptide with LctCE-GS30. Shown are MALDI-TOF 
mass spectra of LctA(1-27) N15R F21H core following the termination of in vitro reactions at the indicated time 
points. The final concentrations of substrate and enzyme was 20 µM and 2 µM, respectively. Numbers above the 
peaks indicate the number of dehydrations. *Asterisk indicates presence of phosphorylation. 
 
3.2.3 Comparison of LctCE-GS30:core and LctM:leader:core (in trans) activities 
 The relative abilities of LctCE-GS30 and LctM with leader provided in trans to catalyze 
the modification of LctA core peptide were evaluated using a quantitative HPLC assay. For this 
evaluation, the synthetases were first subjected to IMAC separation followed by gel filtration to 
yield highly uniform and purified enzymes (Figure 3.17). His6-LctCE-GS30 and His6-LctM were 
then utilized in the modification assays at a 10:1 substrate:enzyme ratio (final concentrations 20 
µM substrate and 2 µM enzyme). In the LctM reaction, the LctA leader peptide was 
supplemented at the same concentration as synthetase enzyme, thus mimicking the ConFusion 
enzyme where the leader and synthetase enzyme by design are present in stoichiometric 
equivalents. Under these conditions, there was no fully modified lacticin core peptide observed 
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in the LctM-catalyzed in trans reaction. Rather, products with −2 and −3 dehydrations were 
observed (Figure 3.9a). However, in the ConFusion enzyme reaction containing LctCE-GS30 
synthetase and core peptide, fully modified material was observed in as little as 30 min with the 
−4 H2O material as the major product within 180 min (Figure 3.9b). It should be noted that the 
disconnect between the extent of modification as determined by MALDI-TOF MS versus HPLC 
analysis is explained by ionization bias. In general, when using MALDI-TOF MS-based 
evaluation, modified precursor peptides tend to ionize better and falsely appear to be in higher 
abundance compared to linear peptide molecules. Similarly, phosphorylated intermediates tend 
to ionize better than non-phosphorylated intermediates. This bias is not observed with HPLC 
analysis where a more accurate representation of fully-modified, partially-modified, and starting 
material populations is achieved.  
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Figure 3.9. Comparison of the activities of LctM versus LctCE-GS30 by a quantitative HPLC time course assay. 
LctA(−1 - −24) leader peptide was provided in trans with LctA(1-27) N15R F21H core peptide for the LctM assay. 
LctA(1-27) N15R F21H core peptide was provided alone for the assay with LctCE-GS30. Shown are the retention 
time windows corresponding to the analytes detected and identified via mass spectrometry. Numbers above the 
peaks indicate the number of dehydrations. *Asterisk indicates presence of phosphorylation. 
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3.2.4 Preparation of Lacticin 481 analogues 
The ultimate goal of in vitro and in vivo reconstitution of lantibiotic biosynthesis is the 
production and identification of lantibiotic analogues with improved pharmacological properties. 
In a previous report, lacticin 481 wt produced by L. lactis CRNZ 481 was isolated and was 
demonstrated to possess high nanomolar inhibitory activity (IC50 = 750 nM) against L. lactis 
HP.54 This level of activity is modest compared to nisin,59 haloduracin,11 microbisporicin,9,60 and 
lacticin 314761 which all possess MICs in the low-nanomolar to high-picomolar range. As such, 
lacticin 481 serves as an ideal candidate for optimization and further improvement. Previous 
reports have demonstrated that lacticin 481 Δ1 (lacticin 481 lacking N-terminal Lys)38 and 
several analogues53,54 could be prepared via mutagenesis approaches to include proteinogenic 
and non-proteinogenic amino acid substitutions. Although analogues with improved bioactivity 
were identified, none of these analogues displayed greater potency in bacteria growth inhibition 
assays compared to in vivo isolated lacticin 481, thus suggesting the importance of the N-
terminal Lys residue.54 It is noteworthy that it has been previously demonstrated that reducing 
the overall cationic charge results in diminished activities of lantibiotics and other cationic 
peptides.29,33,53,62-72 
 The newly developed and optimized LctCE-GS30 ConFusion enzyme can enable for the 
first time, construction of full-length lacticin 481 analogues. Taking the results described 
previously,54 a number of full-length lacticin 481 analogues were prepared including N15R 
F21H, N15R F21Pal, N15R W19Nal F21H, and N15R W19Nal F21H (Pal = pyridynyl alanine, 
Nal = naphthyl alanine, Figure 3.10). The LctA (1-27) core peptide analogues were synthetically 
prepared by Patrick Knerr and the precursors were independently modified using purified His6-
LctCE-GS30 enzyme in the presence of Mg2+, ATP, and BSA in Tris buffer (pH 7.5). Fully-
122 
 
modified product with 4 dehydration and 3 cyclization events was observed in each reaction. 
Partially-processed intermediates were readily separated from the desired product via reversed-
phase HPLC (Figure 3.11). Authentic lacticin 481 (produced by L. lactis CNRZ 481) was 
evaluated along with the above analogues (vide infra) and was previously isolated from culture 
and purified by Juan Velasquez. 
 
 
 
Figure 3.10. Strategy for the production of lacticin 481 analogues containing proteinogenic and non-proteinogenic 
substitutions. Indicated at the top are primary sequences of the core peptides and chemical structures surrounding the 
lantibiotic indicate the type and location of amino acid substitutions. 
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Figure 3.11. MALDI-TOF mass spectra showing core peptide starting material (black) and full-length final product 
(red) for each lacticin analogue produced using LctCE-GS30 ConFusion enzyme. (a) Lacticin 481 N15R F21H, (b) 
lacticin 481 N15R F21Pal, (c) lacticin 481 N15R W19Nal F21H, and (d) lacticin 481 N15R W19Nal F21Pal. SM 
indicates starting material. 
 
3.2.5 Evaluation of in vivo and in vitro activities of lacticin 481 analogues 
The biological activities of fully-modified, full-length lacticin 481 analogues were 
evaluated using cell-based and in vitro inhibition assays. The inhibitory activity of each analogue 
was assessed against L. lactis HP indicator strain (Figure 3.12). The IC50 for lacticin 481 was 785 
nM, and aligns well with the previously reported IC50 (750 nM).54 Excitingly, two lacticin 
analogues, lacticin 481 N15R F21Pal and lacticin 481 N15R F21H, displayed greater inhibitory 
activity compared to in vivo lacticin 481 with IC50 values of 213 and 428 nM, respectively. The 
triply substituted analogues were not as active as in vivo lacticin 481 under the conditions tested.  
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Figure 3.12. Cell growth inhibition curves for lacticin 481 wild-type and analogues tested against L. lactis HP. Inset 
table indicates the calculated IC50 value (defined as the concentration of peptide required to inhibit 50% of cell 
growth) and the MIC (minimal inhibitory concentration) for all peptides tested. 
  
An in vitro transglycosylase inhibition assay was used to further characterize the impact 
of the amino acid substitutions on biological function as described in Chapter 2 for haloduracin. 
As observed with the cell growth inhibition assays against L. lactis HP, the same two analogues 
(N15R F21Pal and N15R F21H) displayed an enhanced ability to inhibit the transglycosylase 
reaction. A summary of the results is displayed in Figure 3.13. Overall, similar trends of efficacy 
were observed in both the assay against whole bacterial cells and in the transglycosylase in vitro 
assay. The combined results and the correlations shared between the two types of assays 
described above highly suggest that inhibition of peptidoglycan biosynthesis is the primary 
pathway by which lacticin 481 exerts its antimicrobial activity, and that improvement of the 
antimicrobial activity is correlated with increased binding affinity with lipid II. 
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Previous studies have demonstrated that all three thioether rings are essential for 
antimicrobial activity of lacticin 481; though the precise partner composition of the 
conformationally-stabilizing bridges is not critical (i.e. Lan could be substituted for MeLan and 
vice versa).53 It is currently not known at the molecular level which thioether rings and the 
residues within those rings are important for lacticin 481 and lipid II interactions. The studies 
described in this chapter have focused rather on substitution of amino acids at specific sites that 
do not affect the overall topology of the overlapping rings. The introduction of an additional 
positive charge into the lacticin 481 compound by the Asn to Arg substitution at position 15 
resulted in greater inhibitory activity against whole cells and in the transglycosylase assay. This 
result was not unanticipated provided the influence of positive charges on the activity of 
lantibiotics62 and other cationic peptides.65 In addition, the substitution of the aromatic Phe 
residue at position 21 for amino acids with basic aromatic side-chains (His or Pal) resulted in 
analogues with further enhancement in specific activity, suggesting that electrostatic interactions 
at this site may play a key role in the ability of these analogues to effectively bind their target. 
Furthermore, substitution of the non-basic aromatic Trp at position 19 with an amino acid 
bearing non-heterocyclic aromatic side-chain (Nal) adversely impacted the specific activity of 
the compound. When both non-proteinogenic amino acids Nal and Pal were incorporated at 
positions 19 and 21, respectively, an analogue was produced with the weakest inhibitory 
properties. Further experiments including analyses to investigate precise molecular interactions 
(i.e. NMR or crystallography) will be required to further distinguish all contributing factors of 
the bioactivity of lacticin 481.  
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Figure 3.13. Inhibition curves for lacticin 481 wild-type and analogues tested in an in vitro transglycosylase 
inhibition assay. Inset table indicates the calculated IC50 value (defined as the concentration of peptide required to 
inhibit 50% of peptidoglycan formation (PG). Lipid II concentration was 4 µM. 
 
3.2.6 Mutagenesis to produce mutant kinase-like enzymes 
The promiscuous activities of several lantibiotic synthetases have been exploited for the 
production of mutants with correct dehydration and cyclization along the modified core peptide. 
Recently, key active site residues of LctM shown to be responsible for elimination of the 
phosphorylated intermediate during the dehydration process were identified in an enzyme 
mutagenesis study.55 It was demonstrated that mutations at either positions Arg399 or Thr405 led 
to the production of a mutant synthetase enzyme with phosphorylation capability, but little 
subsequent elimination activity. Peptides attached to the C-terminus of the LctA leader peptide 
were utilized to probe the phosphorylation substrate scope of the T405A kinase-like enzyme and 
127 
 
it was demonstrated that LctM T405A possesses a remarkable ability to phosphorylate Ser 
residues in many diverse substrates.73 However, just as in previous studies involving LctM-
catalyzed modifications, substrates required the physical attachment to the LctA leader peptide, 
which must be subsequently cleaved to yield a useful phosphopeptide product. 
The T405A and R399M mutations were independently introduced into the LctCE-GS30 
enzyme and the resulting enzymes were evaluated for their phosphorylation activity. Incubation 
of either enzyme with LctA (1-27) N15R F21H core peptide in the presence of Mg2+, ATP, and 
BSA in Tris buffer (pH 7.5) resulted in a multiply phosphorylated product (Figure 3.14). Up to 3 
phosphorylations were observed, and the major product was that which was doubly 
phosphorylated. The promiscuous nature of LctCE ConFusion synthetase in combination with 
the additional benefit of not requiring the physical attachment to the leader peptide prompted 
further investigations to explore the utility of the enzyme for the production of a phosphopeptide 
library.  
 
3.2.7 Efforts toward creating phosphopeptides 
Diverse peptide substrates were designed based on biologically relevant and 
commercially available phosphopeptides that have been previously utilized in studies focused on 
kinase/phosphatase signaling pathways or that have been shown to be substrates for 
phosphorylation by LctM T405A when attached to the C-terminal end of the LctA leader peptide 
(Table 3.1).73 The substrates were prepared by Patrick Knerr via SPPS methodology and the 
ability of LctCE-GS30 T405A to phosphorylate the substrates was assessed by subjecting the 
substrates to the reaction conditions described above and monitoring the reactions by MALDI- 
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Figure 3.14. Phosphorylation of LctA(1-27) N15R F21H by mutated ConFusion enzyme. Shown are MALDI-TOF 
mass spectra before (black) and after (red) treatment with LctCE-GS30 T405A enzyme in the presence of Mg2+ and 
ATP. 
 
TOF MS. Unfortunately, only three of ten substrates tested were phosphorylated by the mutant 
LctCE-GS30 enzyme (Table 3.1). The best substrate among the ten selected was the 
AKT/PKB/RAC peptide, which was phosphorylated at a single site (Figure 3.15). Although the 
promiscuity of the LctCE-GS30 T405A or R399M enzymes was not at the level of the LctM 
T405A or R399M counterpart, the kinase-like ConFusion enzyme methodology does have the 
key benefit of not needing leader peptide attachment or genetic manipulation to fuse the substrate 
of interest to the C-terminal end of the LctA leader peptide.73 Moreover, the phosphorylation 
reaction with mutant LctCE-GS30 T405A has not been optimized and may be better tuned to 
promote greater extent of phosphorylation and enable a broader peptide substrate scope. 
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Peptide Substrate Sequence Phosphorylation? 
AKT/PKB/RAC74 ARKRERTYSFGHHA Yes 
Calcineurin/PP2B75 DLDVPIPGRFDRRVSVAAE No 
PKCδ76 RDMRQTVAVGVIKA No 
PKCμ77 AALVRQMSVAFFFK Yes 
PKC78 RRGRTGRGRRGIFR No 
PKG79 RKRSRAE No 
(previously described)73 RWVRSALLI Yes 
(previously described)73 RLIKSFAYV No 
(previously described)73 RLIKTFAYV No 
(previously described)73 LRRASVA No 
 
Table 3.1. Ten potential substrates for phosphorylation by LctCE-GS30 T405A were prepared and tested. The 
primary peptide sequence for each substrate is shown. Sites of potential phosphorylation are bolded and underlined. 
 
The ability to introduce and remove protein phosphorylations is a powerful means to 
investigate and control signaling events and cascades in many organisms and model systems. 
The unique kinase-like activity of LctCE-GS30 T405A and the elimination activity of wild-type 
LctCE-GS30 open the door of opportunity to control the presence and absence of protein 
phosphorylation in model systems. The non-phosphorylated peptide “ARKRERTYSFGHHA” is 
a substrate for AKT/PKB/RAC-protein kinases which have been identified as proto-oncogenes. 
Previous studies have revealed that AKT regulates a number of cellular functions including cell 
survival, cell growth, cell differentiation, and cell cycle progression.74  
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Figure 3.15. Phosphorylation of the AKT/PKB/RAC peptide by LctCE-GS30 T405A enzyme. Shown are MALDI-
TOF mass spectra before (black) and after (red) completion of reaction. An 80 Da mass increase indicates a single 
phosphorylation of the peptide. 
 
Through the use of LctCE-GS30 wild-type, the phosphorylation of the AKT/PKB/RAC 
peptide was rapidly removed via the elimination activity of the enzyme, thereby generating the 
dehydrated fragment of AKT/PKB/RAC (Figure 3.16). Thus a strategy to phosphorylate and 
eliminate peptides without the need to append a leader sequence or supply one exogenously has 
been demonstrated. A key consideration and limitation of this technique is the concomitant 
dehydration that occurs with elimination of the phosphate group which may introduce a non-
natural, electrophilic amino acid at a critical regulatory site. On the other hand, the 
electrophilicity of the dehydro amino acid thus generated may provide a handle to localize 
phosphorylations as demonstrated previously.80,81 
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Figure 3.16. Elimination of the phosphate group of phosphorylated AKT/PKB/RAC peptide by LctCE-GS30 wild-
type enzyme. Shown are MALDI-TOF mass spectra before (black) and after (red) completion of reaction. An 98 Da 
mass decrease indicates elimination of phosphorylation and concomitant dehydration of the peptide. 
 
3.3. SUMMARY 
 Two key limitations of traditional in vitro biosynthesis of lantibiotics are the difficulty to 
incorporate non-proteinogenic amino acids and the challenges associated with leader peptide 
removal during the final steps of lantibiotic maturation. The latter limitation has been historically 
addressed by two methods. The first involves mutagenesis of the precursor peptide to include 
commercial protease sites, which can have deleterious implications including reduced solubility 
and heterologous expression levels, diminished precursor processing, and non-specific 
proteolytic cleavage after modification of the core peptide. Alternatively, the precursor leader-
core peptide junction can be left unaltered, but a commercial protease must be selected to remove 
as much leader peptide as possible without excision of core peptide residues. Unfortunately, as 
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demonstrated in the case previously described, LysC protease removes a critical N-terminal Lys 
residue during this final step in lacticin 481 preparation.  
 Taking the current model of LctA leader peptide and LctM synthetase interactions, a 
novel strategy was developed that utilized a hybrid protein consisting of the LctA leader peptide 
fused to LctM synthetase via a flexible, proteinogenic linker. The constitutively active properties 
of this enzyme were demonstrated and its ability to catalyze full modification of lacticin 481 core 
peptide was shown. In addition, this novel enzyme was able to process the core peptide faster 
and further to completion compared to an in trans reaction utilizing LctM and LctA leader 
peptide in a one-to-one ratio. A number of analogues of lacticin 481 were prepared and the 
mutations were evaluated for antimicrobial activity against L. lactis HP cells and for their ability 
to inhibit transglycosylation in a lipid II polymerization assay. Two analogues displayed 
improved activities over authentic lacticin 481 isolated from the producing organisms. In 
addition, the introduction of a single point mutation in the constitutively active LctM enzyme 
resulted in the generation of a kinase-like enzyme with modest ability to phosphorylate 
biologically relevant peptides. To date, a ConFusion enzyme with a linker length of 30 amino 
acids has demonstrated remarkable ability to modify synthetic core peptides. Further 
optimization of the enzyme to include longer linker lengths as well as optimized positioning (i.e. 
N-terminal versus C-terminal) and fine-tuning of reaction conditions open opportunities for 
further development in this area of protein engineering. 
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3.4. EXPERIMENTAL 
3.4.1. Materials, strains and plasmids, and general methods 
Materials. 
  All oligonucleotides were purchased from Integrated DNA Technologies. Restriction 
endonucleases, DNA polymerases, and T4 DNA ligase were purchased from New England 
Biolabs or Invitrogen. Media for bacterial culture and chemicals were purchased from Fisher 
Scientific, Sigma Aldrich, or CalBiochem, unless noted otherwise, and used without further 
purification.  
 
Strains and Plasmids. 
 The indicator strain, Lactoccoccus lactis HP ATCC 11602 was obtained from American 
Type Culture Collection, Manassas, VA. Escherichia coli DH5α (UIUC Cell Media Facility) 
was used as host for cloning and plasmid propagation, and E. coli Rosetta 2 (DE3) (Novagen) 
was used as a host for protein expression. Cloning vectors were obtained from Novagen. 
 
General Methods. 
 All molecular biology manipulations were carried out using standard techniques. 
Polymerase chain reaction (PCR) amplifications were carried out using an automated 
thermocycler (C1000, BioRAD). DNA sequencing was performed using appropriate primers by 
the Biotechnology Center (University of Illinois at Urbana-Champaign, UIUC). GC-MS analysis 
was performed at the Roy J. Carver Metabolomics Center (UIUC). LC-ESI-Q/TOF MS analyses 
were conducted using a Synapt MS system equipped with an Acquity UPLC (Waters). MALDI-
TOF MS analyses were conducted at the Mass Spectrometry Facility (UIUC) using a Voyager 
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DE-STR (Applied Biosystems). For MALDI-TOF MS analysis of salt-free samples, a 1 μL 
aliquot of analyte was combined with 1 μL of matrix (saturated α-cyano-4-hydroxy-cinnamic 
acid matrix  in 50% ACN/50% water with 0.1% TFA), and the total volume was spotted onto a 
MALDI target and dried under ambient conditions prior to analysis. Salt containing samples 
were desalted using ZipTipC18 (Millipore), eluted with 4 μL of matrix, and 2 μL was spotted onto 
a MALDI target and dried as described above. 
 
3.4.2. Construction of LctCE-GSG expression plasmid 
 The plasmids pET15b LctA and the pET28b LctM were isolated from E. coli DH5α cells 
previously transformed with the constructs. The partial gene encoding for LctA leader, GSG 
linker, and the 5’-end of LctM was prepared via overlap extension PCR (Figure 3.5). The 
forward megaprimer (FMP) was PCR amplified by 30 cycles of denaturing (94 °C for 1 min), 
annealing (50 °C for 1 min), and extending (72 °C for 1 min) using His6 NheI Ldr FP (5’- 
CGCGGCAGCGCTAGCAAAGAACAAAAC -3’ and LctCE-GSG RP: 5'- 
TTGGTAAGTCTTTTTTTTCATCTGCAGACCAGAACCACTAGTTGCACCTAAAATAAG
GTCCAA -3' as primers and pET15b LctA as template (bold indicates NheI restriction site, 
underlined indicates SpeI and PstI restriction sites). The reverse megaprimer (RMP) was PCR 
amplified by 30 cycles of denaturing (94 °C for 1 min), annealing (50 °C for 1 min), and 
extending (72 °C for 1 min) using LctCE-GSG FP: 5'- 
TTGGACCTTATTTTAGGTGCAACTAGTGGTTCTGGTCTGCAGATGAAAAAAAAGACT
TACCAA -3' and LctM HindIII RP: 5’- ATCTTTTATTTCTTCAAAAGCTTTACCTGTACTC 
-3’ and pET28b LctM as template (bold indicates HindIII restriction site, underlined indicates 
SpeI and PstI restriction sites). The PCR mixtures included 1X PCR Buffer (Invitrogen), dNTPs 
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(0.25 mM each), MgCl2 (1.5 mM), Platinum Taq DNA polymerase (0.05 U/μL), and primers 
(0.5 μM each). Amplifications were confirmed by 2% agarose gel electrophoresis, and the PCR 
products were purified using a QIAQuick PCR Purification Kit (QIAGEN). The overlapping 
products from the FMP and RMP reactions were combined in equal amounts and extended by seven 
cycles of denaturing, annealing and extending using the same PCR conditions. Following the 
extension, the His6 NheI Ldr FP and LctM HindIII RP primers were added (final concentration 2 
μM) and the mixture was subjected to another 25 cycles of denaturing, annealing and extending. 
Amplification of the final PCR product was confirmed and purified by 2% agarose gel 
electrophoresis. The resulting partial gene DNA insert and the original pET28b LctM vector were 
digested with NheI and HindIII at 37 °C for 5 h. The digested insert and vector products were 
purified by 2% and 1% agarose gel electrophoresis, respectively, and gel extracted using a QIAquick 
Gel Extraction Kit (QIAGEN). The resulting DNA products were ligated at 25 °C for 3 h in 1X T4 
DNA Ligase buffer with T4 DNA Ligase (0.7 U/μL). E. coli DH5α cells were transformed with 2.5 
μL of the ligation product by heat shock, and cells were plated on LB-kanamycin agar plates and 
grown for 15 h at 37 °C. Several colonies were picked and used to inoculate separate 5 mL cultures 
of LB-kanamycin medium. The cultures were grown at 37 °C for 12 h, and plasmids were isolated 
using a QIAprep Spin Miniprep Kit (QIAGEN). The sequences of the resulting plasmid products 
were confirmed by DNA sequencing. 
  
3.4.3. Expression and purification of His6-LctCE-GSG 
 E. coli Rosetta 2 (DE3) cells were transformed with the pET28b LctCE-GSG construct 
via electroporation. A single colony transformant was used to inoculate a 30 mL culture of LB 
supplemented with 50 μg/mL kanamycin. The culture was grown at 37 °C for 12 h and was used 
to inoculate 3 L of LB containing 50 μg/mL kanamycin, and cells were grown at 37 °C to OD600 
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≈ 0.6. The culture was incubated at 4 °C on ice for 20 min, then IPTG was added to a final 
concentration of 0.5 mM and the culture was incubated at 18 °C for an additional 16-20 h. Cells 
were harvested by centrifugation at 12,000 ×g for 15 min at 4 °C, and the pellet was resuspended 
in 30 mL of start buffer (20 mM Tris (pH 7.6), 500 mM NaCl, 10% glycerol) and stored at −80 
°C.  
 All protein purification steps were performed at 4 °C. The cell paste was suspended in 
start buffer and the cells were lysed using a high pressure homogenizer (Avestin, Inc.). Cell 
debris was pelleted via centrifugation at 23,700 ×g for 20 min at 4 °C. The supernatant was 
injected via a superloop onto a fast protein liquid chromatography (FPLC) system (ÄKTA, GE 
Heathcare Life Sciences) equipped with a 5 mL HisTrap HP IMAC column previously charged 
with Ni2+ and equilibrated in start buffer. The column was washed with 50 mL of buffer A (30 
mM imidazole, 20 mM Tris (pH 7.6), 500 mM NaCl, 10% glycerol) and the protein was eluted 
using a linear gradient of 0-100% B (buffer B = 200 mM imidazole, 20 mM Tris (pH 7.6), 500 
mM NaCl, 10% glycerol) over 40 min at a 2 mL/min flow rate. UV absorbance (280 nm) was 
monitored and fractions were collected and analyzed by SDS-PAGE (4-20% Tris-glycine 
READY gel, BioRAD). The fractions containing LctCE-GSG were combined and concentrated 
using an Amicon Ultra-15 Centrifugal Filter Unit (30 kDa MWCO, Millipore). Gel filtration 
chromatography was used to further purify the enzyme. The concentrated protein sample was 
injected onto an FPLC system (ÄKTA) equipped with an XK16 16/60 (GE Healthcare Life 
Sciences) column packed with SuperDex 75 resin previously equilibrated in 20 mM HEPES (pH 
8.0) and 100 mM KCl. The protein was eluted with a flow rate of 0.9 mL/min. Both UV 
absorbance (280 nm) and conductance were monitored and fractions were collected. 
Misfolded/aggregated protein was efficiently separated from soluble, correctly folded protein 
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and the desired fractions were combined and concentrated using an Amicon Ultra-15 Centrifugal 
Filter Unit. The resulting protein sample was stored at −80 °C. Protein concentration was 
determined using a Bradford Assay Kit (Pierce) and typical yields were 20-30 mg His6-LctCE-
GSG from 3 L of cell culture. 
 
3.4.4. In vitro reconstitution of ConFusion enzymes 
 LctA(1-27) N15R F21H core peptide (and analogues thereof) were prepared via solid-
phase peptide synthesis and purified to homogeneity by Patrick Knerr. Core peptide (final 
concentration 20 µM) was incubated with purified His6-LctCE-GSG (final concentration 2 µM) 
in the presence of 10 mM MgCl2, 2 mM ATP, and 25 µg/mL BSA in a 50 mM Tris buffer (pH 
7.5) and was incubated at 25 °C for 3.5 h. At 3.5 h, reactions were quenched by the addition of 
TFA to 0.5% final concentration (pH 1-2) and the reactions were desalted by ZipTipC18 and 
analyzed by MALDI-TOF MS. 
 
3.4.5. Antimicrobial activity assays of in vitro prepared lacticin 481 and analogues 
 A non-acidified 50 μL in vitro modification reaction was concentrated to 20 μL via 
vacuum centrifugation. An overnight culture of L. lactis HP ATCC 11602 (indicator strain) was 
grown in GM17 media with 0.5% glucose (v/v) under anaerobic conditions at 30 °C for 15 h. 
Ninety-six well agar plates were prepared by combining 20 mL of molten GM17 with 0.5% 
glucose (v/v) medium agar (cooled to 42 °C) with 50 μL of dense overnight culture (approx 108-
109 CFU/mL). The seeded agar was poured into a sterile OmniTray (Nunc) and allowed to 
solidify at 25 °C for 30 min. An additional 30 mL of molten GM17 with 0.5% glucose (v/v) 
medium was cooled to 42 °C, combined with 75 μL of culture, and poured over the lower 
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solidified agar layer. A sterile 96-well PCR plate was placed in the molten agar upper layer and 
was allowed to solidify at 25 °C for 45 min. After sufficient solidification, the 96-well PCR plate 
was removed. The total 20 μL volume of concentrated in vitro reaction was dispensed into 
separate newly formed wells. Authentic nisin standards were spotted in 15 μL volumes at varied 
concentrations. Plates were left at 30 °C for 15 h and antibacterial activity was qualitatively 
determined by the presence or absence of growth inhibition.  
 
3.4.6. Expansion of the linker of lacticin 481 ConFusion construct 
 The length of the linker between the LctA leader and the LctM synthetase sequences was 
expanded (Figure 3.5) via restriction endonuclease digestion of the pET28b LctCE-GSG 
construct with SpeI and PstI at 37 °C for 5 h. The excised insert byproduct was removed from the 
digested plasmid by purification via 1% agarose gel electrophoresis. The desired digested plasmid 
was subsequently gel extracted using a QIAquick Gel Extraction Kit (QIAGEN).  
 Double-stranded DNA (dsDNA) inserts encoding for linkers of repetitious Gly-Ser residues 
were designed to self-hybridize and generate “preformed” overhangs for ligation at the vector 
restriction sites between the sequences encoding for the leader peptide and the synthetase. These 
inserts of several lengths were prepared by combining 100 nM each of synthetic, self-
complementary DNA oligos (see below for pairs and resulting linker) in PCR tubes and 
subjecting them to denaturing conditions (94 °C for 5 min) following by slow temperature 
gradient return to 25 °C over 30 min. The resulting dsDNA linker and cut pET28b LctCE-GSG 
plasmid products were ligated at 25 °C for 3 h in 1X T4 DNA Ligase buffer with T4 DNA Ligase 
(0.7 U/μL). E. coli DH5α cells were transformed with 2.5 μL of the ligation product by heat shock, 
and cells were plated on LB-kanamycin agar plates and grown for 15 h at 37 °C. Several colonies 
were picked and used to inoculate separate 5 mL cultures of LB-kanamycin medium. The cultures 
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were grown at 37 °C for 12 h, and plasmids were isolated using a QIAprep Spin Miniprep Kit 
(QIAGEN). The sequences of the resulting plasmid products were confirmed by DNA sequencing. 
SpeI recognition site (encodes for Thr Ser) 
 
 
PstI recognition site (encodes for Leu Gln) 
 
 
Target: LctCE-GS10 wt 
 
           1  2  3  4  5  6  7  8  9  10   
    “ThrSerGlySerGlySerGlySerGlySerGlySerLeuGln” 
5’    CTAGTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTCTGCA     3’ 
3’        ACCAAGACCAAGACCAAGACCAAGACCAAGAG         5’ 
 
Target: LctCE-GS20 wt 
 
           1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20   
    “ThrSerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerLeuGln” 
5’    CTAGTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTCTGCA     3’ 
3’        ACCAAGACCAAGACCAAGACCAAGACCAAGACCAAGACCAAGACCAAGACCAAGACCAAGAG         5’ 
 
Target: LctCE-GS30 wt 
 
           1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30   
    “ThrSerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerGlySerLeuGln” 
5’    CTAGTGGTTCCGGCTCTGGTAGCGGCTCTGGTTCCGGCTCTGGTAGCGGCTCTGGTTCCGGCTCTGGTAGCGGCTCTGGTTCCGGCTCTGGTAGCCTGCA     3’ 
3’        ACCAAGGCCGAGACCATCGCCGAGACCAAGGCCGAGACCATCGCCGAGACCAAGGCCGAGACCATCGCCGAGACCAAGGCCGAGACCATCGG         5’ 
 
 
3.4.7. Expression and purification of His6-LctCE-GSn and LctM enzymes 
 E. coli Rosetta 2 (DE3) cells were used as the host for expression of pET28b LctCE-
GS10, pET28b LctCE-GS20, pET28b LctCE-GS30, and pET28b LctM. These enzymes were 
expressed and purified as described in Experimental 3.4.3. The resulting protein samples were 
stored at −80 °C. Protein concentration was determined using a Bradford Assay Kit (Pierce) and 
typical yields were 20-30 mg protein from 3 L of cell culture. 
  
140 
 
           LctM wt   LctCE-GS30 wt 
  
 
Figure 3.17. SDS-PAGE analysis of highly purified LctM and LctCE-GS30 enzymes for use in quantitative end-
point assays. 
 
3.4.8. Evaluation of linker length expansion on extent of core peptide processing 
 The influence of the length of the linker between the LctA leader and the LctM 
synthetase sequences was assessed using the in vitro modification reactions described in 
Experimental 3.4.4. Briefly, core peptide (final concentration 20 µM) was incubated with 
purified His6-LctCE-GSn (ConFusion enzyme with defined linker length, final concentration 2 
µM) in the presence of 10 mM MgCl2, 2 mM ATP, and 25 µg/mL BSA in a 50 mM Tris buffer 
(pH 7.5) and was incubated at 25 °C for 1 h. At 1 h, reactions were quenched by the addition of 
TFA to 0.5% final concentration (pH 1-2) and the reactions were desalted by ZipTipC18 and 
analyzed by MALDI-TOF MS. 
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3.4.9. Comparison of processing efficiencies between LctCE-GS30 and LctM  
 Quantitative end-point assays were used to evaluate the efficiency of core peptide 
processing between LctCE-GS30 ConFusion enzyme with core peptide alone versus LctM with 
leader and core peptide provided in trans. For ConFusion assays, LctA(1-27) N15R F21H core 
peptide (final concentration 20 µM) was incubated with purified His6-LctCE-GS30 (final 
concentration 2 µM) in the presence of 10 mM MgCl2, 2 mM ATP, and 25 µg/mL BSA in a 50 
mM Tris buffer (pH 7.5) at 25 °C. At 0, 5, 15, 30, 60, and 180 min, a 550 µL volume of reaction 
was removed and quenched by the addition of TFA to 0.5% final concentration (pH 1-2). A 500 
µL volume of each reaction was subjected to HPLC analysis (see conditions below) and the 
remainder of each reaction was desalted by ZipTipC18 and analyzed by MALDI-TOF MS. For 
LctM in trans assays, LctA(1-27) N15R F21H core peptide (final concentration 20 µM) and 
LctA(−1 - −24) leader peptide (final concentration 2 µM) was incubated with purified His6-
LctCE-GS30 (final concentration 2 µM) in the presence of 10 mM MgCl2, 2 mM ATP, and 25 
µg/mL BSA in a 50 mM Tris buffer (pH 7.5) and was incubated at 25 °C. At 0, 5, 15, 30, 60, and 
180 min, a 550 µL volume of reaction was removed and quenched by the addition of TFA to 
0.5% final concentration (pH 1-2). A 500 µL volume of each reaction was subjected to HPLC 
analysis (see conditions below) and the remainder of each reaction was desalted by ZipTipC18 
and analyzed by MALDI-TOF MS. 
 The above reaction sets were analyzed using analytical HPLC. HPLC was performed 
using a Beckman Coulter System Gold HPLC equipped with a Phenomenex Jupiter Proteo C12 
column (10 μm, 90 Å, 250 mm x 4.6 mm) equilibrated in 2% solvent B (solvent A =  0.1% TFA 
in water, solvent B = 0.0866% TFA in 80% ACN/20% water). The quenched reactions were 
centrifuged at 15 krpm in a microcentrifuge for 2 min and the resulting supernatant was applied 
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to the column. The mixture of products and intermediates  were resolved and eluted by 
maintaining the mobile phase at 2% B for 1 min, followed by an increase to 100% B over 45 min 
with a flow rate of 1.0 mL/min. Under these conditions, the fully modified −4 H2O product 
eluted at 24.6 min. The −3 H2O product eluted at 25.1 and a mixture of phosphorylated −2 H2O 
and −3 H2O + PO32- intermediates eluted at 26.2 min. All fractions were analyzed by MALDI-
TOF MS as described above.  
 
3.4.10. Preparation of lacticin 481 analogues 
 A number of LctA 1-27 core peptides were prepared by Patrick Knerr. These included 
LctA 1-27 N15R F21H, LctA 1-27 N15R F21Pal, LctA 1-27 N15R W19Nal F21H, and LctA 1-
27 N15R W19Nal F21H. The reactions were uniformly scaled as compared to those previously 
described. Core peptide (final concentration 20 µM) was incubated with purified His6-LctCE-
GS30 (final concentration 2 µM) in the presence of 10 mM MgCl2, 2 mM ATP, and 25 µg/mL 
BSA in a 50 mM Tris buffer (pH 7.5) at 25 °C for 5 h. The extent of the reaction was monitored 
by mass spectrometry by periodically removing aliquots of the reaction and acidifying them with 
TFA, desalting the samples via ZipTipC18, and analyzing by MALDI-TOF MS. By 5 h, the 
maximum extent of reaction was complete and reactions were quenched by the addition of TFA 
to 0.5% final concentration (pH 1-2). The quenched reaction containing a mixture of −4 H2O, −3 
H2O + PO32-, and a minor amount of −3 H2O and −2 H2O products was concentrated by 
lyophilization to one-fifth of the original reaction volume. 
 The individual analogues were then purified using preparative HPLC. HPLC was 
performed on a Waters Delta 600 instrument equipped with a Phenomenex Jupiter Proteo C12 
column (10 μm, 90 Å, 250 mm x 15 mm) equilibrated in 10% B (A: 0.1% TFA in water, B: 
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0.0866% TFA in 80% ACN/20% water (v/v)). The quenched and concentrated reaction was 
centrifuged at 15 krpm in a microcentrifuge for 2 min to remove any insoluble material and the 
resulting supernatant was applied to the column. The products were eluted by maintaining the 
mobile phase at 10% B for 5 min, followed by an increase to 100% B over 50 min with a flow 
rate of 10.0 mL min-1. Under these conditions, lacticin 481 analogues eluted between 23.0 and 
24.5 min. All fractions were analyzed by MALDI-TOF MS as described above. Purified material 
was lyophilized to dryness and stored under N2 at −80 °C until further use. 
 
3.4.11. Specific activity determination against L. lactis HP cells 
 Microtiter plates were used to determine the IC50 values (the concentration at which 50% 
growth inhibition is observed) of indicator strains. Serial dilutions of lacticin 481 peptides were 
prepared in sterile deionized water (SDW). Ninety-six well microtiter plates (Corning Costar) 
were utilized for testing against the anaerobic L. lactis HP strain. The total volume of culture in 
each well was 200 μL; the experimental wells contained 50 μL of diluted lacticin 481 peptides at 
defined concentrations and 150 μL of a 1-in-10 dilution (approximately 1 x 108 CFU mL-1) of an 
indicator strain culture diluted in fresh growth medium. In addition, each plate contained several 
blank (150 μL fresh growth medium and 50 μL SDW) and control wells (150 μL of untreated 1-
in-10 diluted culture and 50 μL SDW). The optical density at 600 nm (OD600) was recorded at 
hourly intervals from 0 to 5 h with an additional measurement at 18 h using a BioTek Synergy 4 
Hybrid plate reader. Plates were incubated at 30 °C between measurements. The triplicate 
readings were averaged, and blanks (growth medium and SDW only) were subtracted from these 
readings. Growth curves were developed using control (culture and SDW only) readings to 
ensure sufficient OD changes for accurate inhibition assessment. Curve fits for IC50 
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determination were produced by fitting the data with Origin8 software using the dose-response 
curve with the equation: y = A1 + (A2 – A1) / (1 +10(Logx0 – x)p), with p = variable Hill slope. A 
50% growth inhibition was determined as half the final OD600 ± 0.05 of control culture. IC50 
values for authentic lacticin 481 and nisin were determined using identical procedures as 
described above.  
 
3.4.12. Inhibition of peptidoglycan formation by lacticin 481 and analogues 
 The gene encoding E. coli PBP1b was previously PCR amplified from MG1655 genomic 
DNA and cloned into pET21b vector (Novagen) as a C-terminal hexa-histidine (His6) fusion 
gene.82 The enzyme was expressed and purified by Tsung-Shing Andrew Wang or Tania Lupoli 
(Dan Kahne and Suzanne Walker Laboratory, Harvard University) as previously published.82 
[14C]GlcNAc-labeled heptaprenyl lipid II analogue was chemo-enzymatically prepared by Dr. 
Yuto Sumida and Dr. Hiro Tsukamoto (Dan Kahne Laboratory) as previously described.83 
 For IC50 determinations, assays were carried out by separately incubating [14C]GlcNAc-
labeled heptaprenyl lipid II analogue (final concentration = 4 μM, typical specific activity = 288 
μCi/μmol) and peptide inhibitors (concentrations are indicated in the figure legends) in low-
binding microcentrifuge tubes (VWR) containing 9 μL of buffer consisting of 50 mM HEPES 
(pH 7.5), 10 mM CaCl2, 1,000 units/mL penicillin G, 0.2 mM octaethylene glycol monodecyl 
ether (decyl-PEG; Anatrace, Maumee, OH), and 11% DMSO (v/v) for 30 min at room 
temperature prior to PBP1b addition (to allow binding to occur). Reactions were started by 
adding 1 μL of PBP1b (from a solution freshly prepared by diluting the 50% glycerol stock 20-
fold into PBP1b dilution buffer consisting of 5 mM Tris (pH 8.0), 8 mM decyl-PEG) to the 
reaction mixture (final PBP1b concentration = 20-100 nM). Reactions were typically stopped 
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after 30-45 min by adding 10 μL of ice-cold 10 mM Tris (pH 8.0) containing 10% Triton X-100. 
Quenched reactions were stored on ice until they were spotted on cellulose chromatography 
paper strips (3MM Whatman chromatography paper #3030-861, cut 1 cm width x 20 cm height) 
Products and starting material were separated using chromatography (isobutyric acid/1 M 
NH4OH, 5:3). The lipid II starting material migrates on the strip, while polymerized product 
remains at the origin. The paper strips were removed from chromatography chambers, allowed to 
dry, cut, and added to separate scintillation vials containing EcoLite(+) liquid scintillation fluid 
(MP Biomedical). Samples were analyzed using a LS6500 scintillation counter (Beckman 
Coulter). The percent radioactivity of the polymer product was calculated by comparing the 
amount of radioactivity that remains at the origin (peptidoglycan) to the total amount of 
radioactivity on the strip.   
 
3.4.13. Construction and expression of His6-LctCE-GS30 T405A and R399M enzymes 
 The engineered plasmid pET28b LctCE-GS30 wt and the native plasmids pET28b LctM 
T405A and pET28b LctM R399M were isolated from E. coli DH5α cells previously transformed 
with the constructs. The partial gene of pET28b LctCE-GS30 wt encoding for LctA leader, GS30 
linker, and the 5’-end of LctM was excised via restriction digestion with NheI and HindIII at 37 
°C for 5 h. The digested partial gene and vector products were purified by 2% and 1% agarose gel 
electrophoresis, respectively, and gel extracted using a QIAquick Gel Extraction Kit (QIAGEN). The 
plasmids pET28b LctM T405A and pET28b LctM R399M were also digested with NheI and 
HindIII at 37 °C for 5 h, gel purified, and gel extracted using the same technique. The partial gene 
and cut pET28b LctM T405A vector were ligated at 25 °C for 3 h in 1X T4 DNA Ligase buffer with 
T4 DNA Ligase (0.7 U/μL). The same ligation procedure was completed using cut pET28b LctM 
R399M. E. coli DH5α cells were transformed with 2.5 μL of the ligation products by heat shock, and 
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cells were plated on LB-kanamycin agar plates and grown for 15 h at 37 °C. Several colonies were 
picked and used to inoculate separate 5 mL cultures of LB-kanamycin medium. The cultures were 
grown at 37 °C for 12 h, and plasmids were isolated using a QIAprep Spin Miniprep Kit (QIAGEN). 
The sequences of the resulting plasmid products were confirmed by DNA sequencing. 
 E. coli Rosetta 2 (DE3) cells were used as the host for expression of pET28b LctCE-
GS30 T405A and pET28b LctCE-GS30 R399M. These enzymes were expressed and purified as 
described in Experimental 3.4.3.. The resulting protein samples were stored at −80 °C. Protein 
concentration was determined using a Bradford Assay Kit (Pierce) and typical yields were 15-20 
mg protein from 3 L of cell culture. 
 
3.4.14. In vitro production and elimination of phosphopeptides 
Phosphorylation of peptides. 
 A number of biologically relevant peptides were designed based on known information 
from Anaspec, a commercial peptide synthesis company (www.anaspec.com). The peptides 
selected have been experimentally examined and have demonstrated the ability to serve as 
surrogate substrates for protein kinases/phosphatases involved in phosphorylation pathways. 
These partial fragments of larger protein substrates are of sufficient length for interaction and 
recognition by the upstream kinase and have the Ser, Thr, or Tyr residue(s) that serves as the 
specific receptor of the phosphate group. The peptides were designed by myself and Patrick 
Knerr and were prepared by Patrick Knerr. These included those listed in Table 3.1. 
 Peptide substrate (final concentration 20 µM) was incubated with purified His6-LctCE-
GS30 T405A (final concentration 2 µM) in the presence of 10 mM MgCl2, 2 mM ATP, and 25 
µg/mL BSA in a 50 mM Tris buffer (pH 7.5) and was incubated at 25 °C for 3 h. At 3 h, 
reactions were quenched by the addition of TFA to 0.5% final concentration (pH 1-2) and the 
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reactions were desalted by ZipTipC18 and analyzed by MALDI-TOF MS. Additional analysis 
included LC-ESI-q/TOF MS and MSMS to identify the specific site of phosphorylation of the 
AKT/PKB/RAC peptide. 
 The phosphorylated and non-phosphorylated peptides were purified using HPLC. HPLC 
was performed using a Beckman Coulter System Gold HPLC equipped with a Phenomenex 
Jupiter Proteo C12 column (10 μm, 90 Å, 250 mm x 4.6 mm) equilibrated in 2% solvent B 
(solvent A =  0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water). The 
quenched reactions were centrifuged at 15 krpm in a microcentrifuge for 2 min and the resulting 
supernatant was applied to the column. The phosphorylated and non-phosphorylated peptides 
were eluted by maintaining the mobile phase at 2% B for 1 min, followed by an increase to 
100% B over 45 min with a flow rate of 1.0 mL/min. Under these conditions, the phosphorylated 
peptide and non-phosphorylated peptide eluted within 22-26 min, respectively and typically had 
a retention time separation of 1.5 – 2.0 min. All fractions were analyzed by MALDI-TOF MS as 
described above. Purified material was lyophilized to dryness and stored under N2 at −80 °C 
until further use. 
Elimination of peptide phosphorylation. 
 Elimination of peptide phosphorylation was studied in two ways: with purified 
phosphopeptide and with phosphorylated/non-phosphorylated peptide reaction mixture. For 
assays with purified phosphopeptide, phosphopeptide substrate (final concentration ~20 µM) was 
incubated with purified His6-LctCE-GS30 wt (final concentration 2 µM) in the presence of 10 
mM MgCl2, 2 mM ATP, and 25 µg/mL BSA in a 50 mM Tris buffer (pH 7.5) and was incubated 
at 25 °C for 3 h. At 3 h, reactions were quenched by the addition of TFA to 0.5% final 
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concentration (pH 1-2) and the reactions were desalted by ZipTipC18 and analyzed by MALDI-
TOF MS. 
 For assays with phosphorylated/non-phosphorylated peptide reaction mixtures, a 
phosphorylation reaction was first ran in which peptide substrate (final concentration 20 µM) 
was incubated with purified His6-LctCE-GS30 T405A (final concentration 2 µM) in the presence 
of 10 mM MgCl2, 2 mM ATP, and 25 µg/mL BSA in a 50 mM Tris buffer (pH 7.5) and was 
incubated at 25 °C for 3 h. At 3 h, a small aliquot of the reaction was removed, desalted using 
ZipTipC18, and analyzed by MALDI-TOF MS to verify that phosphorylation of the peptide had 
occurred. Without any further manipulation, His6-LctCE-GS30 wt was added to 2 µM and the 
reaction was returned to 25 °C for an additional 3 h. At 3 h, reactions were quenched by the 
addition of TFA to 0.5% final concentration (pH 1-2) and the reactions were desalted by 
ZipTipC18 and analyzed by MALDI-TOF MS. 
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CHAPTER 4: STRUCTURAL CHARACTERIZATION AND BIOSYNTHESIS OF 
SUBLANCIN AND OTHER S-LINKED GLYCOPEPTIDE NATURAL PRODUCTS1 
 
4.1. INTRODUCTION 
 Post-translationally modified peptide natural products are a rapidly expanding class of 
compounds with a wide variety of biological activities.2 One such peptide, sublancin, is produced 
by Bacillus subtilis 168, the laboratory strain that was one of the first bacterial strains for which 
the genome was sequenced.3 Sublancin is encoded by the SPβ-prophage in strains that are 
lysogenic for the SPβ bacteriophage, and inhibits the growth of non-lysogenic strains.4 The 
reported structure of sublancin contains a dehydroalanine and one of the thioether crosslinks that 
are characteristic of lantibiotics (Figure 4.1a).5 Like other lantibiotics,6 sublancin is 
biosynthesized as a precursor peptide bearing an N-terminal leader peptide of the double glycine-
type (19 amino acids, Figure 4.1b) and a C-terminal core peptide (37 amino acids) that is 
converted to the mature compound. 
 Interestingly, a search of the B. subtilis 168 genome did not reveal genes for any of the 
four known classes6-9 of lantibiotic biosynthetic enzymes (see Figure 1.6). Intrigued by the 
possibility of a fifth pathway to lanthionine-containing peptides, the biosynthesis of sublancin 
was investigated. It is demonstrated here that this compound, initially reported as a lantibiotic is 
in fact not a lantibiotic, but rather a very unusual S-linked glycopeptide. This chapter describes 
efforts toward the structure revision of sublancin, the reconstitution of the in vitro activity 
 
____________________________________________________ 
1 Reproduced in part with permission from: “Sublancin is not a lantibiotic but an S-linked glycopeptide.” Nat. Chem 
Biol. 2011, 7, 78-80. Copyright 2011 Nature Publishing Group. 
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Figure 4.1. (a) Originally reported structure of sublancin5 proposed to contain a dehydroalanine at position 16 and a 
methyllanthionine bridge arising from dehydration of Thr19 to Dhb19 and subsequent attack of Cys22 on Dhb19 to 
form the thioether linkage. (b) Primary sequence of the SunA precursor peptide containing a 19 amino acid N-
terminal leader peptide (blue) and a 37 amino acid C-terminal core peptide (black). A double glycine-type 
proteolytic cleavage site is underlined in red. 
 
of the S-glycosyltransferase responsible for installing its unique post-translational modification, 
and the in vitro reconstitution of its antimicrobial activity. It addition, it is demonstrated how the 
versatility of the S-glycosyltransferase can be utilized to generate other bioactive S-linked 
products. This discovery of an S-linked glycopeptide and the enzyme responsible for installation 
of this unique post-translational modification is the first of its kind, and has opened the door for 
the identification and characterization of additional S-glycopeptide precursors and their 
biosynthetic enzymes. Indeed, a search of the protein databases suggests that sublancin is a 
member of a larger family of novel S-linked glycopeptides, further expanding the already 
impressive structural diversity of post-translationally modified peptide natural products.10 One 
example of an additional S-glycopeptide and glycosyltransferase pair was examined and is 
reported in this chapter. 
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4.2. RESULTS AND DISCUSSION 
4.2.1 Structural characterization of in vivo produced sublancin 
 Sublancin was purified as described previously5 and analyzed by mass spectrometry. The 
mass of the unmodified core peptide predicted from the sunA gene sequence is 3717.72 Da 
whereas the observed mass of purified sublancin is 3875.74 Da (Figure 4.2). The core peptide 
contains five Cys residues (Figure 4.1b), but native sublancin does not react with iodoacetamide 
demonstrating it does not contain free thiols. However, treatment of sublancin with the reducing 
agent TCEP led to a mass increase of exactly four Da (Figure 4.3). Following treatment of the 
peptide with both TCEP and iodoacetamide, four out of five cysteines were alkylated (Figure 
4.4). Thus, one cysteine is modified such that it is not available for alkylation. 
 Sublancin was further analyzed by tandem mass spectrometry. When native sublancin 
with intact disulfide bridges was subjected to collision induced dissociation, fragmentation of the 
peptide amide bonds did not occur. Rather, the post-translational modification with a mass of 
162 Da, later identified as an S-linked glucosylation (vide infra), was lost from the parent ion 
(Figure 4.5). To allow fragmentation, the disulfide bonds were first reduced and the reduced 
peptide was treated with chymotrypsin, providing a series of peptide digest fragments as 
determined by MALDI-TOF mass spectrometry (Figure 4.6). The fragment spanning residues 
12-32 of sublancin was analyzed by electrospray ionization-quadrupole/time-of-flight mass 
spectrometry. The observed fragmentation pattern combined with the sequence of the precursor  
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Figure 4.2. ESI-Q/TOF MS analysis of native sublancin. Pure sublancin isolated from B. subtilis 168 without any 
further manipulation was analyzed by LC-ESI-Q/TOF MS. Expected [M+H]: 3876.74, observed: 3876.75. 
 
 
 
Figure 4.3. ESI-Q/TOF MS analysis of reduced sublancin. Pure sublancin was reduced using TCEP and analyzed by 
LC-ESI-Q/TOF MS. The mass of reduced sublancin is 4 mass units larger than native sublancin, suggesting that two 
disulfide linkages exist in the native structure of sublancin. Expected [M+H]: 3880.77, observed: 3880.78. 
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Figure 4.4. ESI-Q/TOF MS analysis of reduced and alkylated sublancin. Pure sublancin was reduced and alkylated 
using TCEP and iodoacetamide and analyzed by LC-ESI-Q/TOF MS. Expected [M+H] (for four alkylations): 
4107.86, observed: 4107.83. 
 
 
 
Figure 4.5. ESI-Q/TOF MSMS analysis of native sublancin. Pure sublancin isolated from B. subtilis 168 was 
analyzed by LC-ESI-Q/TOF MSMS. 
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Figure 4.6. MALDI-TOF MS analysis of sublancin digested with chymotrypsin under reducing conditions. 
Sublancin was digested with chymotrypsin under reducing conditions and analyzed by MALDI-TOF MS. The 
resulting mass spectrum is shown. Chymotrypsin cleavage sites (F, W, and Y residues) are indicated in the peptide 
sequence above the spectrum. The masses of the observed ions and their corresponding digest fragments are 
assigned. The results are consistent with Ser16 and Thr19 remaining unmodified and the peptide spanning residues 
Leu12-Tyr32 bearing a +162 Da post-translational modification. 
 
gene sunA indicated that residue 16 is a Ser (Figure 4.7) and not a dehydroalanine as previously 
reported.4 Furthermore, the observed fragments indicate that Thr19 is intact and therefore not 
engaged in a methyllanthionine ring. The data further suggest that Cys22 is carrying a post-
translational modification with a mass of 162 Da (Figure 4.8). This mass is consistent with a 
hexose conjugated to the Cys thiol. 
 
  
162 
 
 
Figure 4.7. ESI-Q/TOF MSMS analysis of residues Leu12-Tyr32 of sublancin. Sublancin was digested with 
chymotrypsin under reducing conditions and analyzed using LC-ESI-Q/TOF MSMS. The digest mixture was 
fractionated using LC and the multiply charged ion corresponding to the peptide spanning residues Leu12-Tyr32 
was selected for MSMS analysis. (a) Fragmentation patterns are indicated for the full b ion series and (b) zoom of 
the spectra showing unmodified Ser and Thr residues.  
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Figure 4.8. ESI-Q/TOF MSMS analysis of residues Leu12-Tyr32 of sublancin. Sublancin was digested with 
chymotrypsin under reducing conditions and analyzed using LC-ESI-Q/TOF MSMS. The digest mixture was 
fractionated using LC and the multiply charged ion corresponding to the peptide spanning residues Leu12-Tyr32 
was selected for MSMS analysis. (a) Fragmentation patterns are indicated for the full y” ion series and (b) zoom of 
the spectra showing modified Cys residue.  
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4.2.2 Identification of the natural sugar modification of sublancin  
 To determine the identity of the hexose, sublancin was subjected to acidic hydrolysis to 
release the sugar.11 Conversion of the acetal to a mixture of two stereoisomer oximes and 
subsequent chemical modification to a trimethylsilylated derivative allowed analysis by GC-MS. 
Comparison with a series of authentic standards treated in the same way demonstrated that the 
hexose of sublancin is glucose (Figure 4.9. See additional supporting data in Experimental 4.4.6).  
 To the best of our knowledge, reports of S-linked glycopeptides are extremely rare. A 
small number of S-linked glycopeptides have been disclosed, but little in depth characterization 
has been done on those discovered. Forty years ago in 1971, two different S-linked glycopeptides 
were reported. The more well-studied peptide, found in human urine,11,12 was identified to 
contain an S-glycosidic bond between an N-terminal Cys and a digalactosyl moiety. This 
octapeptide was partially purified and subjected to dansyl-Edman degradation to determine 
amino acid content and hydrolysis/derivatization followed by gas chromatography analysis to 
identify the bound sugar. Ultimately, it was determined that for each 2 mol of galactose, amino 
acid analysis revealed 2 mol of His and 1 mol each of Asp, Ser, Cys, Glu, Gly, and Ala. 
Sequential analysis indicated a peptide with the sequence “Cys-Glu-His-Ser-His-Asp-Gly-Ala” 
and it was proposed that the digalactose was appended to the Cys residue via an S-glycosidic 
linkage.11,12  
 That year, the same group identified and reported a second S-glycopeptide in human 
erythrocyte membrane.13 The novel peptide was characterized using similar techniques as 
described for the peptide found in human urine, and for this peptide, a triglucosyl group was 
identified as the Cys-bound modification. The human erythrocyte membrane glycopeptide shared 
remarkable sequence homology with that of the urine derived peptide and consisted of the amino 
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acid sequence, “Cys-Glu-Gly-His-Ser-His-Asp-His-Gly-Ala” with the S-linked trisaccharide also 
bound to the N-terminal Cys residue.13 The biosynthesis and function of these peptides has not 
been reported and it is currently unknown if the modifications are enzymatically installed. 
Furthermore, the sequences of these peptides are not found in the predicted human proteome and 
hence their origins are unclear. 
 A third S-linked glycosylation reported is Allergen M, an acidic protein isolated from the 
white muscle albumin of cod.14 The complete primary structure of the protein was elucidated via 
dansyl-Edman degradation and gas chromatography analyses. Combined with previously 
reported information on the C-terminal portion of the protein,15-17 the intact allergen consists of 
113 amino acids (12,328 Da MW) and a single glucosylation at Cys18. Finally, a fourth S-
glycoprotein reported is inter-α-inhibitor, a serine protease inhibitor found in high concentrations 
in human plasma.18 This protein is composed of a light inhibitory chain and two heavy chains of 
unknown function. The heavy chains are heavily post-translationally modified possessing several 
N-linked and O-linked glycosylations. In addition, the heavy chains contain nine Cys residues, 
one of which, Cys26, is proposed to be modified by dihexosylation while the remaining eight 
Cys are involved in disulfide pairs. 
 The conjugation of sugars to Cys through an S-glycosidic linkage results in more stable 
products than the O-glycosidic linkage to Ser, both at low and high pH.19-21 As a result, S-linked 
glycopeptides have been the topic of several recent synthetic investigations.22-26 Indeed, it has 
been demonstrated that sublancin is a remarkably stable peptide that tolerates both low and high 
pH.5 
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Figure 4.9. Gas chromatography-mass spectrometry analysis of sublancin and hexose standards. (a) Hexose 
standards were derivatized and analyzed by GC-MS. (b) The naturally occurring sugar of sublancin was released 
from the peptide natural product via acid hydrolysis, derivatized, and analyzed by GC-MS. The peak corresponding 
to the derivatized sugar of sublancin had a similar retention time as glucose. (c) Sublancin sample was spiked with 
authentic derivatized glucose standard and the spiked mixture was analyzed by GC-MS. (d) The electron-impact 
mass spectrum obtained for the sublancin sugar peak at 10.984 min. Spectra comparison with standards and 
databases confirmed the presence of a TMS-derivatized glucose. 
  
4.2.3 Addressing the disulfide connectivities of native sublancin 
 The bridging patterns of the two disulfide bonds of the peptide were investigated as well. 
Four cysteine residues are available for disulfide pairing resulting in 3 possible connectivity 
arrangements. Minimal structural information was obtained by using tandem mass spectrometry 
to examine native sublancin, therefore, proteolytic degradation followed by peptide mass 
fingerprint analysis of sublancin was used to address disulfide bond connectivities. Sublancin 
was digested with chymotrypsin in the presence or absence of a reducing agent. The resulting 
mass spectra indicated that one disulfide bond is shared between Cys7 and Cys35, and the other 
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Figure 4.10. ESI-Q/TOF MS analysis of sublancin digested with chymotrypsin under non-reducing and reducing 
conditions. (a) Sublancin was digested with chymotrypsin under non-reducing conditions and analyzed using LC-
ESI-Q/TOF MS to investigate disulfide bridge connectivity. Chymotrypsin cleavage sites (F, W, and Y residues) 
and the proposed disulfide bridges are indicated in the peptide sequence above the spectrum. The masses of the 
observed ions and their corresponding digest fragments are assigned. The results support the conclusion that a 
disulfide bond exists between Cys7-Cys36 and between Cys14-Cys29. The results are also consistent with Ser16 
and Thr19 remaining unmodified and the peptide spanning residues Leu12-Tyr32 bearing a +162 Da post-
translational modification. (b) Sublancin was digested with chymotrypsin under reducing conditions and analyzed 
using LC-ESI-Q/TOF MS. Chymotrypsin cleavage sites (F, W, and Y residues) are indicated in the peptide sequence 
above the spectrum. The masses of the observed ions and their corresponding digest fragments are assigned. The 
results support that the disulfide bond existing between Cys7-Cys35 was reduced as the peak corresponding to the 
ion with a mass of 1392.62 Da (native sublancin) was no longer observed. Rather, a peak corresponding to the 
peptide spanning residues Gly1-Trp11 with a mass of 1117.53 Da was observed. In addition, the ion corresponding 
to Leu12-Tyr32 had a 2 Da mass increase compared to the Leu12-Tyr32 ion found in the native sublancin digest. 
These results further suggest that a disulfide bond exists between Cys14-Cys29 in native sublancin. The results are 
also consistent with Ser16 and Thr19 remaining unmodified and residues Leu12-Tyr32 bearing a +162 Da post-
translational modification. 
 
is shared between Cys14 and Cys29 (Figure 4.10). It has been demonstrated for many 
conformationally constrained, bioactive peptides that proper connectivity of disulfides is 
essential for biological activity.27-29 Indeed, reduction of the disulfides of sublancin resulted in 
complete loss of antimicrobial activity against B. subtilis ATCC 6633 in an agar diffusion assay, 
showing their importance for activity (Figure 4.11). 
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Figure 4.11. Antimicrobial activity assay of native, reduced, and reduced and alkylated sublancin. The importance 
of intact disulfides for the bioactivity of sublancin was assessed by testing the activities of native, reduced, and 
reduced and alkylated sublancin against B. subtilis ATCC 6633. Native sublancin samples were prepared by 
incubation in Tris buffer at pH 7.5 and pH 8.3. Reduced sublancin was prepared by incubation in Tris buffer (pH 
8.3) in the presence of TCEP. Reduced and alkylated sublancin was prepared by incubation in Tris buffer (pH 8.3) 
in the presence of TCEP and iodoacetamide. All samples were analyzed by MS. The antimicrobial properties of each 
sample were assessed by its ability to inhibit the growth of B. subtilis ATCC 6633. Authentic sublancin and nisin 
standards were tested as positive controls. As indicated below, both samples of native sublancin (pH 7.5 and pH 8.3) 
retained the ability to inhibit the growth of the indicator strain. Both reduced and reduced and alkylated samples did 
not display antimicrobial activities. 
 
  
169 
4.2.4 NMR analysis of sublancin  
 Provided the known inversion of stereochemistry of the GT2 family of GT-A glycosyl 
transferases, a β-linkage was expected and NMR studies confirmed this assumption. Isotopically 
labeled sublancin was prepared and purified by culturing B. subtilis 168 in minimal media 
enriched with 15NH4Cl and 13C-glucose followed by purification via preparative reversed-phase 
chromatography. Milligram quantities of both 13C-sublancin as well as double labeled 13C/15N-
sublancin was obtained (see Figures 4.42 and 4.43 in Experimental 4.4.14). With the support of 
Dr. John Boettcher (a former graduate student of Prof. Chad Rienstra), several 1D and 2D data 
sets were collected (Figure 4.12). From the 2D data, the unique sugar ring spin system was 
identified with chemical shifts between 3.2 – 4.6 ppm (1H) and 69 – 85 ppm (13C). After 
establishing the assignments of the conjugated glucose we used the NMR spectra to address the 
stereochemistry of the S-linkage. By measuring the 3JH-H coupling constant between the anomeric 
proton (proton 1) and the neighboring proton (proton 2) the dihedral angle was calculated using 
the Karplus relationship.30 Using an NMR data fitting program, the cross peak of 1-2 was fit with 
a 3JH-H coupling constant of 9.965 Hz. This results in a dihedral angle of 171° ± 10° based on the 
Karplus equation and indicates a diaxial orientation of the two protons. Combined with the 
knowledge that the sugar molecule is glucose, the stereochemistry of conjugation to Cys22 must 
be through a β-linkage. The revised structure of sublancin based on our data is shown in Figure 
4.13. In addition, many 3D experiments have been completed and data analysis for full 3D-
strucutre elucidation is currently underway. This revised structure also explains the discrepancy 
noted in the original report between the mass of its proposed structure and the actual mass.5  
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Figure 4.12. (a) Expanded region of a one-dimensional 1H NMR spectrum of sublancin in 100% D2O. (b) A two-
dimensional 13C-HSQC spectrum of [U-13C]-sublancin in 100% D2O. Labels are shown for the aromatic and sugar 
resonances as well as the single threonine resonance (Thr19). (c) (top) Correlations for the proton spin system in the 
COSY spectrum for which an expanded region of the 13C-HSQC is also depicted (bottom). The assignments of the 
sugar resonances are shown. All spectra were acquired at 500 MHz at 25 °C. The spectra were processed with zero 
filling to double the original size and apodized with a sine bell function. 
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Figure 4.13. The revised structure of sublancin. 
 
4.2.5 Bioinformatic analysis of the sublancin biosynthetic gene cluster  
 The sublancin biosynthetic gene cluster is shown in (Figure 4.14).5 It contains the 
precursor gene sunA4 and genes encoding two thiol-disulfide oxidoreductases, BdbA and 
BdbB.31 In addition, it contains two orfs of unkown function, yolJ and yolF. YolF was recently 
suggested to be important for immunity of the producing strain and renamed SunI,32 the function 
of YolJ has not yet been reported. Bioinformatic analysis showed that YolJ has sequence 
similarity to the GT-A glycosyltransferases of the GT2 family33 (Figure 4.15), consistent with 
the observed glucose attached to Cys22. Heretoforth we will refer to the enzyme as SunS, a 
sublancin biosynthetic enzyme.  
 
 
Figure 4.14. The biosynthetic gene cluster of sublancin in B. subtilis 168 consists of the glycosyltransferase gene 
sunS, the precursor gene sunA, the ABC-transporter gene sunT, two thiol-disulfide oxidoreductase genes bdbA and 
bdbB, and the immunity protein gene sunI. 
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                                              1                                               50 
                        SunS NP_390028    (1) ------------------------------------------------MK 
 B thuringiensis BGSC 4AW1 ZP_04099941    (1) -----------------------------------------------MET 
 B thuringiensis BGSC 4CC1 ZP_04082010    (1) ---------------MTNFNYVSKELRYNINFFEIACNKLLTMNIDDNSL 
       B cereus BDRD-ST196 ZP_04265312    (1) ---------------MGNFNYISNELRYNINFFEISYNKLLAMNINDDNL 
Y frederiksenii ATCC 33641 ZP_04632793    (1) ----------------------MSDINYFNSNYLIRLKDFILNSIAESDK 
       B tusciae DSM 2912 YP_003590384    (1) MRGPTVPPHEEMRRALEEKDWIKVERLGFKALRADPADTKAWEILGEALL 
                             Consensus    (1)                M    YI  EL Y    F I     L   I D  L 
                                              51                                             100 
                        SunS NP_390028    (3) LSDIYLELKKGYADSLLYSDLSLL-----VNIMEYEKDIDVMSIQSLVAG 
 B thuringiensis BGSC 4AW1 ZP_04099941    (4) LNDLVTRLEHSHPNSSLLKDLSLIQGNEQYNYIKWGDLSNSQNLNELVFQ 
 B thuringiensis BGSC 4CC1 ZP_04082010   (36) LKKVEKRLALLKHIHKYSEEVNELLCELNSDTVDEINHLSDIQFIEMLKR 
       B cereus BDRD-ST196 ZP_04265312   (36) LNKVSKRISLLRHINKYSEEANGLLSDLHSNVVKELNCLSDTKFIEILKN 
Y frederiksenii ATCC 33641 ZP_04632793   (29) INLLNNWLDKVSFILEIDPRLNCFVVMD-NTFHDIYLDKILNDILVLFER 
       B tusciae DSM 2912 YP_003590384   (51) RQGYGTSARKAFRRAYLFQPQKQLARWNGPAEEGDPILNNGRSHPLVEQL 
                             Consensus   (51) LN L  RL KL  IS L  DLN LL     N VDE   L    IIELL   
                                              101                                            150 
                        SunS NP_390028   (48) YEKSDTPTITCGIIVYNESKRIKKCLNSVKDDFNEIIVLDSYSTDDTVDI 
 B thuringiensis BGSC 4AW1 ZP_04099941   (54) YEKAPYPSITCGILTYNEERCIKRCLDSLGSQFDEILVLDSHSTDNTTKI 
 B thuringiensis BGSC 4CC1 ZP_04082010   (86) FLVTKRIKVSVNIMTLNEERCIERCIRSIKNFADEIIVLDTGSTDKTLEI 
       B cereus BDRD-ST196 ZP_04265312   (86) FLTTKKIKISVNIMTLNEERCIARCIESIQDLADEIIILDTGSTDKTREI 
Y frederiksenii ATCC 33641 ZP_04632793   (78) IYQVSLPTISAVIIVKDEERCIYRCIESILDYVDEIVIVDTGSTDSTMDI 
       B tusciae DSM 2912 YP_003590384  (101) LAWPRVPTVAAVIVAKNESRCIGRCLESLKGAVDEILVVDTGSTDDTAAL 
                             Consensus  (101) F  TK PTIS  IIT NEERCI RCIESIKD  DEIIVLDTGSTD TLDI 
                                              151                                    * *     200 
                        SunS NP_390028   (98) IKCDFPD-VEIKYEKWKNDFSYARNKIIEYATSEWIYFIDADNLYSKE-N 
 B thuringiensis BGSC 4AW1 ZP_04099941  (104) INRDFPM-VKVIYEPWIDDFSFHRNKLISLTSSEWIYYIDADN-YCVD-S 
 B thuringiensis BGSC 4CC1 ZP_04082010  (136) IQKEFPD-VKLYCTEWKDNFSECRNQLIDYSTGDWIFQIDADEDLEIN-Q 
       B cereus BDRD-ST196 ZP_04265312  (136) IRNNFPD-AKLYRIEWKNDFSECRNRLIDYSTGDWVLQIDADEHLEIK-Q 
Y frederiksenii ATCC 33641 ZP_04632793  (128) INSIVSDKIKTYSTPWENDFSHARNFAKRKAKKDWLMFIDADEYLDGKGD 
       B tusciae DSM 2912 YP_003590384  (151) AETFPG--VRVLFYAWKDDFAAARNFGLDHIAADWVLWIDADEWVHPDDK 
                             Consensus  (151) IN DFPD VKLYY  WKNDFS ARNKLIDYATSDWIYFIDADE LEID Q 
                                              201                                            250 
                        SunS NP_390028  (146) KGKIAKVARVLEFFSID--CVVSPYIEEYTGHLYSDTR---RMFRLNGKV 
 B thuringiensis BGSC 4AW1 ZP_04099941  (151) TNKFKRVAKLIQFLSID--CIISPMIKEHIGHVYTDNR---KMFSVKKGI 
 B thuringiensis BGSC 4CC1 ZP_04082010  (184) EDLRDFLELFYEFPKSP--MVICPKIKNHDNQELDFNK---RIFKKNDNL 
       B cereus BDRD-ST196 ZP_04265312  (184) KDIREFLELLYEFPISP--VVICPKIKNHDNQELDFNK---RIFRKKDNL 
Y frederiksenii ATCC 33641 ZP_04632793  (178) YNEVKEILLILQFLSIKNEMVICPFISNHNGYNVTTVR---RFFLNNTDI 
       B tusciae DSM 2912 YP_003590384  (199) PLIREAAAMLDAVTPTP---VLHPMIVNRLGSTTSIAMNVPRLFPRRGDL 
                             Consensus  (201)   IRE LALLLEF SIP  MVICP IKNH GH LS NR   RIFRKN  L 
                                              251                                            300 
                        SunS NP_390028  (191) KFHGKVHEEP-----MNYNHSLPFNFIVNLKVYHNGYNPSENNIKSKTRR 
 B thuringiensis BGSC 4AW1 ZP_04099941  (196) QFKGKVHEEP-----INADGSIPQNITVDIMICHDGYDPEVINLSEKNDR 
 B thuringiensis BGSC 4CC1 ZP_04082010  (229) RYFGMIHEDLRYN--IQKKGDDLIYFTTDFVLNHDGYKPEIIELKNKYKR 
       B cereus BDRD-ST196 ZP_04265312  (229) KYFGIIHEDLRYD--IQKKGSDLIYFTTDFTFNHDGYKPEIRESKNKCKR 
Y frederiksenii ATCC 33641 ZP_04632793  (225) NYFGLVHEEP------RINNTKPYYISVNITFIHDGYMHEIVKNKRKTDR 
       B tusciae DSM 2912 YP_003590384  (246) RFHGRIHEQIAPVKGNRYTDLRTRDYLVMIRILHDGYDPAHTDIRAKLQR 
                             Consensus  (251) KFFGLIHEEP     IN  GS P YFTVDI I HDGY PEIIEIK K KR 
                                              301                                            350 
                        SunS NP_390028  (236) NINLTEEMLRLEPENPKWLFFFGREL-HLLDKDEEAID------YLKKSI 
 B thuringiensis BGSC 4AW1 ZP_04099941  (241) NIKLTRQMMEEEPSNPKWLYFYAREL-HYASEDTHIIET-----LLIKAI 
 B thuringiensis BGSC 4CC1 ZP_04082010  (277) NLDLENEMVRIEPDNIRWFYFLARERKLAGYSDEAVIHT-----LVQGIK 
       B cereus BDRD-ST196 ZP_04265312  (277) NLKLQHKMMHIEPDNIRWYYFLAREQKQAIYSDEEVVNT-----LVQGIE 
Y frederiksenii ATCC 33641 ZP_04632793  (269) NLSLLSKMMLLEPNNLRWKYFYYRDGIEVIDLLNAEVGIKSSLILNEQYD 
       B tusciae DSM 2912 YP_003590384  (296) NIRLLNQMVQEEPADPTWLMYLGREVLSAGDVKKG-TS------LLLAAE 
                             Consensus  (301) NIKL   MM IEPDNPRWLYFLAREL  AID DEAVI T     LL GAE 
 
Figure 4.15. (continued on next page) 
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                                              351                                            400 
                        SunS NP_390028  (279) NNYKKFNDQRHFIDALVLLCTLLLQRNNYVDLTLYLDILETEYPRCVDVD 
 B thuringiensis BGSC 4AW1 ZP_04099941  (285) DLYKQSTYKRYQPEAILLLCSILFQKRQIRKLNEYLDLLEELQPLCSDVN 
 B thuringiensis BGSC 4CC1 ZP_04082010  (322) NSKNEQKTNHFYFLSLLMLADIYHNNHNFEALHGIANELSNGFPYCIDGL 
       B cereus BDRD-ST196 ZP_04265312  (322) NSKDNHENNHFYLRSLLMLADIYDSQRDFEALHGIVNELSNRFPYCIDGL 
Y frederiksenii ATCC 33641 ZP_04632793  (319) FSKSNIREDEFTFALLDLLAKNNLRQSKFDDVDIITDIMNCFLPENSNSY 
       B tusciae DSM 2912 YP_003590384  (339) ERAKTTPGFGALLEIQRLLVQAYLFESAYDEAERVAERMQETDPQFPDSH 
                             Consensus  (351) NSKKN   N FYLEALLLLA IYLQQ NFDDL  ILDIL   FP CID   
                                              401                                            450 
                        SunS NP_390028  (329) YFRSAILLVDMQNKLTSLSNMIDEA---LTDERYSAINTTKDHFKRILIS 
 B thuringiensis BGSC 4AW1 ZP_04099941  (335) YYRSLILFYDIRLKTGKLLDTLKSSE--LENNKYSFIDSSKDHIKALLIE 
 B thuringiensis BGSC 4CC1 ZP_04082010  (372) YYNLISSWAYQSSQISLLTEKSFQHM-RKVESPYSIINSNGYHIFYLLGM 
       B cereus BDRD-ST196 ZP_04265312  (372) YYSLINNWANQSSQISNLIQNTFQHM-RKIESPFSIINSNGYHMFYLLGM 
Y frederiksenii ATCC 33641 ZP_04632793  (369) YYKCLINIVELKSKYKELLDKTILYRERNIDPQY---------------- 
       B tusciae DSM 2912 YP_003590384  (389) YYLAHIRVEKAKRLLQAAEEDLRRLR-AQGDDYAGLVNVDADIHAWKADL 
                             Consensus  (401) YYRSII W DIKSKIS LLD T  H  R ID  YSIINS GDHI YLL M 
                                              451                                            500 
                        SunS NP_390028  (376) LNIQLENWERVKEISGEIKNDNM------KKEIKQYLANSLHNIEHVLKG 
 B thuringiensis BGSC 4AW1 ZP_04099941  (383) LYCSIDDWEGAFTLFDELQSTEA------RNKFLRRVKTINTHISKKI-- 
 B thuringiensis BGSC 4CC1 ZP_04082010  (421) LYFNVGNYAKAFQMFSIIKDDIM------LDEIKSNLNVLKDNIENFLSK 
       B cereus BDRD-ST196 ZP_04265312  (421) LYFNLGNYEKSFQMFSIIKDDTL------LDEIRSKLNAIKDNIENFSSK 
Y frederiksenii ATCC 33641 ZP_04632793  (403) -------------------------------------------------- 
       B tusciae DSM 2912 YP_003590384  (438) LQANLCGLTGRIAEAKARYTDLYGHCPGYDEAIAQQIALIDQQARQIIQN 
                             Consensus  (451) LY NL NWEKAF MF  IK D M       DEIK  L  I  NIEN I   
                                              501 
                        SunS NP_390028  (420) IEV-- 
 B thuringiensis BGSC 4AW1 ZP_04099941  (425) ----- 
 B thuringiensis BGSC 4CC1 ZP_04082010  (465) ----- 
       B cereus BDRD-ST196 ZP_04265312  (465) ----- 
Y frederiksenii ATCC 33641 ZP_04632793  (403) ----- 
       B tusciae DSM 2912 YP_003590384  (488) PQQDR 
                             Consensus  (501)       
 
Figure 4.15. Sequence alignment of SunS with glycosyltransferases sharing high homology. BLAST analysis 
resulted in several glycosyltransferases (hypothetical and experimentally defined) sharing sequence homology with 
SunS and located in a cluster with a putative peptide substrate (see Figure 4.26b). Shown is the sequence alignment 
of SunS and the top hits from the BLAST search in August 2010. The asterisks (*) above the sequences indicate the 
putative divalent metal (Mg2+, Mn2+) binding site. The C-termini of these proteins appear less conserved and may 
confer upon SunS the unique ability to glycosylate a Cys. The C-terminus of SunS also has homology with proteins 
involved in lectin binding. 
 
4.2.6 In vitro reconstitution of SunS glycosyltransferase activity  
 To confirm its function, sunS was cloned and expressed in Escherichia coli as an N-
terminal fusion protein with a hexa-histidine tag (His6-SunS, Figure 4.16). Upon purification by 
immobilized metal affinity chromatography, His6-SunS was incubated with the purified 
precursor peptide His6-SunA, also expressed in E. coli. Addition of uridine diphosphate α-D-
glucose (UDP-Glc) and Mg2+ resulted in conversion of SunA to a product consistent with 
glucosylation (Figure 4.17). Subsequent chymotrypsin digest and ESI-MSn analysis verified that 
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glucose was attached to Cys22 (Figure 4.18), demonstrating the strong regioselectivity of the 
glycosyltransferase as the SunA substrate contains five Cys residues.  Because His6-SunS 
glycosylated reduced His6-SunA, the presence of the disulfides is not required for substrate 
recognition. 
 
 
Figure 4.16. Purification of SunS glycosyltransferase. The gene sunS was cloned and expressed in Escherichia coli 
as an N-terminal fusion protein with a hexa-histidine tag (His6-SunS). His6-SunS consists of 442 amino acids and 
has a predicted molecular weight of 51,928 Da.  Shown is an SDS-PAGE (BioRAD Ready Gel 4-20%) analysis of 
purified SunS protein. 
 
 
 
Figure 4.17. In vitro reconstitution of SunS activity. MALDI-TOF mass spectra of His6-SunA before (black) and 
after (red) incubation with His6-SunS, UDP-glucose, and Mg2+. 
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Figure 4.18. Determination of the site of in vitro modification of His6-SunA by His6-SunS. (a) ESI-Q/TOF MS 
analysis of glucose-modified His6-SunA digested with chymotrypsin under reducing conditions. His6-SunA was 
modified with glucose, digested with chymotrypsin under reducing conditions, and analyzed by using LC-ESI-
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Q/TOF MS. Chymotrypsin cleavage sites (F, W, and Y residues) are indicated in the peptide sequence above the 
spectrum. The masses of the observed ions and their corresponding digest fragments are assigned. The results are 
consistent with Ser54 and Thr57 remaining unmodified and the peptide spanning residues Leu50-Tyr70 bearing a 
+162 Da post-translational modification. (b) ESI-Q/TOF MSMS analysis of residues Leu50-Tyr70 of glucose-
modified His6-SunA. His6-SunA was modified with glucose, digested with chymotrypsin under reducing conditions, 
and analyzed by using LC-ESI-Q/TOF MSMS.  The digest mixture was fractionated using LC and the multiply 
charged ion corresponding to residues Leu50-Tyr70 was selected for MSMS analysis. Fragmentation patterns are 
indicated for the y” ion series (upper) and the b ion series (lower). The results confirm that Ser54 and Thr57 remain 
unmodified and that Cys60 has a +162 Da post-translational modification. 
 
4.2.7 Probing the precursor peptide and NDP-sugar specificity of SunS  
 Interestingly, the enzyme displays strong chemoselectivity for glycosylation of a thiol 
because the His6-SunA mutant C22S (subcloned and expressed by Dr. Huan Wang of Prof. 
Wilfred van der Donk group) was not a substrate (Figure 4.19). The inability of SunS to modify 
the SunA C22S mutant peptide demonstrates its exclusive reactivity toward thiol-containing 
amino acid acceptors.  
 
 
Figure 4.19. Modification of His6-SunA C22S with glucose was attempted by incubation with His6-SunS in the 
presence of UDP-Glc, MgCl2, and TCEP in Tris (pH 7.5) buffer. The reaction was analyzed by MALDI-TOF MS. 
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 To further probe the substrate specificity of the peptide, four mutant SunA peptides were 
prepared and analyzed by Dr. Huan Wang. Interestingly, three of the four Cys residues in SunA 
that are not glucosylated  are flanked by Gln and Ala, whereas Cys22 that is glucosylated has 
two flanking Gly residues. When these two glycines were mutated to Gln and Ala, the resulting 
SunA-G21Q/G23A peptide was still glucosylated by SunS (Figure 4.20a). Mutation of these 
flanking glycines to charged residues (Lys or Glu) also did not prevent glucosylation (Figure 
4.20b-d) demonstrating that the flanking residues do not provide the basis of substrate 
recognition. 
 
 
Figure 4.20. Modification of (a) His6-SunA G21Q G23A, (b) His6-SunA G21E, (c) His6-SunA G23E,and (d) His6-
SunA G23Kwith glucose was achieved by incubation with His6-SunS in the presence of UDP-Glc, MgCl2, and 
TCEP in Tris (pH 7.5) buffer. The reactions were analyzed by MALDI-TOF MS. 
 
 To evaluate whether the leader peptide guides SunS activity, I engineered a Factor Xa 
cleavage site into the SunA substrate at the junction of the leader and core peptides (Figure 
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4.21a). Expression of His6-SunA-Xa and proteolytic cleavage with Factor Xa allowed 
purification of the 37-residue core peptide. Incubation with His6-SunS and UDP-Glc resulted in 
full glucosylation of Cys22, demonstrating that the leader peptide is not required for enzyme 
activity (Figure 4.21b).  
 
 
Figure 4.21. (a) Sequences of His6-SunA and His6-SunA Xa peptides. His6 tag (red), leader peptide (blue), and core 
peptide (black) are indicated. Factor Xa cleavage site is underlined. (b) SunA core peptide was modified with 
glucose by incubation with His6-SunS in the presence of UDP-Glc, MgCl2, and TCEP in Tris (pH 7.5) buffer. The 
leader peptide was not added to the reaction. The reaction was analyzed by MALDI-TOF MS. The overlay of mass 
spectra obtained by MALDI-TOF MS analysis of the mixture before (black) and after SunS reaction (red) is shown. 
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 To determine the substrate selectivity of SunS, the enzyme was incubated with His6-
SunA and Mg2+ in the presence of UDP-α-D-N-acetylglucosamine (UDP-GlcNAc) and UDP-α-
D-galactose (UDP-Gal) resulting in glycosylation of SunA at Cys22 (Figure 4.22a-b). GlcNAc-
modified His6-SunA peptide was digested with chymotrypsin to afford digest fragments 
indicating glycosylation at the expected Cys residue. Tandem MS analysis of the peptide of 
interest confirmed N-acetylglucosaminylation at Cys22 (see Experimental 4.4.11). Surprisingly, 
even guanosine diphosphate α-D-mannose (GDP-Man) and UDP-α-D-xylose (UDP-Xyl) proved 
to be substrates (Figure 4.22c-d). In the absence of SunS, no activity was detectable.  
  
Figure 4.22. (a) MALDI-MS data for modification of His6-SunA with various sugars. His6-SunA was modified with 
various sugars by incubation with His6-SunS in the presence of respective NDP-sugar, MgCl2, and TCEP in Tris (pH 
7.5) buffer. The reaction was analyzed by MALDI-TOF MS. Modification of SunA with (a) N-acetylglucosamine, 
(b) galactose, (c) mannose, and (d) xylose. 
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 Analysis of the glycosylation reactions with UDP-GlcNAc, UDP-Gal, GDP-Man, and 
UDP-Xyl demonstrated that the reactivity of these substrates was somewhat less efficient than 
the corresponding reaction with UDP-glucose but all reactions could be coerced to high 
conversion (Table 4.1. See Experimental 4.4.14). Thus, SunS is highly promiscuous with respect 
to its nucleotide-sugar donor co-substrate. These findings provide a new tool for 
glycodiversification of peptide natural products34,35 and enables the addition of rationally 
designed S-linked structures to the natural product repertoire.   
 
 
UDP-Glc > UDP-Gal > GDP-Man > UDP-GlcNAc > UDP-Xyl 
 
Table 4.1. Summary of results for the kinetics of SunS glycosyltransferase activity with NDP-sugars. The relative 
amounts of sugar-modified and unmodified His6-SunA peptide was determined by quantifying the HPLC peak area 
corresponding to each form of the peptide by integration. Percent conversion was calculated by dividing the peak 
area of sugar-modified peptide by the sum of the peak areas corresponding to sugar-modified and unmodified 
peptide. As indicated in the table, the observed conversions suggest that SunS displays preference for NDP-sugars in 
the order from most preferred to least preferred substrate. 
 
  
Sugar Concentration of NDP-Sugar Observed % Conversion
5 mM 95.2
50 μM 92.6
500 nM 11.0
5 mM 91.6
50 μM 69.9
500 nM 6.2
5 mM 90.6
50 μM 54.9
500 nM 4.2
5 mM 87.4
50 μM 57.9
500 nM 2.5
5 mM 69.4
50 μM 39.4
500 nM 1.4
Glc
Gal
Man
GlcNAc
Xyl
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4.2.8 In vitro reconstitution of sublancin biosynthesis  
 Reduction of the disulfides of sublancin resulted in complete loss of antimicrobial 
activity against B. subtilis ATCC 6633 in an agar diffusion assay, showing their importance for 
activity (Figure 4.12). An in vitro oxidative folding protocol was therefore developed to 
investigate the effect of glycosylation on the antimicrobial activity of sublancin. His6-SunA-Xa 
glucosylated by His6-SunS was treated with Factor Xa, followed by oxidative folding through the 
addition of a mixture of oxidized and reduced glutathione and EDTA.36 Subsequent analysis by 
antimicrobial assays, proteolytic digests, and ESI-MSn analysis verified the complete in vitro 
reconstitution of sublancin biosynthesis with the correct disulfide connectivities (see supporting 
data in Experimental 4.4.18). Leaving out any of the three steps (glucosylation, proteolysis or 
oxidative refolding) resulted in inactive material (Figure 4.23). These observations show that 
glucosylation is required for bioactivity and that the leader peptide inhibits bioactivity. It was not 
possible to investigate whether SunS can also glycosylate oxidatively folded SunA because the 
enzyme required the presence of reducing agent for activity. 
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Figure 4.23. Antimicrobial activity assay of in vitro prepared sublancin with omission of single steps. The 
importance of each step (glycosylation, leader peptide removal, and disulfide formation) in the in vitro preparation 
of sublancin was demonstrated through an antimicrobial activity assay against B. subtilis ATCC 6633. Sublancin 
samples were prepared in parallel whereby a different step of the preparation process was omitted for each of the 
samples. Glucose was used as the modifying sugar. The antimicrobial properties of each sample were assessed by its 
ability to inhibit the growth of B. subtilis ATCC 6633. Authentic sublancin standards were tested as positive 
controls. The steps that were used are indicated below. The sample in which all three steps (glycosylation, leader 
peptide removal, and disulfide formation) were used displayed a zone of inhibition (far left). The samples which did 
not undergo glucosylation (middle left), had the leader peptide intact (middle right), or did not undergo oxidative 
folding (far right) did not show inhibitory activity.  
 
4.2.9 In vitro production of sublancin analogues 
 Interestingly, the SunA core peptides with different sugar moieties attached to Cys22 
were also amenable to oxidative folding resulting in various sublancin analogues with the correct 
disulfide connectivities as determined by proteolytic digests and ESI-MSn analysis (see 
Experimental 4.4.18). Bioassays demonstrated that the native (glucosylated) sublancin was 
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slightly more active than these analogues (Figure 4.24), but it cannot be ruled out that small 
differences observed in the inhibition zones may be the result of small amounts of co-eluting 
peptides with alternative disulfide topologies that may be present in the final material. 
Regardless, although glycosylation is required for bioactivity, the stereochemistry of the hexose 
appears to be less critical.  
  
Figure 4.24. Antimicrobial activity assays of in vitro produced sublancin and sublancin analogues against B. subtilis 
6633. The type of sugar attached to Cys22 is indicated. Compounds were produced by incubating His6-SunA-Xa 
with His6-SunS and NDP-sugar, followed by proteolysis with Factor Xa to remove the leader peptide, and 
subsequent oxidative folding to generate the disulfides. Authentic sublancin standards produced and purified from B. 
subtilis 168 were used as positive controls. 
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4.2.10 Efforts toward identifying the specific molecular target of sublancin  
 It is unknown if sublancin has a precise molecular target which it utilizes to affect 
sensitive bacteria cells. In a previous report, the bioactivity of sublancin was evaluated against a 
panel of Gram-positive and Gram-negative bacteria.5 Sublancin was active against only a subset 
of Gram-positive species. Inhibitory activity was strongest against related bacilli including B. 
megaterium and B. subtilis 6633 with low micromolar MICs, and relatively weaker against cocci 
including Staphylococcus aureus and Streptococcus pyogenes (mid to high micromolar MICs). 
This overall narrow spectrum and weaker inhibitory activity may be an indication that sublancin 
does not bind to a precise target or may do so, but with weak affinity. 
 Lipid II has been identified as the molecular target for many peptide-based antibiotics 
including members of the post-translationally modified lantibiotics family37-40 and several 
glycopeptides.41-46 A recently developed transglycosylase assay47 was utilized to determine if 
sublancin binds to lipid II (see Section 2.2.6). Sublancin did not demonstrate any ability to bind 
lipid II to inhibit the transglycosylase reaction even at high concentrations up to 200 μM (Figure 
4.25). 
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Figure 4.25. In vitro transglycosylase assays using PBP1b, lipid II, and sublancin peptide. Sublancin does not 
demonstrate inhibition at concentrations as high as 200 μM. When errors bars are not visible, the error was smaller 
than the size of the symbol used. The horizontal axes indicate the concentrations of sublancin used in the reaction. 
The vertical axes indicate the relative amount of peptidoglycan formed in each reaction. The %PG (relative) is 
defined by [polymerized peptidoglycan / (total free lipid II + polymerized peptidoglycan)] normalized to 100%. 
 
4.2.11 Discovery of biosynthetic gene clusters for putative S-linked glycopeptides 
 A search of the databases revealed several gene clusters in diverse host organisms that are 
similar to the sublancin cluster, including genes for putative precursor peptides and putative S-
glycosyltransferases (Figure 2.26). The precursor peptides have low sequence identity but all are 
rich in Cys residues in the predicted core peptide. Thus, S-linked glycopeptides may be more 
common than currently appreciated. Many putative precursor peptides have 5 Cys residues 
within their predicted core peptide sequences, and therefore may share structural features with 
sublancin including two disulfide bonds and a single modified Cys residue.  
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                                           1                                               50 
        sublancin precursor NP_390031   (1) MEKLFKEVKLEELENQKG-------------------SGLGKAQCAALWL 
              B cereus E33L YP_245531   (1) MNKFIRELKAEELTKHVG--------------------GVDSKNETVIHD 
              B cereus E33L YP_245532   (1) MNKFIRELKTEELTKHVG--------------------GIDPKNETVIHD 
              B cereus E33L YP_245533   (1) MNKFIRELKTEELTKHVG--------------------GIDPKNETVIHD 
              B cereus E33L YP_245534   (1) MNKFMRELKTEELTKHVG--------------------GIDPKNETVIHD 
B thuringiensis BGSC 4AW1 ZP_04099938   (1) MKELIKELNLEELETFEGGYDGVNYMHQHDGGGAGGGSGIGTAQCAYFKA 
  Plantaricin ASM1 precursor AB474371   (1) MSKLVKTLTVDEISKIQTN----------------GGKPAWCWYTLAMCG 
      E faecalis HIP11704 ZP_05566853   (1) MSKLLRELTDKEIQSSLSN----------------GGSTCSMYKALLPGH 
                            Consensus   (1) MNK IRELK EELTKHVG                    GID KNETVIHD 
 
                                            51             *                 85 
        sublancin precursor NP_390031  (32) QCASGGT------IGC-GGGAVACQNYRQFCR---- 
              B cereus E33L YP_245531  (31) GGGAGPNCK-SLLNQCILKNFKACGLFDQYCYREWL 
              B cereus E33L YP_245532  (31) GGGAGPNCR-RLAQSCILKNFKSCGLFDQFC----- 
              B cereus E33L YP_245533  (31) GGGAGPNCK-MLLLGCQMKYISQCNLWTQFCRS--- 
              B cereus E33L YP_245534  (31) GGGAGPNCK-VLFVGCRAKDWELCQLWYDFCR---- 
B thuringiensis BGSC 4AW1 ZP_04099938  (51) LCYSGGSEWLGGYGGCGSTQ-NNCELARKYC----- 
  Plantaricin ASM1 precursor AB474371  (35) AGYDSGTCD-YMYSHCFGVKHSSGGGGSYHC----- 
      E faecalis HIP11704 ZP_05566853  (35) IAACAASAYFYGSSGCTAMRY-VSEYIRKNC----- 
                            Consensus  (51) GGGAGPNC   L  GC  K    C L  QFC      
 
Figure 4.26. (a) Representative gene clusters containing both a short open reading frame that may encode a 
substrate peptide and a glycosyl transferase with homology to SunS. Glycosyl transferase genes shown in green; 
genes encoding substrate peptide in black; genes encoding transporters shown in red; genes encoding thiol/disulfide 
isomerases shown in yellow, and genes encoding putative immunity proteins shown in light blue. (b) Sequence 
alignments of the sublancin precursor peptide with other peptides. Database mining of sequenced genomes revealed 
several clusters that could potentially harbor genes that encode for glycopeptide precursor peptides. These precursor 
peptide genes were found clustered near genes encoding for putative glycosyltransferase enzymes and were found 
among phylogenetically diverse bacteria. Fully conserved residues are in red font. Overall the sequence conservation 
is low, except for among the four variants in B. cereus where the conservation is moderate in the predicted core 
peptides (the peptide following the predicted GG or GS protease cleavage site). All leader peptides are rich in Glu, 
as previously noted as a general observation in leader peptides involved in natural product peptide biosynthesis.2 All 
cysteines are highlighted in green. Like sublancin, the precursor peptides from all organisms except B. cereus and E. 
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faecalis contain five cysteine residues. The cysteine that is glycosylated in sublancin is indicated with an asterisk 
and is conserved in all peptides. The precursor peptides from B. cereus and E. faecalis have an even number of 
cysteine residues. If they are involved in two disulfides as in sublancin, then they cannot be glycosylated. The 
glycosyltransferases in their gene clusters may then function as O-glycosyl transferases. 
 
 Each identified cluster contains a single gene encoding for a putative glycosyltransferase 
enzyme which is predicted to install a sugar post-translational modification onto the precursor 
core peptide (Figure 4.27). There is high sequence variability at the N-termini of the selected set 
of glycosyltransferases; however, from residues 100 to 300, there is remarkable sequence 
conservation. Finally, the sequences of the C-terminal tail amongst the putative 
glycosyltransferases are again highly variable. Analysis of the SunS amino acid sequence by I-
TASSER, a de novo protein structure prediction program,48 identified two distinct domains that 
included an N-terminal catalytic domain of approximately 370 residues and a C-terminal tail of 
approximately 50 residues (Figure 4.28). The N-terminal 370 amino acids shares high sequence 
identity with human UDP-GalNAc polypeptide alpha-N-acetylgalactosaminyltransferase-2 
catalytic domain, whereas the C-terminal tail does not share significant identity with other 
known proteins. Interestingly, this polypeptide alpha-N-acetylgalactosaminyltransferase-2 
homolog has a disposable C-terminal domain in addition to its catalytic N-terminal domain. In an 
effort to determine if SunS also possesses a disposable C-terminal domain, Dr. Huan Wang 
introduced a stop codon just 3’ of the 370 amino acid of SunS and subsequently expressed and 
purified the predicted N-terminal catalytic domain of the glycosyltransferase. Remarkably, the 
truncated protein still possessed glycosyltransferase activity, albeit its high specificity for 
exclusive modification of Cys22 was lost. More than one site of glycosylation along the SunA 
precursor sequence was observed (H. Wang and W. van der Donk, unpublished results). 
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                                             1                                               50 
                       SunS NP_390028    (1) ----------MKLSDIYLELKKGYADSLLYS------------------- 
      B cereus BDRD-ST196 ZP_04265312    (1) MGNFNYISNELRYNINFFEISYNKLLAMNINDDNLLNKVSKRISLLRHIN 
B thuringiensis BGSC 4CC1 ZP_04082010    (1) MTNFNYVSKELRYNINFFEIACNKLLTMNIDDNSLLKKVEKRLALLKHIH 
      E faecalis HIP11704 ZP_05566852    (1) -------------------------------------------------- 
        E faecalis TX0104 ZP_03947483    (1) -----------MYSENFIANDWFNVEVFNKNKYTLTNQENK--------- 
B thuringiensis BGSC 4AW1 ZP_04099941    (1) ---------METLNDLVTRLEHSHPNSSLLKDLSLIQ------------- 
            E faecalis V583 NP_817067    (1) -----------MYSENFITNDWFNVEVFNKNKYTLTNQENK--------- 
                            Consensus    (1)             Y DNF  I    L   N    SL N   K          
                                             51                                             100 
                       SunS NP_390028   (22) -------DLS--LLVNIMEYEKDIDVMSIQSLVAGYEKSDTPTITCGIIV 
      B cereus BDRD-ST196 ZP_04265312   (51) KYSEEANGLLSDLHSNVVKELNCLSDTKFIEILKNFLTTKKIKISVNIMT 
B thuringiensis BGSC 4CC1 ZP_04082010   (51) KYSEEVNELLCELNSDTVDEINHLSDIQFIEMLKRFLVTKRIKVSVNIMT 
      E faecalis HIP11704 ZP_05566852    (1) ---------------------------------------MLRNFSVIIIC 
        E faecalis TX0104 ZP_03947483   (31) ----DVTELWLQILKGLKFPNELKETVSYSKNLKELSLKTHAEVSVCIIA 
B thuringiensis BGSC 4AW1 ZP_04099941   (29) ------GNEQ--YNYIKWGDLSNSQ--NLNELVFQYEKAPYPSITCGILT 
            E faecalis V583 NP_817067   (31) ----DVTELWLQILKGLKFPNELKETVSYSKNLKELSLKTHAEVSVCIIA 
                            Consensus   (51)     D  EL   L   L         V F  LLK F       ISV II  
                                             101                                            150 
                       SunS NP_390028   (63) YNESKRIKKCLNSVKD---DFNEIIVLDSYSTDDTVDIIKCDFPD-VEIK 
      B cereus BDRD-ST196 ZP_04265312  (101) LNEERCIARCIESIQD---LADEIIILDTGSTDKTREIIRNNFPD-AKLY 
B thuringiensis BGSC 4CC1 ZP_04082010  (101) LNEERCIERCIRSIKN---FADEIIVLDTGSTDKTLEIIQKEFPD-VKLY 
      E faecalis HIP11704 ZP_05566852   (12) KNEERVIKRCIESIQKNLKKNDEIIVVDTGSTDNTIKIISSIENV--KLF 
        E faecalis TX0104 ZP_03947483   (77) KNEQDSIRKCINSIYE---FSDEIIFIDTGSIDSTKKIVKEIASEKVKIF 
B thuringiensis BGSC 4AW1 ZP_04099941   (69) YNEERCIKRCLDSLGS---QFDEILVLDSHSTDNTTKIINRDFPM-VKVI 
            E faecalis V583 NP_817067   (77) KNEQDSIRKCINSIYE---FSDEIIFIDTGSIDLTKKIVKEIASEKVKIF 
                            Consensus  (101)  NEER IKRCI SI D    ADEIIVLDTGSTD T KIIK  FPD VKIF 
                                             151                        * *                 200 
                       SunS NP_390028  (109) YEKWKNDFSYARNKIIEYATSEWIYFIDADNLYSKENKGKIAKVARVLEF 
      B cereus BDRD-ST196 ZP_04265312  (147) RIEWKNDFSECRNRLIDYSTGDWVLQIDADEHLEIKQKD-IREFLELLYE 
B thuringiensis BGSC 4CC1 ZP_04082010  (147) CTEWKDNFSECRNQLIDYSTGDWIFQIDADEDLEINQED-LRDFLELFYE 
      E faecalis HIP11704 ZP_05566852   (60) NYEWKDDFADARNFGISKAKKDWIFFIDSDEIMSKGCLEQLNASINEAMA 
        E faecalis TX0104 ZP_03947483  (124) DYTWQDDFSDARNYSIQKASKEWILIIDADEYVSSDELIKLRLLIDMLDR 
B thuringiensis BGSC 4AW1 ZP_04099941  (115) YEPWIDDFSFHRNKLISLTSSEWIYYIDADNYCVDSTNK-FKRVAKLIQF 
            E faecalis V583 NP_817067  (124) DYTWQDDFSDARNYSIQKASKEWILIIDADEYVSSDELTKLRLLIDMLDR 
                            Consensus  (151)    WKDDFSDARN LI  AS EWIF IDADEYLS      LR LIDLL   
                                             201                                            250 
                       SunS NP_390028  (159) FSIDC---VVSPYIEEYTGHLYSDTRRMFRLNGKVKFHGKVHEEPMNYN- 
      B cereus BDRD-ST196 ZP_04265312  (196) FPISP--VVICPKIKNHDNQELDFNKRIFRKKDNLKYFGIIHEDLRYDIQ 
B thuringiensis BGSC 4CC1 ZP_04082010  (196) FPKSP--MVICPKIKNHDNQELDFNKRIFKKNDNLRYFGMIHEDLRYNIQ 
      E faecalis HIP11704 ZP_05566852  (110) YSENNEKLVFSPKAVNTDDSVFYNAGRIFANDGNIKYEGCVHEYPVVTD- 
        E faecalis TX0104 ZP_03947483  (174) FKFKDS-LRVSCAIYQLDNVITHGQSRLFRNNNKIKYYGLIHEELRNNK- 
B thuringiensis BGSC 4AW1 ZP_04099941  (164) LSIDC---IISPMIKEHIGHVYTDNRKMFSVKKGIQFKGKVHEEPINADG 
            E faecalis V583 NP_817067  (174) FKFKDS-LRVSCAIYQLDNVITHGQSRLFRNNNKIKYYGLIHEELRNNK- 
                            Consensus  (201) F      LVISP I NHDN I   NKRIFR N  IKYFGLIHEELRN    
                                             251                                            300 
                       SunS NP_390028  (205) --HSLPFNFIVNLKVYHNGYNPSENNIKSKTRRNINLTEEMLRLEPENPK 
      B cereus BDRD-ST196 ZP_04265312  (244) KKGSDLIYFTTDFTFNHDGYKPEIRESKNKCKRNLKLQHKMMHIEPDNIR 
B thuringiensis BGSC 4CC1 ZP_04082010  (244) KKGDDLIYFTTDFVLNHDGYKPEIIELKNKYKRNLDLENEMVRIEPDNIR 
      E faecalis HIP11704 ZP_05566852  (159) KSLTLVSLKLPRVIVRHDGYEKEVRADKNKTVRNITLIKKILQEEPNNSQ 
        E faecalis TX0104 ZP_03947483  (222) -GLDPIFNVESEITFFHDGYKEILR--KEKCERNIRLLAKMLEKEPDNVR 
B thuringiensis BGSC 4AW1 ZP_04099941  (211) ---SIPQNITVDIMICHDGYDPEVINLSEKNDRNIKLTRQMMEEEPSNPK 
            E faecalis V583 NP_817067  (222) -GLDPIFNVESEITFFHDGYKEILR--KEKCERNIRLLAKMLEKEPDNVR 
                            Consensus  (251)    S I N  SDI V HDGYKPEIR  K K  RNIKL  KML  EPDNIR 
                                             301                                            350 
                       SunS NP_390028  (253) WLFFFGRELHLLDKDEEAIDYLKKSINNYKKFN-------DQRHFIDALV 
      B cereus BDRD-ST196 ZP_04265312  (294) WYYFLAREQKQAIYSDEEVVNTLVQGIENSKD-----NHENNHFYLRSLL 
B thuringiensis BGSC 4CC1 ZP_04082010  (294) WFYFLARERKLAGYSDEAVIHTLVQGIKNSKN-----EQKTNHFYFLSLL 
      E faecalis HIP11704 ZP_05566852  (209) YYYYYYRDSKPLITIEEYEQGMLNFFEKFPDS----------PYIDQVVR 
        E faecalis TX0104 ZP_03947483  (269) WAYLYCRDSFSINSNIDFEKILLPFLIKNMDESISCENILLTNYTHLILF 
B thuringiensis BGSC 4AW1 ZP_04099941  (258) WLYFYARELHYASEDTHIIETLLIKAIDLYKQS------TYKRYQPEAIL 
            E faecalis V583 NP_817067  (269) WAYLYCRDSFSINANIDFEKILLPFLIKNMDESISYENILLTNYTHLILF 
                            Consensus  (301) W YFYARE   I   DE I  LL   IKN K            Y   ALL 
 
Figure 4.27. (continued on next page)    
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                                             351                                            400 
                       SunS NP_390028  (296) LLCTLLLQRNNYVDLTLYLDILETEYPR-----CVDVDYFRSAILLVDMQ 
      B cereus BDRD-ST196 ZP_04265312  (339) MLADIYDSQRDFEALHGIVNELSNRFPY-----CIDGLYYSLINNWANQS 
B thuringiensis BGSC 4CC1 ZP_04082010  (339) MLADIYHNNHNFEALHGIANELSNGFPY-----CIDGLYYNLISSWAYQS 
      E faecalis HIP11704 ZP_05566852  (249) DLAYHYIQVGKNELAEEYINMLFESAENGAKENYHLAILYTGMNEMGKIK 
        E faecalis TX0104 ZP_03947483  (319) LITKKYIIDGKSSLASKCIEVLEKMLPN-----SSDVTFYKFLNKQHSLY 
B thuringiensis BGSC 4AW1 ZP_04099941  (302) LLCSILFQKRQIRKLNEYLDLLEELQPL-----CSDVNYYRSLILFYDIR 
            E faecalis V583 NP_817067  (319) LITKKYIIDGKSSLASKCIKVLEKMLPN-----SSDVTFYKFLNKQHSLY 
                            Consensus  (351) LL  IYIQ      L   I VLE   P      C DV YYK LN    I  
                                             401                                            450 
                       SunS NP_390028  (341) NKLTSLSNMIDEALT---DERYSAINTTKDHFKRILISLNIQLENWERVK 
      B cereus BDRD-ST196 ZP_04265312  (384) SQISNLIQNTFQHMR-KIESPFSIINSNGYHMFYLLGMLYFNLGNYEKSF 
B thuringiensis BGSC 4CC1 ZP_04082010  (384) SQISLLTEKSFQHMR-KVESPYSIINSNGYHIFYLLGMLYFNVGNYAKAF 
      E faecalis HIP11704 ZP_05566852  (299) AQQKDILKLLVYAHD-NVLQQEEELFDKGYIFDDLISILFFQIEEYETAY 
        E faecalis TX0104 ZP_03947483  (364) EQQFEFLKEVIQFRKNNEYDQYSQIGCNLLHYDLLISGLLFDVKSYDYSY 
B thuringiensis BGSC 4AW1 ZP_04099941  (347) LKTGKLLDTLKSSELE--NNKYSFIDSSKDHIKALLIELYCSIDDWEGAF 
            E faecalis V583 NP_817067  (364) EQQFEFLKEVIQFRKNNEYDQYSQIGCNLLHYDLLISGLLFDVKSYDYSY 
                            Consensus  (401)  Q   LL  L Q  K      YS I SN  HF  LL  LYFNV  YE AF 
                                             451                                    492 
                       SunS NP_390028  (388) EISG-------EIKNDNMKKEIKQYLANSLHNIEHVLKGIEV 
      B cereus BDRD-ST196 ZP_04265312  (433) QMFS-------IIKDDTLLDEIRSKLNAIKDNIENFSSK--- 
B thuringiensis BGSC 4CC1 ZP_04082010  (433) QMFS-------IIKDDIMLDEIKSNLNVLKDNIENFLSK--- 
      E faecalis HIP11704 ZP_05566852  (348) KICEKLDSCGYASNISKMISKLKVVLSPNSKNFR-------- 
        E faecalis TX0104 ZP_03947483  (414) QYFLKLDLA-NYFSELEIPDEYKMLINKYRENES-------- 
B thuringiensis BGSC 4AW1 ZP_04099941  (395) TLFD-------ELQSTEARNKFLRRVKTINTHISKKI----- 
            E faecalis V583 NP_817067  (414) QYFLKLDLA-NYFSELEIPDEYKMLINKYRENES-------- 
                            Consensus  (451) QIF         I D  M DEIK  LN  KDNI          
 
Figure 4.27. Sequence alignments of SunS with other putative glycosyltransferases located near genes encoding 
short peptides. Database mining of sequenced genomes revealed several clusters containing a gene for a putative 
glycosyltransferase. These glycosyltransferase genes were found clustered near genes encoding for potential for 
glycopeptide precursor peptides. The putative glycosyltransferase enzymes were found among phylogenetically 
diverse bacteria. The asterisks (*) above the sequences indicate the putative divalent metal (Mg2+, Mn2+) binding 
site. 
 
 
 
Figure 4.28. De novo structure prediction results for SunS. N-Terminal domain shown on left side of image, C-
terminal domain on right side. 
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 In addition to the presence of a substrate peptide and glycosyltransferase, many of the 
identified biosynthetic clusters contain two genes encoding for putative thiol-disulfide 
oxidoreductase/isomerase or thioredoxin-like proteins with sequence homology to bdbA and 
bdbB genes. Each cluster also contains a gene encoding for a putative ATP-dependent transporter 
much like that of sunT which encodes for the dedicated bi-functional transporter and protease 
responsible for export and leader peptide removal in the final steps of sublancin maturation. 
 
4.2.12 Identification and characterization of thuringiencin 
 One of the many putative S-linked glycopeptide biosynthetic gene clusters identified 
through bioinformatics analysis was further characterized. The biosynthetic gene cluster found in 
Bacillus thuringiensis serovar andalousiensis BGSC 4AW1 (Figure 4.29) contains a putative 
precursor gene (termed thuA, NCBI: bthur0009_56250, ZP_04099938) encoding for 80 residues 
including the N-terminal Met. Based on sequence homology with other known bacteriocins and 
the glycopeptide sublancin, it is predicted that this precursor sequence contains an N-terminal 
leader peptide of 38 residues and a C-terminal core peptide of 42 amino acids (Figure 4.30a). 
The C-terminal region of the leader peptide is remarkably glycine rich and its leader sequence 
 
Figure 4.29. Putative biosynthetic gene cluster identified via genome mining for the production of the S-
glycopeptide, thuringienicin. The gene encoding for the glycosyltransferase shown in green; gene encoding substrate 
peptide in black; genes encoding transporter shown in red; and genes encoding thiol/disulfide isomerases shown in 
yellow. 
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resembles that of the double glycine type. Overall, the ThuA leader peptide is significantly 
longer than that of SunA (19 residues). In consideration of the dispensability of the SunA leader 
peptide, this two-fold increase in length may suggest that the ThuA leader sequence will have an 
influence on core peptide modification. The predicted thuringienicin core peptide displays high 
sequence similarity with sublancin. Both peptides share a GXGXAQCA motif at their core 
peptide N-termini as well as a CXSGG(T/S) sequence just N-terminal to their expected Cys 
glycosylation site (Figure 4.30b).  
 
                1                                               50 
     SunA   (1) MEKLFKEVKLEELENQK-------------------GSGLGKAQCAALWL 
     ThuA   (1) MKELIKELNLEELETFEGGYDGVNYMHQHDGGGAGGGSGIGTAQCAYFKA 
Consensus   (1) M  L KEL LEELE                      GSGIG AQCA     
 
                51                           81 
     SunA  (32) QCASGGT-----IG-CGGGAVACQNYRQFCR 
     ThuA  (51) LCYSGGSEWLGGYGGCGSTQNNCELARKYC- 
Consensus  (51)  C SGG       G CG     C   R FC  
 
Figure 4.30. (a) Primary sequence of the full length precursor peptide ThuA. Leader is shown in blue, core peptide 
in black, and predicted cleavage site is underlined in red. (b) Sequence alignment of SunA and ThuA precursor 
peptides. Fully conserved residues text in red and highlighted in yellow. Similar residues highlighted in green. Fully 
conserved Cys residues of the core peptide bolded and underlined. 
 
 Like the gene cluster for the biosynthesis of sublancin, genes encoding for enzymes of 
similar function were also found in the thuringiencin biosynthetic gene cluster including two 
putative thiol-disulfide oxidoreductases (NCBI: bthur0009_56260 and unannotated gene 
immediately downstream to bthur0009_56280), an ATP-dependent transporter with an N-
terminal transport domain and C-terminal protease domain (NCBI: bthur0009_56260), and a 
putative glycosyltransferase (NCBI: bthur0009_56280) sharing 39.3% amino acid sequence 
identity with SunS. To date, none of these genes or their gene products have been characterized. 
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4.2.13 In vitro reconstitution of ThuS glycosyltransferase activity  
 To confirm its predicted function, the gene encoding for the putative glycosyltransferase 
(termed thuS) was cloned from isolated Bacillus thuringiensis serovar andalousiensis BGSC 
4AW1 genomic DNA and was expressed in Escherichia coli as an N-terminal fusion protein 
with a hexa-histidine tag (His6-ThuS, Figure 4.31). Upon purification by immobilized metal 
affinity chromatography, His6-ThuS was incubated with the putative precursor peptide His6-
ThuA, also cloned and expressed in E. coli. Addition of uridine diphosphate α-D-glucose (UDP-
Glc) and Mg2+ resulted in conversion of ThuA to a product consistent with glucosylation at two 
sites (Figure 4.32). Subsequent trypsin digest and ESI-q/TOF MS analysis led to the 
identification of a digest fragment spanning residues Ala69-Arg96 that contained the two glucose 
modifications (Figure 4.33a), numbering relative to predicted start site of full-length His6-ThuA 
peptide). Tandem mass spectrometry analysis of this digest fragment verified that single glucose 
modifications were installed at residues Cys85 and Ser76 (Figure 4.33b). 
 
 
Figure 4.31. Purification of ThuS glycosyltransferase. The gene thuS was cloned and expressed in Escherichia coli 
as an N-terminal fusion protein with a hexa-histidine tag (His6-ThuS). His6-ThuS consists of 447 amino acids and 
has a predicted molecular weight of 52,240 Da.  Shown is an SDS-PAGE (BioRAD Ready Gel 4-20%) analysis of 
purified ThuS protein. 
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 The ability of ThuS to modify its precursor peptide at two different sites was not 
anticipated provided that SunS was only able to modify its substrate at a single site. Moreover, 
each site of modification by ThuS is chemically different as well. A total of 5 Cys reside within 
the ThuA core peptide. Despite its promiscuous chemoselectivity, ThuS shares similar 
regioselective properties as SunS and catalyzes modification of residues in which the residue to 
be modified is flanked by small hydrophobic residues located approximately halfway along the 
core peptide backbone. Mutagenesis studies of the ThuA precursor sequence are necessary to 
fully identify the specific “rules” ThuS follows to preferentially modify the core peptide at a 
limited number of sites.  
 
 
Figure 4.32. In vitro reconstitution of ThuS activity. MALDI-TOF MS spectra of His6-ThuA before (black) and 
after (red) incubation with His6-ThuS, UDP-glucose, and Mg2+. 
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Figure 4.33. Determination of the site of in vitro modification of His6-ThuA by His6-ThuS. (a) His6-ThuA was 
modified with glucose, digested with trypsin under reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. 
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Trypsin cleavage sites (K and R residues) are indicated in the peptide sequence above the spectrum. The masses of 
the observed ions and their corresponding digest fragments are assigned. The results are consistent with residues 
Ala69-Arg96 bearing two +162 Da post-translational modifications. (b) The digest mixture was fractionated using 
LC and the multiply charged ion corresponding to doubly modified Ala69-Arg96 (3177.3232 Da) was selected for 
MSMS analysis. Fragmentation pattern is indicated for the y” ion series. The results confirm that both Cys85 and 
Ser76 have a +162 Da post-translational modification. 
 
4.2.14 ThuS displays the ability to modify unnatural substrate peptides  
 The successful in vitro reconstitution of ThuS glycosyltransferase activity confirms an 
additional substrate-enzyme pair involved in the biosynthesis of an S-linked glycopeptide. 
Though many other pairs are likely to exist, ThuA-ThuS and SunA-SunS represent the only 
substrate-enzyme cognate pairs identified and characterized to date for S-glycosylation. To 
determine the ability of the glycosyltransferases to act upon unnatural, but homologous 
substrates, a precursor peptide (SunA or ThuA) was incubated with either glycosyltransferase 
(SunS or ThuS) in the presence of UDP-Glc and Mg2+. Remarkably, ThuS was able to doubly 
modify SunA peptide (Figure 4.34). Subsequent chymotrypsin treatment of ThuS-modified SunA 
peptide generated a series of digest fragments (Figure 4.35). The digest fragment corresponding 
to residues Leu12-Tyr32 contained both sugar modifications. Tandem mass spectrometry 
analysis of this digest fragment clearly identified a glucosylation at Cys22 (Figure 4.36). The 
second glucosylation occurred on either Ser16, Thr19, or Cys29 in a mutually exclusive manner 
(Figure 4.37). Thus, a mixture of modified ThuA products was obtained bearing modifications at 
Cys22 and Ser16, modifications at Cys22 and Thr19, or modifications at Cys22 and Cys29. SunS 
glycosyltransferase was not able to modify ThuA peptide. 
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Figure 4.34. Modification of His6-SunA with glucose was achieved by incubation with His6-ThuS in the presence of 
UDP-Glc, MgCl2, and TCEP in Tris (pH 7.5) buffer. The reaction was analyzed by MALDI-TOF MS. The overlay 
of mass spectra obtained by MALDI-TOF MS analysis of the mixture before (black) and after ThuS reaction (red) is 
shown. 
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Figure 4.35. His6-SunA was double\y modified with glucose by His6-ThuS, digested with chymotrypsin under 
reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. Chymotrypsin cleavage sites (F, W, and Y 
residues) are indicated in the peptide sequence above the spectrum. The masses of the observed ions and their 
corresponding digest fragments are assigned. The results are consistent with the peptide spanning residues Leu50-
Tyr70 bearing two +162 Da post-translational modifications. "(Glc)" indicates that one of the three sites is modified 
on any given peptide sample (see Figure 4.37)  
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Figure 4.36. ESI-Q/TOF MSMS analysis of residues Leu50-Tyr70 of doubly glucose modified His6-SunA by His6 
ThuS. His6-SunA was double modified with glucose, digested with chymotrypsin under reducing conditions, and 
analyzed by using LC-ESI-Q/TOF MSMS. The digest mixture was fractionated using LC and the multiply charged 
ion corresponding to residues Leu50-Tyr70 + 2 Glc (2253.9150 Da) was selected for MSMS analysis. 
Fragmentation patterns are indicated for the y” ion series. The results confirm that Cys60 (Cys22 for core peptide 
numbering) has a +162 Da post-translational modification. 
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Figure 4.37. (continued on next page) 
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Figure 4.37. ESI-Q/TOF MSMS analysis of residues Leu50-Tyr70 of doubly glucose-modified His6-SunA by His6 
ThuS. His6-SunA was doubly modified with glucose, digested with chymotrypsin under reducing conditions, and 
analyzed by using LC-ESI-Q/TOF MSMS.  The digest mixture was fractionated using LC and the multiply charged 
ion corresponding to residues Leu50-Tyr70 + 2 Glc (2253.9150 Da) was selected for MSMS analysis. All panels are 
derived from the same single mass spectrum, but peaks are assigned according to different species representing the 
2253.9150 Da ion. Fragmentation patterns are indicated for the b ion series. (a) Peak assignments demonstrating 
presence of glucosylation on residues Cys22 and Ser16 (core peptide numbering). (b) Peak assignments 
demonstrating presence of glucosylation on residues Cys22 and Thr19 (core peptide numbering). (c) Peak 
assignments demonstrating presence of glucosylation on residues Cys29 (core peptide numbering).  
 
 Based on the sequence homology shared between ThuA and SunA, the known topology 
of sublancin, and the results of the in vitro reconstitution of ThuS glycosyltransferase activity, a 
structure for the final product of the S-glycopeptide from Bacillus thuringiensis 4AW1, termed 
thuringienicin, has been proposed (Figure 4.38). Considering the activity of ThuS, two post-
translational modifications are likely to exist on this natural product at positions Cys28 and 
Ser19. However it may be possible that only one glycosylation is present on the in vivo produced 
thuringienicin at Cys28, and that the double modification is in fact an artifact of an overactive 
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glycosyltransferase in the in vitro activity assays. However, the recently reported structure of the 
antimicrobial peptide glycocin F demonstrates that two glycosylations, at a Cys and Ser residue, 
can exist on a single S-glycopeptide natural product.49,50 It may then be possible that a single 
glycosylation, as observed with sublancin, is an anomaly. Furthermore, the sugar on 
thuringiencin may not be glucose. The isolation and purification of the natural product from the 
producing organism will greatly enhance our understanding of the structure, post-translational 
modification, and biosynthesis of this novel product. 
 
 
Figure 4.38. Proposed structure for the novel S-glycopeptide thuringienicin based on in vitro studies. Glycosylations 
were identified at residues Ser19 and Cys 28 of the core peptide. 
 
4.3. SUMMARY 
 In an effort to identify a fifth pathway to produce lanthionine-containing peptides, a novel 
and unusual class of S-linked glycopeptides were discovered and examined. The work presented 
in this chapter represents a significant breakthrough in the structural characterization and 
biosynthesis of S-linked glycopeptides and opens the opportunity for the discovery of additional 
natural products of this type. The structure of in vivo produced sublancin was studied in depth 
202 
using various approaches and the results of these studies offer a long-awaited answer to the 
questionable mass discrepancies noted in the original report describing sublancin. The revised 
structure aligns with the original reported mass of the natural product and establishes S-
glucosylation as a new post-translational modification. 
 Examination of the sublancin biosynthetic gene cluster found in the B. subtilis 168 
genome lead to the identification of a gene with sequence homology with known 
glycosyltransferases. The gene was cloned and heterologously expressed in E. coli. The 
recombinant protein was remarkably tolerant to variability of the NDP-sugar co-substrate and 
was able to glycosylate the sublancin precursor peptide with not only its native hexose sugar, 
glucose, but also a number of sugars including N-acetylglucosamine, galactose, mannose, and 
xylose. The SunS glycosyltransferase enzyme displayed remarkable chemo- and regio-selectivity 
for modification of only a single Cys among five available residues. Mutagenesis studies of the 
SunA precursor peptide demonstrated that flanking residues are not the recognition units utilized 
for regiospecificity of the glycosyltransferase enzyme. Unlike the lantibiotics and several other 
ribosomal peptide natural products made via leader peptide-directed biosynthesis, the leader 
peptide of SunA precursor was completely dispensible and is not a required element for the post-
translational modification of sublancin. 
 Using an in vitro production strategy, a number of sublancin analogues were produced to 
possess different sugar modifications at Cys22. Bioactivity assays against B. subtilis 6633 
demonstrated that the native (glucosylated) sublancin was slightly more active than the other 
analogues. In addition, glycosylation, leader peptide removal, and correct disulfide connectivity 
all were required for antimicrobial activity. 
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 Bioinformatic analysis of sequenced genomes led to the identification of several 
biosynthetic gene clusters that may produce S-linked glycopeptides in a diverse range of bacteria. 
Each identified biosynthetic gene cluster harbors genes encoding for a putative precursor 
peptide, glycosyltransferase, transporter, and additional tailoring enzymes. One cluster from 
Bacillus thuringiensis serovar andalousiensis BGSC 4AW1 was studied further. Its precursor 
peptide and glycosyltransferase were cloned, expressed, and characterized. The 
glycosyltransferase, ThuS, was found to function as an S- and O-glycosyltransferase and was 
able to catalyze the addition of glucose to a Cys and Ser residue of its native precursor peptide in 
a highly specific fashion. In addition, ThuS could modify Cys, Thr, and Ser residues along the 
core peptide of SunA. This glycosyltransferase demonstrates remarkable catalytic capabilities 
and is the second example of an enzyme of this type. Its unique catalytic properties, in 
combination with its good stability and solubility, make it an attractive target for crystallographic 
studies. Given the increased chemical stability of S-linked glycopeptides, SunS and ThuS have 
great potential for use in preparation of such compounds and provide a new tool for the 
glycodiversification of peptide natural products. 
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4.4. EXPERIMENTAL 
4.4.1. Materials, strains and plasmids, and general methods 
Materials. 
  All oligonucleotides were purchased from Integrated DNA Technologies. Restriction 
endonucleases, DNA polymerases, and T4 DNA ligase were purchased from New England 
Biolabs or Invitrogen. Factor Xa was purchased from New England Biolabs and chymotrypsin 
was purchased from Worthington Biochemical Corporation. Media for bacterial culture and 
chemicals were purchased from Fisher Scientific, Sigma Aldrich, or CalBiochem, unless noted 
otherwise, and used without further purification. Isotopically labeled media components were 
purchased from ISOTEC - Sigma Aldrich. 
 
Strains and Plasmids. 
 Bacillus subtilis 168 (sublancin producing organism) was obtained from Bacillus 
Genetics Stock Center, Ohio State University, Columbus, OH. The indicator strain, Bacillus 
subtilis ATCC 6633 was obtained from American Type Culture Collection, Manassas, VA. 
Escherichia coli DH5α (UIUC Cell Media Facility) was used as host for cloning and plasmid 
propagation, and E. coli BL21 (DE3) and E. coli Rosetta 2 (DE3) (Novagen) were used as hosts 
for protein expression. Cloning vectors (pET15b and pET28b) were obtained from Novagen. 
 
General Methods. 
 All molecular biology manipulations were carried out using standard techniques. 
Polymerase chain reaction (PCR) amplifications were carried out using an automated 
thermocycler (C1000, BioRAD). DNA sequencing was performed using appropriate primers by 
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the Biotechnology Center (University of Illinois at Urbana-Champaign, UIUC). GC-MS analysis 
was performed at the Roy J. Carver Metabolomics Center (UIUC). LC-ESI-Q/TOF MS analyses 
were conducted using a Synapt MS system equipped with an Acquity UPLC (Waters). MALDI-
TOF MS analyses were conducted at the Mass Spectrometry Facility (UIUC) using a Voyager 
DE-STR (Applied Biosystems). For MALDI-TOF MS analysis of salt-free samples, a 1 μL 
aliquot of analyte was combined with 1 μL of matrix (saturated α-cyano-4-hydroxy-cinnamic 
acid matrix  in 50% ACN/50% water with 0.1% TFA), and the total volume was spotted onto a 
MALDI target and dried under ambient conditions prior to analysis. Salt containing samples 
were desalted using ZipTipC18 (Millipore), eluted with 4 μL of matrix, and 2 μL was spotted onto 
a MALDI target and dried as described above. 
 
LC-ESI-Q/TOF MS and MSMS analyses. 
 A 5 μL volume of sample was injected on a Waters Acquity UPLC system equipped with 
a BEH C8 column (1.7 um, 100 mm x 1.0 mm) equilibrated in 3% B (solvent A =  0.1% formic 
acid in water, solvent B = 0.1% formic in methanol). The sample was fractionated by employing 
a gradient of 3%-97% B over 12 min and directly subjected to ESI-Q/TOF MS using a Waters 
Synapt mass spectrometer. Data was acquired in ESI positive mode with the capillary voltage set 
to 3.0-3.5 kV. Nitrogen was used as cone gas (0 L/h) and desolvation gas (600 L/h). The 
ionization source and desolvation gas were heated to 120 °C and 300 °C, respectively. The 
transfer collision energy was set to 4 V for both MS and MSMS analyses. The trap collision 
energy was set to 6 V (constant) for MS. For MSMS analysis, multiply charged parent ions were 
selected and fragmented using collision induced dissociation (nitrogen) with a trap collision 
energy ramp ranging from 20-60 V or a constant value between 25-45 V. The applied collision 
206 
energies for MSMS were analyte dependent. [Glu1]-Fibrinopeptide B (Sigma) was directly 
infused as lock mass with lock spray sampling at minute intervals. The acquired spectra were 
processed using MaxEnt3 software and analyzed by Protein/Peptide Editor in BioLynx 4.1 
(Waters). 
 
4.4.2. Isolation and purification of sublancin 
 A culture of B. subtilis 168 was grown in LB media under aerobic conditions at 37 °C for 
12-15 h. The overnight culture was used to inoculate (at 1%) 500 mL volumes of Medium A in 2 
L flasks. Medium A consisted of 900 mL of Medium A nutrient broth combined with 100 mL of 
10X Medium A salts. Medium A nutrient broth was prepared by dissolving 20 g sucrose, 11.7 g 
citric acid, 4 g Na2SO4, 4.2 g (NH4)2HPO4, and 5 g yeast extract in 900 mL of millipore water. 
The pH was adjusted to 6.8-6.9 using NaOH and the medium was autoclaved. Medium A salts 
(10X) were prepared by dissolving 7.62 g KCl, 4.18 g MgCl2-6 H2O, 0.543 g MnCl2-4 H2O, 0.49 
g FeCl3-6 H2O, and 0.208 g ZnCl2 in 1 L of millipore water followed by sterilization via 0.22 μm 
filtration. The Medium A cultures were grown under aerobic condition at 37 °C for 28-48 h with 
vigorous agitation. A color change to pinkish-brown was observed and the pH of cultures had 
lowered to 6-6.5. Sublancin production was consistently observed when these events occurred.  
 Cultures were acidified to pH 2.5 with concentrated phosphoric acid (85% in water) and 
centrifuged to remove cells and insoluble material. Sublancin was isolated by ammonium sulfate 
precipitation. Briefly, a 500 mL volume of sublancin-containing culture supernatant was 
combined with 245 g (NH4)2SO4 in a 1 L glass bottle to provide a 75% ammonium sulfate 
saturation at 4 °C. The precipitation mixture was stirred at 4 °C for 24 h and precipitated 
sublancin was isolated from the solution by centrifugation. The pelleted peptide was re-
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solubilized in 50/50 ACN/water with 0.1% TFA and was analyzed by MALDI-TOF MS. A 1 μL 
aliquot of sample was combined with 1 μL of matrix consisting of saturated α-cyano-4-hydroxy-
cinnamic acid matrix in 50% ACN/50% water with 0.1% TFA, and the total volume was spotted 
onto a MALDI target and dried under ambient conditions prior to analysis. The sublancin 
containing product were combined, lyophilized to dryness, and stored under N2 at −80 °C until 
purification by preparative HPLC.   
 Preparative HPLC was performed using a Waters Delta 600 instrument equipped with a 
Phenomenex Jupiter Proteo C12 column (10 μm, 90 Å, 250 mm x 15 mm) equilibrated in 2% B 
(solvent A =  0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water). Dry 
sublancin material was resuspended in 2% B and was applied to the column. Sublancin was 
eluted by maintaining the mobile phase at 2% B for 1 min, followed by an increase to 100% B 
over 45 min with a flow rate of 10.0 mL/min. Under these conditions, sublancin eluted at 22.7 
min. All fractions were analyzed by MALDI-TOF MS as described above. Purified sublancin 
was lyophilized to dryness and stored under N2 at −80 °C until further use. Typical yields were 
10-15 mg sublancin per liter of processed Medium A culture. 
 
4.4.3. Bioinformatics analysis of gene clusters 
Analysis of the biosynthetic gene cluster of sublancin 
 Information on the biosynthetic gene cluster responsible for in vivo production of 
sublancin containing genes sunI, sunA, sunT, bdbA, yolJ (sunS), and bdbB was accessed via the 
National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) with the 
following accession numbers: RefSeq = NC_000964 and GenBank = AL009126. The gene 
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cluster is 5080 nucleotides in length, is of chromosomal origin, and is found between base pairs 
2,270,305 – 2,265,225 (complement). 
 
Analysis of the biosynthetic gene cluster of thuringiencin. 
 Information on the biosynthetic gene cluster responsible for production of thuringienicin 
containing genes: thuA (bthur0009_56250), sunT homolog (bthur0009_56260), bdbA homolog 
(bthur0009_56270), thuS (bthur0009_56280), and bdbB homolog (unannotated, immediately 
downstream of bthur0009_56280) was accessed via the National Center for Biotechnology 
Information (NCBI, http://www.ncbi.nlm.nih.gov/) with the following accession numbers: 
RefSeq = NZ_ACNG00000000 and GenBank = ACNG01000000. The gene cluster is 4713 
nucleotides in length, is of chromosomal origin, and is found between base pairs 5,424,818 – 
5,429,531. 
 
4.4.4. Iodoacetamide assays for detection of free cysteines 
 To detect the presence of free cysteine thiols in native and reduced sublancin, an 
iodoacetamide assay was used. For the detection of free Cys residues in native sublancin, 
reactions contained 50 mM Tris (pH 8.3), 10 mM iodoacetamide, and 25 μM sublancin. For the 
detection of free Cys residues in reduced sublancin, reactions contained 50 mM Tris (pH 8.3), 5 
mM TCEP, 10 mM iodoacetamide, and 25 μM sublancin (50 μL total volume). All reactions 
were incubated for 2.5 h at 25 °C in the dark. At 2.5 h, 10 μL of reaction was quenched with 5% 
TFA to pH 1-2. Samples were desalted using Zip-TipC18 prior to MALDI-TOF MS analysis. 
Samples evaluated by LC-ESI-Q/TOF MS were analyzed without further manipulation. The 
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detection of free cysteines was determined by the presence or absence of carboxyamidomethyl 
(CAM) thiol modifications. 
 
4.4.5. Chymotrypsin digests of sublancin 
 For analysis of native sublancin, the peptide was digested under non-reducing conditions 
in order to maintain the integrity of the in vivo formed disulfides. The digestion sample contained 
100 mM Tris (pH 7.5), 0.05 mg/mL chymotrypsin (Worthington), and 0.5 mg/mL sublancin. For 
analysis of the reduced peptide, 0.5 mg/mL sublancin was digested in 100 mM Tris (pH 7.5), 5 
mM TCEP, 0.05 mg/mL chymotrypsin. All reactions were incubated at 25 °C for 5 h and then 
quenched with 5% TFA to pH 1-2. Quenched samples were desalted with a ZipTipC18 prior to 
analysis by MALDI-TOF MS or by LC-ESI-Q/TOF MS. 
 
4.4.6. Determination of the natural sugar modification of sublancin 
 The presence of glucose on Cys22 of sublancin isolated from B. subtilis 168 was 
confirmed via acid-catalyzed hydrolysis and derivatization of the sugar, analysis by gas 
chromatography-mass spectrometry (GC-MS), and comparison to derivatized hexose standards. 
Lyophilized sublancin (approximately 0.5-1.0 mg) was dissolved in 1 mL of 0.5 M HCl in water 
and heated at 75 °C in a high-pressure, sealed vessel for 5 h. The reaction was cooled, transferred 
to a microcentrifuge tube with the aid of millipore water, and quenched by addition of aqueous 
NaOH to pH 5. The total volume was concentrated via vacuum centrifugation. After complete 
drying, 50 μL of 20 mg/mL O-methylhydroxylamine hydrochloride (Fluka) in pyridine was 
added to the sample. The sample was vortexed for 1 min and was incubated at 50 °C for 1 h. 
Next, 50 μL of N-trimethylsilyl-N-methyl trifluoroacetamide (Fluka) was added. Again, the 
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sample was vortexed for 1 min and incubated at 50 °C for 1 h. The sample was cooled at 25 °C 
for 5 min prior to vortexing for 1 min followed by centrifugation at 15 krpm in a microcentrifuge 
for 2 min. Hexose sugar standards D-(+)-glucose, D-(+)-galactose, D-(+)-mannose, and D-(−)-
fructose were also treated and derivatized using the conditions described above.  
 The derivatized hexose of sublancin and sugar standards were analyzed individually and 
in combinations using an Agilent GC-MS system (6890N GC, HP 5973 mass selective detector) 
equipped with a Phenomenex ZB-1MS column (30 m x 0.32 mm i.d., 0.25 μm df) (Figure 4.39a-
h). Samples were introduced via split injection (3:1 split ratio). The temperature gradient used 
was 150 °C for 2 min,  then 150 °C to 185 °C over 3.5 min (10 °C/min ramp), then 185 °C to 210 
°C over 12.5 min (2 °C/min ramp), then 210 °C to 300 °C over 9 min (10 °C/min ramp). The 
carrier gas was helium and was set at a 3.0 mL/min flow rate. The mass selective detector was 
operated in positive ion scan mode (25-800 m/z). Analyses were performed using electron 
impact (EI) mode and to preserve the filament of the ionization source, MS records were 
performed 4 min after injection. 
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Figure 4.39a. GC-MS analysis of glucose. D-(+)-Glucose standard was derivatized as described in methods and 
analyzed by GC-MS. The total ion chromatogram (TIC) is shown with the retention times as indicated (upper). 
Below the chromatogram are EI mass spectra corresponding to the peaks at 11.017 min (lower left) and 11.399 min 
(lower right) that correspond to the two isomers of the sugar generated during derivatization. The characteristic ions 
for TMS derivatized glucose are annotated within the spectra (319, 205, 147, 103, and 73 m/z). 
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Figure 4.39b. GC-MS analysis of galactose. D-(+)-Galactose standard was derivatized and analyzed by GC-MS. 
The TIC is shown with the retention times as indicated (upper). Below the chromatogram EI mass spectra 
corresponding to the peaks at 10.890 min (lower left) and 11.332 min (lower right) are shown that correspond to the 
two isomers of the sugar generated during derivatization. The characteristic ions for TMS derivatized galactose are 
annotated within the spectra (319, 205, 147, 103, and 73 m/z). 
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Figure 4.39c. GC-MS analysis of mannose. D-(+)-Mannose standard was derivatized and analyzed by GC-MS. The 
TIC is shown with the retention times as indicated (upper). Below the chromatogram, EI mass spectra corresponding 
to the peaks at 10.811 min (lower left) and 11.143 min (lower right) are shown that correspond to the two isomers of 
the sugar generated during derivatization. The characteristic ions for TMS derivatized mannose are annotated within 
the spectra (319, 205, 147, 103, and 73 m/z). 
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Figure 4.39d. GC-MS analysis of fructose. D-(-)-Fructose standard was derivatized and analyzed by GC-MS. The 
TIC is shown with the retention times as indicated (upper). Below the chromatogram, EI mass spectra corresponding 
to the peaks at 10.489 min (lower left) and 10.675 min (lower right) are shown that correspond to the two isomers of 
the sugar generated during derivatization. The characteristic ions for TMS derivatized fructose are annotated within 
the spectra (307, 217, 147, 103, and 73 m/z). 
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Figure 4.39e. Resolution of derivatized standards by GC-MS. A mixture of derivatized D-(+)-glucose, D-(+)-
galactose, D-(+)-mannose, and D-(-)-fructose standards was analyzed by GC-MS. Shown are the TIC for the 
mixture (upper) and the overlay of the TIC for the mixture and the total ion chromatograms from each individually 
analyzed sugar (lower). The EI mass spectra corresponding to the individual peaks of the mixture were essentially 
identical to the spectra obtained when each sugar standard was analyzed individually (Figure 4.39a-d). 
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Figure 4.39f. GC-MS analysis of the sugar attached to sublancin. The S-linked hexose sugar conjugated to Cys22 of 
in vivo isolated sublancin was chemically released via acid hydrolysis, derivatized, and analyzed by GC-MS. The 
TIC is shown with the retention times as indicated (upper). EI mass spectra corresponding to the peaks at 11.023 
min (lower left) and 11.395 min (lower right) are shown that correspond to the two isomers of the sugar generated 
during derivatization. The hexose sugar was identified as glucose, as determined by retention time and comparison 
of the mass spectra with the glucose standard. The characteristic ions for TMS derivatized glucose are annotated 
within the spectra (319, 205, 147, 103, and 73 m/z). 
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Figure 4.39g. Identification of the sugar in sublancin as glucose. An overlay of the total ion chromatograms for the 
sublancin-derived and silylated sugar sample and for the mixture of silylated sugar standards is shown (upper: full 
chromatogram, lower: zoom to peaks of interest). 
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Figure 4.39h. Confirmation of glucose as the sugar in sublancin by spiking with a standard. To confirm the presence 
of S-linked glucose conjugated to Cys22 of in vivo isolated sublancin, the sublancin derived sugar sample was 
spiked with glucose standard and analyzed by GC-MS. An overlay of the total ion chromatograms for the sublancin 
derived sugar sample and for the sublancin sample with glucose spike is shown (upper: full chromatogram, lower: 
zoom to peaks of interest). The EI-MS mass spectra corresponding to the sublancin sample with glucose spike were 
similar to the spectra obtained when the sublancin derived sugar sample (without added glucose) was analyzed. The 
characteristic ions for TMS derivatized glucose were observed. 
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4.4.7. Molecular cloning of precursor and glycosyltransferase genes 
Molecular cloning of sunA and sunS genes. 
 Genomic DNA was isolated from an overnight culture of B. subtilis 168 using a 
Microbial DNA Isolation Kit (MO-BIO) according to the manufacturer’s protocol. The gene 
sunA was PCR amplified by 30 cycles of denaturing (94 °C for 1 min), annealing (50 °C for 1 
min), and extending (72 °C for 1 min) using SunA NdeI FP (5’- 
CGGCAGCCATATGGAAAAGCTATTTAAAGA -3’) and SunA XhoI RP (5’- 
GATCCTCGAGTTATCTGCAGAATTGACGATAG -3’) as primers and B. subtilis 168 
genomic DNA as template (bold indicates restriction sites). The PCR mixture included 1X PCR 
Buffer (Invitrogen), dNTPs (0.25 mM each), MgCl2 (1.5 mM), Platinum Taq DNA polymerase 
(0.05 U/μL), and primers (0.5 μM each). Amplifications were confirmed by 2% agarose gel 
electrophoresis, and the PCR products were purified using a QIAQuick PCR Purification Kit 
(QIAGEN). The insert DNA fragment and pET15b vector were double digested in separate 
reactions containing 1X NEBuffer 4 (New England Biolabs) with NdeI and XhoI for 15 h at 37 
°C. The sunA and pET15b digests were purified by 2% and 1% agarose gel electrophoresis, 
respectively, and gel extracted using a QIAquick Gel Extraction Kit (QIAGEN). The resulting 
DNA products were ligated at 25 °C for 5 h in 1X T4 DNA Ligase buffer with T4 DNA Ligase 
(0.7 U/μL). E. coli DH5α cells were transformed with 2.5 μL of the ligation product by heat 
shock, and cells were plated on LB-ampicillin agar plates and grown for 15 h at 37 °C. Several 
colonies were picked and used to inoculate separate 5 mL cultures of LB-ampicillin medium. 
The cultures were grown at 37 °C for 12 h, and plasmids were isolated using a QIAprep Spin 
Miniprep Kit (QIAGEN). The sequences of the resulting plasmid products were confirmed by 
DNA sequencing. 
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 The gene sunS (previously designated as yolJ) was PCR amplified by 30 cycles of 
denaturing (94 °C for 1 min), annealing (50 °C for 1 min), and extending (72 °C for 2 min) using 
SunS NdeI FP (5’- GCGGCAGCCATATGAAACTGAGTGATATTTA -3’) and SunS XhoI RP 
(5’- GTGCTCGAGTCATACTTCAATTCCTTTCAGG -3’) as primers and B. subtilis 168 
genomic DNA as template (bold indicates restriction sites). The PCR mixture included 1X PCR 
Buffer (Invitrogen), dNTPs (0.25 mM each), MgCl2 (1.5 mM), Platinum Taq DNA polymerase 
(0.05 U/μL), and primers (0.5 μM each). Amplifications were confirmed by 2% agarose gel 
electrophoresis, and the PCR products were purified using a QIAQuick PCR Purification Kit 
(QIAGEN). The insert DNA fragment and pET28b vector were double digested in separate 
reactions containing 1X NEBuffer 4 (New England Biolabs) with NdeI and XhoI for 15 h at 37 
°C. The sunS and pET28b digests were purified by 2% and 1% agarose gel electrophoresis, 
respectively, and gel extracted using a QIAquick Gel Extraction Kit (QIAGEN). The resulting 
DNA products were ligated at 25 °C for 5 h in 1X T4 DNA Ligase buffer with T4 DNA Ligase 
(0.7 U/μL). E. coli DH5α cells were transformed with 2.5 μL of the ligation product by heat 
shock, and cells were plated on LB-kanamycin agar plates and grown for 15 h at 37 °C. Several 
colonies were picked and used to inoculate separate 5 mL cultures of LB-kanamycin medium. 
The cultures were grown at 37 °C for 12 h, and plasmids were isolated using a QIAprep Spin 
Miniprep Kit (QIAGEN). The sequences of the resulting plasmid products were confirmed by 
DNA sequencing. 
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Molecular cloning of thuA and thuS genes. 
 Genomic DNA was isolated from an overnight culture of B. thuringiensis serovar 
andalousiensis BGSC 4AW1 using a Microbial DNA Isolation Kit (MO-BIO) according to the 
manufacturer’s protocol. The gene thuA was PCR amplified by 30 cycles of denaturing (94 °C 
for 1 min), annealing (50 °C for 1 min), and extending (72 °C for 1 min) using ThuA NdeI FP 
(5’- CGGCAGCCATATGAAAGAACTAATCAAAGA -3’) and ThuA XhoI RP (5’- 
GATCCTCGAGTTAACAGTATTTTCTTGCTAATTCAC -3’) as primers and B. subtilis 168 
genomic DNA as template (bold indicates restriction sites). The PCR mixture included 1X PCR 
Buffer (Invitrogen), dNTPs (0.25 mM each), MgCl2 (1.5 mM), Platinum Taq DNA polymerase 
(0.05 U/μL), and primers (0.5 μM each). Amplifications were confirmed by 2% agarose gel 
electrophoresis, and the PCR products were purified using a QIAQuick PCR Purification Kit 
(QIAGEN). The insert DNA fragment and pET15b vector were double digested in separate 
reactions containing 1X NEBuffer 4 (New England Biolabs) with NdeI and XhoI for 15 h at 37 
°C. The thuA and pET15b digests were purified by 2% and 1% agarose gel electrophoresis, 
respectively, and gel extracted using a QIAquick Gel Extraction Kit (QIAGEN). The resulting 
DNA products were ligated at 25 °C for 5 h in 1X T4 DNA Ligase buffer with T4 DNA Ligase 
(0.7 U/μL). E. coli DH5α cells were transformed with 2.5 μL of the ligation product by heat 
shock, and cells were plated on LB-ampicillin agar plates and grown for 15 h at 37 °C. Several 
colonies were picked and used to inoculate separate 5 mL cultures of LB-ampicillin medium. 
The cultures were grown at 37 °C for 12 h, and plasmids were isolated using a QIAprep Spin 
Miniprep Kit (QIAGEN). The sequences of the resulting plasmid products were confirmed by 
DNA sequencing. 
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 The gene thuS was PCR amplified by 30 cycles of denaturing (94 °C for 1 min), 
annealing (50 °C for 1 min), and extending (72 °C for 2 min) using ThuS NheI FP (5’- 
CCATATGGCTAGCGTGGAAACATTAAAC -3’) and ThuS XhoI RP (5’- 
GTGCTCGAGTTATATTTTTTTGCTGATATGAGTATTTATTG -3’) as primers and B. 
subtilis 168 genomic DNA as template (bold indicates restriction sites). The PCR mixture 
included 1X PCR Buffer (Invitrogen), dNTPs (0.25 mM each), MgCl2 (1.5 mM), Platinum Taq 
DNA polymerase (0.05 U/μL), and primers (0.5 μM each). Amplifications were confirmed by 
2% agarose gel electrophoresis, and the PCR products were purified using a QIAQuick PCR 
Purification Kit (QIAGEN). The insert DNA fragment and pET28b vector were double digested 
in separate reactions containing 1X NEBuffer 4 (New England Biolabs) with NdeI and XhoI for 
15 h at 37 °C. The sunS and pET28b digests were purified by 2% and 1% agarose gel 
electrophoresis, respectively, and gel extracted using a QIAquick Gel Extraction Kit (QIAGEN). 
The resulting DNA products were ligated at 25 °C for 5 h in 1X T4 DNA Ligase buffer with T4 
DNA Ligase (0.7 U/μL). E. coli DH5α cells were transformed with 2.5 μL of the ligation product 
by heat shock, and cells were plated on LB-kanamycin agar plates and grown for 15 h at 37 °C. 
Several colonies were picked and used to inoculate separate 5 mL cultures of LB-kanamycin 
medium. The cultures were grown at 37 °C for 12 h, and plasmids were isolated using a QIAprep 
Spin Miniprep Kit (QIAGEN). The sequences of the resulting plasmid products were confirmed 
by DNA sequencing. 
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4.4.8. Molecular engineering and mutagenesis of precursor genes 
Molecular engineering of a Factor Xa cleavage site into the sunA gene. 
 A site-directed mutagenesis approach was used to install a proteolytic cleavage site 
directly N-terminal to the core peptide of SunA. The primers were designed to contain nucleotide 
sequences necessary to encode the amino acids IEGR in place of four wild-type peptide residues 
(QKGS). The plasmid pET15b sunA Xa was PCR amplified by 30 cycles of denaturing (94 °C 
for 1 min), annealing (55 °C for 1 min), and extending (72 °C for 6 min) using SunA Xa FP (5'- 
GAGGAACTCGAAAACATCGAAGGTCGTGGATTAGGAAAAGCT -3') and SunA Xa RP 
(5'- AGCTTTTCCTAATCCACGACCTTCGATGTTTTCGAGTTCCTC -3') as primers and 
pET15b sunA as template (underline indicates nucleotide change). The PCR mixture included 2X 
Pfx Amp Buffer (Invitrogen), dNTPs (2.5 mM each), MgSO4 (1 mM), Platinum Pfx DNA 
polymerase (0.05 U/μL), and primers (1.5 μL each). Amplifications were confirmed by 1% 
agarose gel electrophoresis. To digest the methylated template prior to transformation, 1X 
REACT 4 buffer and 1 μL of DpnI (Invitrogen) was added to the PCR product and the digest 
was incubated at 37 °C for 3 h. E. coli DH5α cells were transformed with 2.5 μL of the digest 
product by heat shock, and cells were plated on LB-ampicillin agar plates and grown for 15 h at 
37 °C. Several colonies were picked and used to inoculate separate 5 mL cultures of LB-
ampicillin medium. The cultures were grown at 37 °C for 12 h, and plasmids were isolated using 
a QIAprep Spin Miniprep Kit (QIAGEN). The sequences of the resulting plasmid products were 
confirmed by DNA sequencing. 
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Mutagenesis of the sunA and sunA Xa genes to produce various mutant precursor peptides. 
 Site-directed mutagenesis of pET15b sunA and pET15b sunA Xa constructs was 
performed by either site-directed mutagenesis or multi-step overlap extension PCR. These 
constructs were designed in collaboration with Dr. Huan Wang and mutagenesis was performed 
by Dr. Huan Wang.  
 
4.4.9. Overexpression and purification of His6-SunA precursor peptides. 
 E. coli BL21 (DE3) cells or E. coli Rosetta 2 (DE3) cells were transformed via 
electroporation with a  pET15b SunA construct (BL21 used for pET15b SunA; Rosetta 2 was 
used for all pET15b SunA constructs containing mutations: pET15b SunA Xa, pET15b SunA 
C22S, pET15b SunA G21E, pET15b SunA G23E, pET15b SunA G23K, and pET15b SunA Xa 
G21Q/G23A). A single colony transformant was used to inoculate a 30 mL culture of LB 
supplemented with 100 μg/mL ampicillin (and 25 μg/mL chloramphenicol for Rosetta 2 cells). 
The culture was grown at 37 °C for 12 h and was used to inoculate 3 L of LB containing 100 
μg/mL ampicillin (and 25 μg/mL chloramphenicol for Rosetta 2 cells), and cells were grown at 
37 °C to OD600 ≈ 0.6-0.8. IPTG was added to a final concentration of 1 mM and the culture was 
incubated at 37 °C for an additional 3 h. His6-SunA peptides were expressed as insoluble 
peptides. Cells were harvested by centrifugation at 12,000 ×g for 15 min at 4 °C, and the pellet 
was resuspended in 30 mL of start buffer (20 mM NaH2PO4 (pH 7.5), 500 mM NaCl, 0.5 mM 
imidazole, 20% glycerol) and stored at −80 °C. 
 The cell paste was suspended in start buffer and the suspension was sonicated on ice for 
20 min to lyse the cells. Cell debris was removed by centrifugation at 23,700 ×g for 30 min at 
4 °C. The supernatant was discarded and the pellet containing the insoluble peptide was 
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resuspended in 30 mL of start buffer. The sonication and centrifugation steps were repeated. 
Again the supernatant was discarded and the pellet was resuspended in 30 mL of buffer 1 (6 M 
guanidine HCl, 20 mM NaH2PO4 (pH 7.5), 500 mM NaCl, 0.5 mM imidazole). The sample was 
sonicated and insoluble material was removed by centrifugation at 23,700 ×g for 30 min at 4 °C, 
followed by filtration of the supernatant through a 0.45 μm filter. The filtered sample was 
applied to a 5 mL HisTrap HP (GE Healthcare Life Sciences) immobilized metal affinity 
chromatography (IMAC) column previously charged with NiSO4 and equilibrated in buffer 1. 
The column was washed with two column volumes of buffer 1, followed by two column volumes 
of buffer 2 (4 M guanidine HCl, 20 mM NaH2PO4 (pH 7.5), 500 mM NaCl, 30 mM imidazole). 
The peptide was eluted with 1-2 column volumes of elution buffer (4 M guanidine HCl, 20 mM 
NaH2PO4 (pH 7.5), 500 mM NaCl, 1 M imidazole).  The fractions were desalted using a 
ZipTipC18 and analyzed by MALDI-TOF MS. The fractions containing the desired peptide were 
pooled and purified using preparative HPLC.  
 Preparative HPLC was performed using a Waters Delta 600 instrument equipped with a 
Waters Delta-Pak C4 column (15 μm, 300 Å, 100 mm x 25 mm) equilibrated in 2% B (solvent A 
=  0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water). Peptide containing 
material was applied to the column and was fractionated using a gradient from 2-100% B over 45 
min with a flow rate of 8.0 mL/min. All fractions were analyzed by MALDI-TOF MS as 
described above. Purified peptide was lyophilized to dryness and stored under N2 at −80 °C until 
further use. Typical yields from 3 L of cell culture were 15-20 mg His6-SunA, 5-8 mg His6-SunA 
Xa, 3-5 mg of each of His6-SunA C22S, His6-SunA G21E, His6-SunA G23E, His6-SunA G23K, 
and 1-1.5 mg of His6-SunA Xa G21Q/G23A. 
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4.4.10. Overexpression and purification of His6-SunS 
 E. coli Rosetta 2 (DE3) cells were transformed with the pET28b SunS construct via 
electroporation. A single colony transformant was used to inoculate a 30 mL culture of LB 
supplemented with 50 μg/mL kanamycin. The culture was grown at 37 °C for 12 h and was used 
to inoculate 3 L of LB containing 50 μg/mL kanamycin, and cells were grown at 37 °C to OD600 
≈ 0.6. The culture was incubated at 4 °C on ice for 20 min, then IPTG was added to a final 
concentration of 0.5 mM and the culture was incubated at 18 °C for an additional 16-20 h. Cells 
were harvested by centrifugation at 12,000 ×g for 15 min at 4 °C, and the pellet was resuspended 
in 30 mL of start buffer (20 mM Tris (pH 8.0), 500 mM NaCl, 1 mM TCEP, 10% glycerol) and 
stored at −80 °C.  
 All protein purification steps were performed at 4 °C. The cell paste was suspended in 
start buffer and the cells were lysed using a high pressure homogenizer (Avestin, Inc.). Cell 
debris was pelleted via centrifugation at 23,700 ×g for 20 min at 4 °C. The supernatant was 
injected via a superloop onto a fast protein liquid chromatography (FPLC) system (ÄKTA, GE 
Heathcare Life Sciences) equipped with a 5 mL HisTrap HP IMAC column previously charged 
with Ni2+ and equilibrated in start buffer. The column was washed with 50 mL of buffer A (30 
mM imidazole, 20 mM Tris, pH 8.0, 1 M NaCl) and the protein was eluted using a linear 
gradient of 0-100% B (buffer B = 200 mM imidazole, 20 mM Tris, pH 8.0, 1 M NaCl) over 40 
min at a 2 mL/min flow rate. UV absorbance (280 nm) was monitored and fractions were 
collected and analyzed by SDS-PAGE (4-20% Tris-glycine READY gel, BioRAD). The 
fractions containing SunS were combined and concentrated using an Amicon Ultra-15 
Centrifugal Filter Unit (10 kDa MWCO, Millipore). Gel filtration purification was used to 
further purify SunS. The concentrated protein sample was injected onto an FPLC system 
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(ÄKTA) equipped with an XK16 16/60 (GE Healthcare Life Sciences) column packed with 
SuperDex 75 resin previously equilibrated in 20 mM HEPES (pH 7.5), 100 mM KCl, and 1 mM 
TCEP. The protein was eluted with a flow rate of 0.9 mL/min. Both UV absorbance (280 nm) 
and conductance were monitored and fractions were collected. Misfolded/aggregated protein was 
efficiently separated from soluble, correctly folded protein and the desired fractions were 
combined and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit. The resulting 
protein sample was stored at −80 °C. Protein concentration was determined using a Bradford 
Assay Kit (Pierce) and typically yields were 15-18 mg His6-SunS from 3 L of cell culture. 
 
4.4.11. Enzymatic in vitro sugar modification of SunA peptides by SunS 
 His6-SunA (50 μM) was incubated with His6-SunS (2 μM) in a reaction buffer containing 
50 mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, and 5 mM NDP-sugar (final concentrations). 
Five NDP-sugars were independently evaluated: uridine-5′-diphosphate-α-D-glucose (UDP-Glc, 
CalBiochem), uridine-5′-diphosphate-α-D-galactose (UDP-Gal, CalBiochem), uridine-5′-
diphosphate-α-D-N-acetylglucosamine (UDP-GlcNAc, Sigma), guanosine-5′-diphosphate-α-D-
mannose (GDP-Man, CalBiochem), and uridine-5′-diphosphate-α-D-xylose (UDP-Xyl, Complex 
Carbohydrate Research Center, University of Georgia). The reactions were incubated at 25 °C 
for various durations of time (1-12 h depending on future use). Reactions were either 
immediately used for subsequent proteolytic leader peptide removal reactions and oxidative 
folding or quenched with 5% TFA to pH 1-2 for MALDI-TOF MS analysis. For MALDI-TOF 
MS analysis, samples were desalted using ZipTipC18 and analyzed as described above. For 
modification of His6-SunA mutant peptides (His6-SunA Xa, His6-SunA C22S, His6-SunA G21E, 
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His6-SunA G23E, His6-SunA G23K, and His6-SunA Xa G21Q/G23A, reactions were conducted 
under identical conditions as described above. 
 
4.4.12. Chymotrypsin digests of sugar modified His6-SunA peptides 
 Modified His6-SunA (taken directly from the SunS reaction) was digested in 100 mM 
Tris (pH 7.5), 5 mM TCEP, and 0.1 mg/mL chymotrypsin (Worthington). All reactions were 
incubated at 25 °C for 5 h and then quenched with 5% TFA to pH 1-2. Quenched samples were 
desalted with a ZipTipC18 prior to analysis by MALDI-TOF MS or analyzed by LC-ESI-Q/TOF 
MS without further manipulation. Representative data for GlcNAc labeled His6-SunA are shown 
in Figure 4.40a and b. 
 
 
Figure 4.40a.  ESI-Q/TOF MS analysis of N-acetylglucosamine modified His6-SunA digested with chymotrypsin 
under reducing conditions. His6-SunA was modified with N-acetylglucosamine, digested with chymotrypsin under 
reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. Chymotrypsin cleavage sites (F, W, and Y 
residues) are indicated in the peptide sequence above the spectrum. The masses of the observed ions and their 
corresponding digest fragments are assigned. The results are consistent with Ser54 and Thr57 remaining unmodified 
and the peptide spanning residues Leu50-Tyr70 bearing a +203 Da post-translational modification.  
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Figure 4.40b. ESI-Q/TOF MSMS analysis of the peptide spanning residues Leu50-Tyr70 of N-acetylglucosamine-
modified His6-SunA. His6-SunA was modified with N-acetylglucosamine, digested with chymotrypsin under 
reducing conditions, and analyzed by using LC-ESI-Q/TOF MSMS.  The digest mixture was fractionated using LC 
and the multiply charged ion corresponding to residues Leu50-Tyr70 was selected for MSMS analysis. 
Fragmentation patterns are indicated for the y” ion series (upper) and the b ion series (lower). The results confirm 
that Ser54 and Thr57 remain unmodified and Cys60 has a +203 Da post-translational modification. 
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4.4.13. Base-catalyzed β-elimination of glucose from Cys22 of sublancin 
 Two different strong bases were used to evaluate the ability to β-eliminate the sugar from 
in vivo isolated sublancin peptide (Figure 4.41). For elimination with a strong base under 
reducing conditions, pure sublancin was dissolved to a final concentration of 25 μM in a solution 
containing 0.3 M NaBH4 and 0.1 M NaOH and was incubated at 4 °C for 5 h followed by 
quenching the reaction with 5% TFA to pH 1-2. The sample was desalted using a ZipTipC18 and 
analyzed by MALDI-TOF and ESI-Q/TOF MS (Figure 4.41a, c, and d). For elimination with a 
strong base under non-reducing conditions, pure sublancin was dissolved to a final concentration 
of 25 μM in a solution containing 0.1 M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in n-PrOH 
and was incubated at 25 °C for 5 h followed by quenching the reaction with 5% TFA to pH 1-2. 
The sample was desalted using a ZipTipC18 and analyzed by MALDI-TOF MS (Figure 4.41b). 
Sublancin samples that were subjected to base-catalyzed β-elimination were digested under 
reducing conditions with chymotrypsin in a similar manner as described for modified His6-SunA 
peptides and analyzed by ESI-Q/TOF MSMS  (Figure 4.41c and d). 
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Figure 4.41a. Investigation of the site of modification on Cys22 by chemical degradation. MALDI-TOF MS 
analysis of base-catalyzed β-elimination of the sugar of sublancin. The sugar of sublancin was β-eliminated by 
treating native sublancin with NaBH4 under basic conditions and analyzed by MALDI-TOF MS. Elimination to 
form an alkene followed by reduction of the alkene was observed. The overlay of mass spectra obtained by MALDI-
TOF MS analysis of sublancin before (blue) and after treatment with NaBH4 (red) is shown. 
 
 
 
Figure 4.41b. Non-reductive elimination of the sugar of sublancin. The sugar of sublancin was β-eliminated by 
treating native sublancin with DBU and analyzed by MALDI-TOF MS. Elimination to form an alkene was 
observed. The overlay of mass spectra obtained by MALDI-TOF MS analysis of sublancin before (blue) and after 
treatment with DBU (magenta) is shown. 
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Figure 4.41c. ESI-Q/TOF MS analysis of base-catalyzed β-elimination of the sugar and chymotrypsin digest of 
sublancin. The sugar of sublancin was β-eliminated by treating native sublancin with NaBH4 under basic conditions, 
digested with chymotrypsin under reducing conditions, and analyzed by LC-ESI-Q/TOF MS. The resulting mass 
spectrum is shown. Chymotrypsin cleavage sites (F, W, and Y residues) are indicated in the peptide sequence above 
the spectrum. The masses of the observed ions and their corresponding digest fragments are assigned. The results are 
consistent with Ser54 and Thr57 remaining unmodified and the chemical conversion from Cys22 bearing a +162 Da 
post-translational modification to form an Ala at position 22. 
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Figure 4.41d. ESI-Q/TOF MSMS analysis of the peptide spanning residues Leu12-Tyr32 after base-catalyzed β-
elimination of the sugar and chymotrypsin digest of sublancin. The sugar of sublancin was β-eliminated by treating 
native sublancin with NaBH4 under basic conditions, the product was digested with chymotrypsin under reducing 
conditions, and analyzed using LC-ESI-Q/TOF MSMS. The digest mixture was fractionated using LC and the 
multiply charged ion corresponding to the peptide spanning residues Leu12-Tyr32 was selected for MSMS analysis. 
Fragmentation patterns are indicated for the y” ion series (upper) and the b ion series (lower). The results support 
that Ser16 and Thr19 remain unmodified and Cys22 has lost its post-translational modification and was converted to 
an Ala residue. 
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4.4.14. Production of isotopically labeled sublancin and NMR analysis  
 Four samples of sublancin were prepared for NMR analysis. For a sample in 100% D2O, 
lyophilized sublancin was dissolved in 100% D2O (Cambridge Isotope Laboratories) to exchange 
amide protons and simplify the NMR spectrum in the down field region. The sample was 
lyophilized, the procedure was repeated twice, and the final sample was dissolved in D2O to a 
final concentration of approximately 2.5 mM. For a sample in 90% H2O/10% D2O, lyophilized 
sublancin was dissolved in 90% H2O/10% D2O to a final concentration of approximately 2.5 
mM.  
 A 13C-labeled sublancin sample was obtained by growing B. subtilis 168 on minimal 
medium containing uniformly 13C-labeled glucose.51 An culture of B. subtilis 168 was grown in 
LB medium for 15 h with aeration. This culture was used to inoculate a 500 mL volume of 
minimal media in a 2 L flask. The minimal media contained the following components per 500 
mL total volume: 25 mL of 20% 13C-glucose, 100 mL of 5X M9 salts, 5 mL of 4 mg/mL 
Leucine, 500 µL of 20 mg/mL CaCl2, 500 µL of 120 mg/mL MgSO4, 100 µL of 5 mg/mL D-
biotin, 100 µL of 5 mg/mL thiamine-HCl, 500 µL of 1000X heavy metal stock solution, and 
368.3 mL of millipore water to bring total volume to 500 mL. The 5X M9 salts solution 
consisted of 64 g Na2HPO4 7H2O, 15 g KH2PO4, 2.5 g NaCl, 5 g NH4Cl, and 1 L millipore 
water. The 1000X heavy metal stock solution was prepared by combining the following 
components in 1 M HCl, stirred overnight at 25° C, and filter sterilized to remove insoluble 
material. 
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    Component  Amount 
    MoNa2SO4•2H2O 500 mg 
    CoCl2   250 mg 
    CuSO4•5H2O  175 mg 
    MnSO4•H2O  1 g 
    MgSO4•7H2O  8.75 g 
    ZnSO4•7H2O  1.25 g 
    FeCl2•4H2O  1.25 g 
    CaCl2•2H2O  2.5 g 
    H3BO3   1 g 
    1 M HCl  to 1 L 
 
 A 13C/15N-labeled sublancin sample was obtained by growing B. subtilis 168 on minimal 
medium containing uniformly 13C-labeled glucose and 15NH4Cl.51 The minimal media contained 
the following components per 500 mL total volume: 25 mL of 20% 13C-glucose, 100 mL of 5X 
M9 salts, 5 mL of 4 mg/mL leucine, 500 µL of 20 mg/mL CaCl2, 500 µL of 120 mg/mL MgSO4, 
100 µL of 5 mg/mL D-biotin, 100 µL of 5 mg/mL thiamine-HCl, 500 µL of 1000X heavy metal 
stock solution, and 368.3 mL of millipore water to bring the total volume to 500 mL. The 5X M9 
salts solution consisted of 64 g Na2HPO4 7H2O, 15 g KH2PO4, 2.5 g NaCl, 5 g 15NH4Cl, and 1 L 
millipore water. The 1000X heavy metal stock solution were prepared as described above. 
 A culture of B. subtilis 168 was grown in LB medium for 15 h with aeration. This culture 
was used to inoculate a 500 mL volume of minimal media in a 2 L flask and was grown at 37° C 
with aeration for up to 96 hrs. The production of labeled sublancin was monitored by periodic 
sampling of the growing culture and analysis via MALDI-TOF mass spectrometry. Breifly, a 1 
mL aliquot of B. subtilis 168 minimal media culture was acidified to pH 2 with concentrated 
phosphoric acid (85% in water). The sample was centrifuged to remove cells and the supernatant 
was ZipTipC18 desalted, and analyzed by mass spectrometry. Typically, isolation and purification 
process was started 24 h after the first detection of labeled product. Labeled sublancin was 
generally observed within 48-72 h post-inoculation. Isotopically labeled sublancin was purified 
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using identical conditions as described above for natural abundance sample (acidification, cell 
harvest, ammonium sulfate precipitation, and preparative HPLC). A natural abundance sublancin 
sample was prepared during the preparation of the labeled peptides as a control. 
 
 
Figure 4.42. MALDI-TOF mass spectrum of purified 13C-labeled sublancin. Expected [M+H]: 4040.38, observed: 
4038.96. 
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Figure 4.43. MALDI-TOF mass spectrum of purified 13C/15N-labeled sublancin. Expected [M+H]: 4090.38, 
observed: 4086.41. 
 
 
 
Figure 4.44. MALDI-TOF mass spectrum of purified natural abundance sublancin that was produced in parallel 
with the isotopic labeling preparations except using natural abundance culture growth medium. Expected [M+H]: 
3876.74, observed: 3880.76. 
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 All solution NMR spectra were acquired by Dr. John Boettcher at the NMR Facility 
(School of Chemical Sciences, University of Illinois at Urbana-Champaign) on a Varian INOVA 
500 MHz spectrometer equipped with a 5 mm triple resonance (1H−13C−15N) triaxial gradient 
probe, using VNMRJ version 2.1B with the BioPack suite of pulse programs released in early 
2006. One and two-dimensional 1H homonuclear spectra were acquired on both unlabeled 
sublancin samples at 25° C. Two-dimensional COSY, TOCSY and NOESY spectra were 
measured for an average of 2 h per spectrum, digitizing 1024 points in the indirect 1H dimension 
(t1,max = 128 ms) and were utilized by Dr. Boettcher to establish correlations among backbone 
resonances and the conjugated glucose ring of the sublancin sample. A 13C-HSQC spectrum was 
acquired on a 13C-labeled sublancin sample digitizing 256 points in the 13C dimension (t1,max = 15 
ms). These spectra were utilized to establish correlations between carbon and proton resonances 
of the conjugated glucose of sublancin. An additional COSY spectra with a long pulse delay (9 
ms) was acquired with the unlabeled sublancin sample in 100% D2O for measurement of 3JH-H 
couplings. Spectra were processed with NMRPipe52, and analyzed in Sparky53. The 3JH-H 
couplings were measured using the ACME program supplied as a feature of the NMRPipe 
software.54  
 Initial efforts focused on the region of the spectrum from 6.0 ppm to 7.5 ppm that was 
previously suggested to contain resonances from the Dha residue, as reported by Paik et al.5 For 
this specific investigation the sample in 100% D2O was used to avoid overlap with amide proton 
resonances as was also done by Paik et al.. The previous study relied on one-dimensional 1H 
spectra and chemical shift analysis to propose that the resonance at 6.2 ppm belonged to the Dha 
residue and the remaining resonances were attributed to aromatic side chain protons. However, 
whereas the resonance at 6.2 ppm was seen in the proton spectrum no correlations to carbon 
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atoms were seen in the 13C-HSQC spectrum. The 13C-HSQC spectrum does show correlations of 
the protons downfield of 6.0 ppm with carbon atoms with chemical shifts between ~112-133 
ppm. These observations are consistent with the aromatic side chains found in sublancin. The 
resonance at 6.2 ppm can at present not be assigned but is likely arising from a proton attached to 
a heteroatom that is resistant to exchange with solvent. The data do rule out, however, that this 
resonance is associated with a Dha residue, which agrees with the mass spectrometric analysis. 
 With a 13C-HSQC spectrum in hand, the focus was shifted onto the unique chemical 
shifts of the carbon atoms found in sugars. All the carbons in the glucose group were predicted to 
have chemical shifts between ~70 and 90 ppm. Chemical shifts in this range are not commonly 
found for amino acids except for the beta carbon of Thr. Only a single Thr is present in 
sublancin, whereas 7 carbon resonances can be seen in this region of the HSQC spectrum. 
Combining this information with the connectivity observed in the COSY spectrum, assignments 
were made for the resonances arising from the sugar protons and carbons. Unique assignments 
were possible for positions 1, 2 and 6, relying on the downfield shift of the anomeric carbon and 
proton resonances to assign C1/H1, and using the COSY correlations to subsequently assign 
C2/H2. C6/H6 was also assigned based on both chemical shift and COSY correlations. The 3, 4 
and 5 carbon chemical shifts and the associated proton chemical shifts could not be assigned site-
specifically due to degeneracy in the proton chemical shifts. A tentative assignment of the 
resonance of the beta carbon of threonine 19 was also made. 
 After establishing the assignments of the conjugated glucose the NMR spectra were used 
by Dr. Boettcher to determine the stereochemistry of the glycosylation site. By measuring the 
3JH-H  coupling constant between the anomeric proton (proton 1) and the neighboring proton 
(proton 2) the dihedral angle was calculated using the Karplus relationship.30 A COSY spectrum 
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acquired with a long pulse delay was used to determine the 3JH-H coupling constant between these 
two protons. Using the ACME software the cross peak of 1-2 was fit with a 3JH-H coupling 
constant of 9.965 Hz. This results in a dihedral angle of 171° ± 10° based on the Karplus 
equation30 and indicates a diaxial orientation of the two protons. Combined with the knowledge 
that the sugar molecule is a glucose, the stereochemistry of conjugation to Cys22 must be 
through a β-linkage. 
 
4.4.15. Kinetics of SunS glycosyltransferase activity using end-point assays 
 To evaluate the NDP-sugar substrate preference of His6-SunS, His6-SunA was modified 
with different NDP-sugars at varied NDP-sugar concentrations and products were quantified 
using HPLC. His6-SunA (5 μM) was incubated with His6-SunS (2 μM) in a 250 μL reaction 
buffer containing 50 mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, and varying concentrations 
of NDP-sugar (final concentrations). NDP-sugar concentrations were 5 mM, 50 μM, or 500 nM. 
All five NDP-sugars were independently evaluated: UDP-Glc, UDP-Gal, UDP-GlcNAc, GDP-
Man, and UDP-Xyl. The reactions were incubated at 25 °C for 1 h. Reactions were quenched 
with TFA to pH 1-2 and analyzed by MALDI-TOF MS and the extent of glycosylation was 
quantified by analytical HPLC. For MALDI-TOF MS analysis, samples were desalted using 
ZipTipC18 and analyzed as described above (Figure 4.45a-e upper). 
  HPLC analysis was performed using a Beckman Coulter System Gold HPLC equipped 
with a Grace-Vydac Protein C4 column (5 μm, 300 Å, 250 mm x 4.6 mm) equilibrated in 2% 
solvent B (solvent A =  0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% 
water). A 200 μL volume of quenched SunS reaction was applied to the column. Sugar-modified 
and unmodified His6-SunA wt peptide were eluted by maintaining the mobile phase at 2% B for 
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1 min, followed by an increase to 100% B over 45 min with a flow rate of 1.0 mL/min. Under 
these conditions, sugar-modified His6-SunA wt peptide and unmodified His6-SunA wt peptide 
eluted at 24.3 and 24.8 min, respectively (Figure 4.44a-e lower). All fractions were analyzed by 
MALDI-TOF MS as described above. The relative amounts of sugar-modified and unmodified 
His6-SunA peptide was determined by quantifying the peak area corresponding to each form of 
the peptide by integration. Percent conversion was calculated by dividing the peak area of sugar-
modified peptide by the sum of the sugar-modified and unmodified peak areas. 
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Figure 4.45a-e. Kinetics of SunS glycosyltransferase activity using end-point assays. To identify the NDP-sugar 
substrate preference of SunS, His6-SunA was modified with different NDP-sugars at varied NDP-sugar 
concentrations and products were analyzed by MALDI-TOF MS and quantified using HPLC. The 
glycosyltransferase reactions were run for 1 h, quenched, and the reaction mixture was analyzed by MALDI-TOF 
MS. The reaction mixture, containing unmodified starting material and glycosylated product, was fractionated by 
HPLC and relative amounts of unmodified and modified His6-SunA peptide were quantified by peak integration. For 
each NDP-sugar tested, an overlay of MALDI-TOF mass spectra (upper) and an overlay of analytical HPLC 
chromatograms (lower) are shown. 
 
 
 
Figure 4.45a. SunS glycosyltransferase activity with UDP-glucose. 
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Figure 4.45b. SunS glycosyltransferase activity with UDP-galactose. 
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Figure 4.45c. SunS glycosyltransferase activity with GDP-mannose. 
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Figure 4.45d. SunS glycosyltransferase activity with UDP-N-acetylglucosamine. 
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Figure 4.45e. SunS glycosyltransferase activity with UDP-xylose. 
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4.4.16. Proteolysis of SunA Xa precursor and purification of leader and core peptides 
 To assess whether the leader peptide of SunA is required for SunS-catalyzed core peptide 
modification, His6-SunA Xa precursor peptide was proteolytically cleaved using Factor Xa 
protease to generate leader peptide and unmodified core peptide. His6-SunA Xa (1.0 mg/mL) 
was digested in 50 mM Tris (pH 7.5), 100 mM NaCl, 2 mM CaCl2, and 0.1 mg/mL Factor Xa 
(New England Biolabs). The reaction was incubated at 25 °C for 2.5 h and an aliquot of the 
reaction was quenched with 5% TFA to pH 1-2 prior to desalting by ZipTipC18 and analysis by 
MALDI-TOF MS. At 2.5 h, no starting material was observed by MS (Figure 4.46a), and the 
remainder of reaction was quenched with 5% TFA to pH 1-2. The leader and core peptide were 
then purified using HPLC. HPLC was performed using a Beckman Coulter System Gold HPLC 
equipped with a Phenomenex Jupiter Proteo C12 column (10 μm, 90 Å, 250 mm x 4.6 mm) 
equilibrated in 2% solvent B (solvent A =  0.1% TFA in water, solvent B = 0.0866% TFA in 
80% ACN/20% water). The quenched proteolysis reaction containing a mixture of core and 
leader peptide was centrifuged at 15 krpm in a microcentrifuge for 2 min and the resulting 
supernatant was applied to the column. The core and leader peptides were eluted by maintaining 
the mobile phase at 2% B for 1 min, followed by an increase to 100% B over 45 min with a flow 
rate of 1.0 mL/min. Under these conditions, the leader peptide and core peptide eluted at 22.7 
and 25.5 min, respectively. All fractions were analyzed by MALDI-TOF MS as described above. 
Purified material was lyophilized to dryness and stored under N2 at −80 °C until further use. 
Typical yields were 0.2 mg of leader and 0.15 mg of core peptide per mg of His6-SunA Xa 
(Figure 4.46b-c). 
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Figure 4.46a. His6-SunA Xa was digested with Factor Xa protease and analyzed by MALDI-TOF MS. The cleavage 
products (leader and core peptide) were then purified using reversed-phase HPLC and analyzed by MALDI-TOF 
MS. The resulting mass spectrum of crude cleavage mixture is shown. Factor Xa cleavage occurred C-terminal to 
Arg38 resulting in leader peptide (Gly1-Arg38) and core peptide (Gly39-Arg75). Non-specific cleavage occurred C-
terminal to Arg71 to produce a truncated core peptide (Gly39-Arg71). The masses of the observed ions and their 
corresponding digest fragments are assigned.  
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Figure 4.46b. The mass spectrum of HPLC purified leader peptide (Gly1-Arg38) is shown. The masses of the 
observed ions and their corresponding digest fragments are assigned. Expected [M+H]: 4367.84, observed: 4369.14. 
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Figure 4.46c. The mass spectrum of HPLC purified core peptide (Gly39-Arg75) is shown. The masses of the 
observed ions and their corresponding digest fragments are assigned. Expected [M+H]: 3721.29, observed: 3717.92. 
 
4.4.17. Evaluation of the requirement of leader peptide for core peptide modification by 
SunS 
 Purified leader and core peptide were incubated in combination (in trans) and 
independently in the presence of SunS reaction components. For the in trans reaction, leader 
peptide (10 μM) and core peptide (10 μM) were incubated with His6-SunS (2 μM) in a reaction 
buffer containing 50 mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, and 5 mM UDP-glucose (all 
final concentrations). For the independent reactions, leader peptide (10 μM) or core peptide (10 
μM) was incubated with His6-SunS (2 μM) in a reaction buffer containing 50 mM Tris (pH 7.5), 
1 mM MgCl2, 1 mM TCEP, and 5 mM UDP-glucose. All reactions were incubated at 25 °C for 1 
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h and then quenched with 5% TFA to pH 1-2. Quenched samples were desalted using a 
ZipTipC18 prior to analysis by MALDI-TOF MS (Figure 4.47a-b). 
 
 
Figure 4.47a. SunA core peptide was modified with glucose by incubation with His6-SunS in the presence of UDP-
Glc, MgCl2, and TCEP in Tris (pH 7.5) buffer. The leader peptide was not added to the reaction. The reaction was 
analyzed by MALDI-TOF MS. The overlay of mass spectra obtained by MALDI-TOF MS analysis of the mixture 
before (black) and after SunS reaction (red) is shown. Expected [M+H] (with glycosylation): 3882.41, observed: 
3883.91. 
 
 
252 
 
 
Figure 4.47b. SunA leader peptide was not modified with glucose by incubation with His6-SunS in the presence of 
UDP-Glc, MgCl2, and TCEP in Tris (pH 7.5) buffer. The core peptide was not added to the reaction. The reaction 
was analyzed by MALDI-TOF MS. The overlay of mass spectra obtained by MALDI-TOF MS analysis of the 
mixture before (black) and after SunS reaction (red) is shown. Expected [M+H] (without glycosylation): 4367.84, 
observed: 4368.81. 
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Figure 4.47c. SunA core peptide was modified with glucose by incubation with His6-SunS in the presence of SunA 
leader peptide, UDP-Glc, MgCl2, and TCEP in Tris (pH 7.5) buffer. SunA core peptide and leader peptide were 
present in equimolar concentrations. The reaction was analyzed by MALDI-TOF MS. The overlay of mass spectra 
obtained by MALDI-TOF MS analysis of the mixture before (black) and after SunS reaction (red) is shown. 
Expected [M+H] (core peptide with glycosylation): 3882.41, observed: 3882.88. 
 
  
4.4.18. In vitro preparation of sublancin and sublancin analogues for bioactivity assays and 
LC-ESI-Q/TOF MSn analysis 
 Sublancin and sublancin analogues containing non-natural sugars were prepared by 
modifying His6-SunA Xa peptide with a sugar (SunS reaction), proteolytic removal of the leader 
peptide (Factor Xa reaction), and oxidative folding of sublancin to afford the disulfide linkages 
(oxidative folding reaction). Sugar modified His6-SunA Xa was prepared in 250 μL of 50 mM 
Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, 5 mM NDP-sugar, 50 μM His6-SunA Xa, and 2 μM 
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His6-SunS. The reaction was incubated at 25 °C for 12 h. The extent of sugar modification was 
verified by removing a 5 μL aliquot of the reaction, quenching with 5% TFA to pH 1-2, desalting 
using a ZipTipC18, and analysis by MALDI-TOF and ESI Q/TOF MS. Following analysis, the 
leader peptide of sugar modified His6-SunA Xa was proteolytically cleaved by the addition of 
NaCl and CaCl2 to 100 mM and 2 mM, respectively, and the addition of Factor Xa to 0.075 
mg/mL (final concentrations). The reaction was incubated at 25 °C for 4-6 h and the extent of 
cleavage was monitored by MALDI-TOF MS as stated above. Following analysis, the disulfides 
of the modified sublancin core peptide were formed by addition of Tris (pH 7.5), oxidized 
glutathione (GSSG), reduced glutathione (GSH), and EDTA to final concentrations of 50 mM, 2 
mM, 2 mM, and 0.1 mM, respectively. The total volume of the oxidative folding reaction was 
500 μL and the reaction was incubated at 25 °C for an additional 12 h. The extent of disulfide 
formation was monitored by removing a 5 μL aliquot of the reaction, quenching with 5% TFA to 
pH 1-2, desalting using a ZipTipC18, and analyzing by MALDI-TOF MS. Disulfide formation 
was observed as a peak with a −4 Da mass difference compared with material that was not 
subjected to oxidative folding. 
 
4.4.19. Evaluation of in vitro prepared sublancin and sublancin analogues 
 The in vitro preparation of sublancin and sublancin analogues was evaluated in three 
ways. The sugar modification, leader peptide removal, and oxidative folding are all required to 
obtain bioactivity against the indicator strain B. subtilis ATCC 6633. As such, the in vitro 
prepared peptides were assessed using the antimicrobial activity assay described below. 
 In addition to bioactivity assays, sublancin and analogues were structurally characterized 
via LC-ESI-Q/TOF tandem MS and the resulting fragmentation patterns of the acquired mass 
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spectra were compared to native and reduced authentic sublancin analyzed under identical 
conditions (Figure 4.48a-f). For additional confirmation of correct disulfide bond formation of in 
vitro prepared sublancin and sublancin analogues, the fully modified peptides were 
independently proteolytically digested with chymotrypsin and the reactions were analyzed by 
LC-ESI-Q/TOF MS. Briefly, in vitro prepared peptide (SunS treated, Factor Xa treated, and 
oxidatively folded) was digested under non-reducing conditions in 100 mM Tris (pH 7.5) and 
0.05 mg/mL chymotrypsin. All reactions were incubated at 25 °C for 3 h and then quenched with 
5% TFA to pH 1-2. Quenched samples were analyzed by LC-ESI-Q/TOF MS without further 
manipulation (Figure 4.49a-e). 
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Figure 4.48a-f. ESI-Q/TOF MSMS analysis of in vitro prepared sublancin and sublancin analogues. His6-SunA Xa 
was modified with sugar, digested with Factor Xa, oxidatively folded, and analyzed by using LC-ESI-Q/TOF 
MSMS. Material for all four sugars and aglycon material was analyzed. If disulfide bonds were correctly formed 
during the oxidative folding process, then fragmentation of the peptide backbone was not expected to occur. Rather, 
the post-translation modification (S-linked glycosylation) was expected to be lost from the parent ion (loss of 162 
Da).As controls, an authentic sublancin sample (isolated and purified from B. subtilis 168) and a reduced sublancin 
sample (authentic sublancin treated with TCEP) were independently analyzed using identical instrument settings as 
with in vitro prepared samples.   
 
 
 
Figure 4.48a. His6-SunA Xa was modified with glucose, digested with Factor Xa, oxidatively folded, and analyzed 
by using LC-ESI-Q/TOF MSMS. Fragmentation of the amide bonds of sublancin (Glc) did not occur, rather, the 
glucosylation was lost from the parent ion (-162 Da). 
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Figure 4.48b. His6-SunA Xa was modified with galactose, digested with Factor Xa, oxidatively folded, and 
analyzed by using LC-ESI-Q/TOF MSMS. Fragmentation of the amide bonds of sublancin (Gal) did not occur, 
rather, the galactosylation was lost from the parent ion (-162 Da). 
 
 
Figure 4.48c. His6-SunA Xa was modified with mannose, digested with Factor Xa, oxidatively folded, and analyzed 
by using LC-ESI-Q/TOF MSMS. Fragmentation of the amide bonds of sublancin (Man) did not occur, rather, the 
mannosylation was lost from the parent ion (-162 Da). 
258 
 
 
Figure 4.48d. His6-SunA Xa was modified with N-acetylglucosamine, digested with Factor Xa, oxidatively folded, 
and analyzed by using LC-ESI-Q/TOF MSMS. Fragmentation of the amide bonds of sublancin (GlcNAc) did not 
occur, rather, the N-acetylglucosaminylation was lost from the parent ion (-203 Da). 
 
 
Figure 4.48e. His6-SunA Xa was unmodified, digested with Factor Xa, oxidatively folded, and analyzed by using 
LC-ESI-Q/TOF MSMS. Fragmentation of the amide bonds of sublancin (aglycon) did not occur. 
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Figure 4.48f. As a control, pure sublancin isolated from B. subtilis 168 was analyzed using LC-ESI-Q/TOF MSMS. 
Fragmentation of the amide bonds of sublancin did not occur, rather, the glycosylation was lost from the parent ion 
(-162 Da). 
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Figure 4.49a-e. ESI-Q/TOF MS analysis of in vitro prepared sublancin and sublancin analogues digested with 
chymotrypsin under non-reducing conditions. His6-SunA Xa was modified with sugar, digested with Factor Xa, 
oxidatively folded, and digested with chymotrypsin under non-reducing conditions. The reactions were analyzed by 
LC-ESI-Q/TOF MS to investigate extent of glycosylation and correct disulfide bridge connectivity. Chymotrypsin 
cleavage sites (F, W, and Y residues) and the proposed disulfide bridges are indicated in the peptide sequence above 
the spectrum. The masses of the observed ions and their corresponding digest fragments are assigned. The results 
support that a disulfide bond exists between Cys7-Cys36 and between Cys14-Cys29. The results are consistent with 
residues Leu12-Tyr32 bearing a glycosylation in reactions which His6-SunA Xa peptide was modified with a sugar. 
 
  
Figure 4.49a. ESI-Q/TOF MS analysis of in vitro prepared sublancin (Glc) digested with chymotrypsin under non-
reducing conditions. His6-SunA Xa was modified with glucose, digested with Factor Xa, oxidatively folded, 
digested with chymotrypsin under non-reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. 
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Figure 4.49b. ESI-Q/TOF MS analysis of in vitro prepared sublancin (Gal) digested with chymotrypsin under non-
reducing conditions. His6-SunA Xa was modified with galactose, digested with Factor Xa, oxidatively folded, 
digested with chymotrypsin under non-reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. 
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Figure 4.49c. ESI-Q/TOF MS analysis of in vitro prepared sublancin (Man) digested with chymotrypsin under non-
reducing conditions. His6-SunA Xa was modified with mannose, digested with Factor Xa, oxidatively folded, 
digested with chymotrypsin under non-reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. 
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Figure 4.49d. ESI-Q/TOF MS analysis of in vitro prepared sublancin (GlcNAc) digested with chymotrypsin under 
non-reducing conditions. His6-SunA Xa was modified with N-acetylglucosamine, digested with Factor Xa, 
oxidatively folded, digested with chymotrypsin under non-reducing conditions, and analyzed by using LC-ESI-
Q/TOF MS. 
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Figure 4.49e. ESI-Q/TOF MS analysis of in vitro prepared sublancin (aglycon) digested with chymotrypsin under 
non-reducing conditions. His6-SunA Xa was not modified with a sugar, digested with Factor Xa, oxidatively folded, 
digested with chymotrypsin under non-reducing conditions, and analyzed by using LC-ESI-Q/TOF MS. 
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4.4.20. Antimicrobial activity assays of in vitro prepared sublancin and sublancin analogues 
 The 500 μL reactions described above (SunS reaction, Factor Xa reaction, folding 
reaction) were concentrated to 20 μL via vacuum centrifugation. An overnight culture of B. 
subtilis ATCC 6633 (indicator strain) was grown in LB media under aerobic conditions at 37 °C 
for 12 h. Ninety-six well agar plates were prepared by combining 20 mL of molten LB medium 
agar (cooled to 42 °C) with 50 μL of dense overnight culture (approx 108-109 CFU/mL). The 
seeded agar was poured into a sterile OmniTray (Nunc) and allowed to solidify at 25 °C for 30 
min. An additional 30 mL of molten LB medium was cooled to 42 °C, combined with 75 μL of 
culture, and poured over the lower solidified agar layer. A sterile 96-well PCR plate was placed 
in the molten agar upper layer and was allowed to solidify at 25 °C for 45 min. After sufficient 
solidification, the 96-well PCR plate was removed. The total 20 μL volume of each concentrated 
in vitro reaction was dispensed into separate newly formed wells. Authentic sublancin standards 
were spotted in 15 μL volumes at the concentrations indicated. Plates were left at 25 °C for 15 h 
and antibacterial activity was qualitatively determined by the presence or absence of growth 
inhibition.  
 
4.4.21. Antimicrobial activity assay with native, reduced, and reduced and alkylated 
sublancin 
 The importance of intact disulfides for the bioactivity of sublancin was assessed by 
testing the activities of native, reduced, and reduced and alkylated sublancin against B. subtilis 
ATCC 6633. Native sublancin was prepared by dissolving pure sublancin in 50 mM Tris (pH 7.5 
or pH 8.3). Reduced sublancin was prepared by dissolving pure sublancin in 50 mM Tris (pH 
8.3) with 5 mM TCEP. Reduced and alkylated sublancin was prepared by dissolving pure 
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sublancin in 50 mM Tris (pH 8.3), 5 mM TCEP, and 10 mM iodoacetamide. All reactions 
contained sublancin at a final concentration of 50 μM and were prepared on a 50 μL scale. All 
reactions were incubated at 25 °C for 3 h in the dark, then concentrated to 20 μL prior to 
dispensing into separate wells of a bioactivity plate (prepared as described above) seeded with B. 
subtilis ATCC 6633. Authentic sublancin and nisin standards were spotted in 15 μL volumes at 
the concentrations indicated. Plates were left at 25 °C for 15 h and antibacterial activity was 
qualitatively determined by the presence or absence of growth inhibition. 
 
4.4.22. Antimicrobial activity assay of in vitro prepared sublancin with omission of single 
steps 
 The importance of each step (glycosylation, leader peptide removal, and disulfide 
formation) in the in vitro preparation of sublancin was demonstrated through an antimicrobial 
activity assay against B. subtilis ATCC 6633. Sublancin samples were prepared in parallel 
whereby one step of the preparation process was omitted.  
 To prepare non-glucosylated sublancin, leader peptide of unmodified His6-SunA Xa was 
first removed by combining 50 mM Tris (pH 7.5), 100 mM NaCl, 2 mM CaCl2, 0.075 mg/mL 
Factor Xa, and 50 μM His6-SunA Xa in a 250 μL reaction. The reaction was incubated at 25 °C 
for 6 h. The disulfides were formed by addition of Tris (pH 7.5), oxidized glutathione (GSSG), 
reduced glutathione (GSH), and EDTA to final concentrations of 50 mM, 2 mM, 2 mM, and 0.1 
mM, respectively. The 500 μL total volume reaction was incubated at 25 °C for 12 h. 
 To prepare sublancin with the leader peptide intact, His6-SunA Xa was first glucosylated 
by combining 50 mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, 5 mM UDP-glucose, 50 μM 
His6-SunA Xa, and 2 μM His6-SunS in 250 μL. The reaction was incubated at 25 °C for 12 h. 
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The disulfides of the modified His6-SunA Xa peptide were formed by addition of Tris (pH 7.5), 
oxidized glutathione (GSSG), reduced glutathione (GSH), and EDTA to final concentrations of 
50 mM, 2 mM, 2 mM, and 0.1 mM, respectively. The 500 μL total volume reaction was 
incubated at 25 °C for 12 h. 
 To prepare unfolded sublancin, His6-SunA Xa was first glucosylated by combining 50 
mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, 5 mM UDP-glucose, 50 μM His6-SunA Xa, and 
2 μM His6-SunS in 250 μL. The reaction was incubated at 25 °C for 12 h. The leader peptide of 
glucosylated His6-SunA Xa was then cleaved by addition of 50 mM Tris (pH 7.5), 100 mM 
NaCl, 2 mM CaCl2, 0.075 mg/mL Factor Xa (final concentrations) to the 250 μL reaction. The 
reaction was incubated at 25 °C for 6 h. 
 As a positive control, all three steps were performed in the following order: SunS 
glucosylation reaction, Factor Xa leader peptide cleavage reaction, and oxidative folding 
reaction. All of the above reactions were concentrated to 20 μL via vacuum centrifugation and 
the total 20 μL volumes were separately dispensed into separate wells of a bioactivity plate 
(prepared as described above) seeded with B. subtilis ATCC 6633. Authentic sublancin standards 
were spotted in 15 μL volumes at the concentrations indicated. Plates were left at 25 °C for 15 h 
and antibacterial activity was qualitatively determined by the presence or absence of growth 
inhibition.  
 
4.4.23. Efforts toward identifying the molecular target of sublancin 
 The gene encoding E. coli PBP1b was previously PCR amplified from MG1655 genomic 
DNA and cloned into pET21b vector (Novagen) as a C-terminal hexa-histidine (His6) fusion 
gene.47 The enzyme was expressed and purified by Tsung-Shing Andrew Wang or Tania Lupoli 
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(Dan Kahne and Suzanne Walker Laboratory, Harvard University) as previously published.47 
[14C]GlcNAc-labeled heptaprenyl lipid II analogue was chemo-enzymatically prepared by Dr. 
Yuto Sumida and Dr. Hiro Tsukamoto (Dan Kahne Laboratory) as previously described.55 
 For IC50 determinations, assays were carried out by separately incubating [14C]GlcNAc-
labeled heptaprenyl lipid II analogue (final concentration = 4 μM, typical specific activity = 288 
μCi/μmol) and peptide inhibitors (concentrations are indicated in the figure legends) in low-
binding microcentrifuge tubes (VWR) containing 9 μL of buffer consisting of 50 mM HEPES 
(pH 7.5), 10 mM CaCl2, 1,000 units/mL penicillin G, 0.2 mM octaethylene glycol monodecyl 
ether (decyl-PEG; Anatrace, Maumee, OH), and 11% DMSO (v/v) for 30 min at room 
temperature prior to PBP1b addition (to allow binding to occur). Reactions were started by 
adding 1 μL of PBP1b (from a solution freshly prepared by diluting the 50% glycerol stock 20-
fold into PBP1b dilution buffer consisting of 5 mM Tris (pH 8.0), 8 mM decyl-PEG) to the 
reaction mixture (final PBP1b concentration = 20-100 nM). Reactions were typically stopped 
after 30-45 min by adding 10 μL of ice-cold 10 mM Tris (pH 8.0) containing 10% Triton X-100. 
Quenched reactions were stored on ice until they were spotted on cellulose chromatography 
paper strips (3MM Whatman chromatography paper #3030-861, cut 1 cm width x 20 cm height) 
Products and starting material were separated using chromatography (isobutyric acid/1 M 
NH4OH, 5:3). The lipid II starting material migrates on the strip, while polymerized product 
remains at the origin. The paper strips were removed from chromatography chambers, allowed to 
dry, cut, and added to separate scintillation vials containing EcoLite(+) liquid scintillation fluid 
(MP Biomedical). Samples were analyzed using a LS6500 scintillation counter (Beckman 
Coulter). The percent radioactivity of the polymer product was calculated by comparing the 
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amount of radioactivity that remains at the origin (peptidoglycan) to the total amount of 
radioactivity on the strip.   
 
4.4.24. Overexpression and purification of His6-ThuA precursor peptide 
 His6-ThuA was overexpressed and purified as described for His6-SunA peptides (see 
Experimental 4.4.8) 
 
 4.4.25. Overexpression and purification of His6-ThuS 
 E. coli Rosetta 2 (DE3) cells were transformed with the pET28b ThuS construct via 
electroporation. A single colony transformant was used to inoculate a 30 mL culture of LB 
supplemented with 50 μg/mL kanamycin. The culture was grown at 37 °C for 12 h and was used 
to inoculate 3 L of LB containing 50 μg/mL kanamycin, and cells were grown at 37 °C to OD600 
≈ 0.6. The culture was incubated at 4 °C on ice for 20 min, then IPTG was added to a final 
concentration of 0.5 mM and the culture was incubated at 18 °C for an additional 16-20 h. Cells 
were harvested by centrifugation at 12,000 ×g for 15 min at 4 °C, and the pellet was resuspended 
in 30 mL of start buffer (20 mM Tris (pH 8.0), 500 mM NaCl, 1 mM TCEP, 10% glycerol) and 
stored at −80 °C.  
 All protein purification steps were performed at 4 °C. The cell paste was suspended in 
start buffer and the cells were lysed using a high pressure homogenizer (Avestin, Inc.). Cell 
debris was pelleted via centrifugation at 23,700 ×g for 20 min at 4 °C. The supernatant was 
injected via a superloop onto a fast protein liquid chromatography (FPLC) system (ÄKTA, GE 
Heathcare Life Sciences) equipped with a 5 mL HisTrap HP IMAC column previously charged 
with Ni2+ and equilibrated in start buffer. The column was washed with 50 mL of buffer A (30 
270 
mM imidazole, 20 mM Tris, pH 8.0, 1 M NaCl) and the protein was eluted using a linear 
gradient of 0-100% B (buffer B = 200 mM imidazole, 20 mM Tris, pH 8.0, 1 M NaCl) over 40 
min at a 2 mL/min flow rate. UV (280 nm) was monitored and fractions were collected and 
analyzed by SDS-PAGE (4-20% Tris-glycine READY gel, BioRAD). The fractions containing 
SunS were combined and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit (10 
kDa MWCO, Millipore). Gel filtration purification was used to further purify ThuS. The 
concentrated protein sample was injected onto an FPLC system (ÄKTA) equipped with an XK16 
16/60 (GE Healthcare Life Sciences) column packed with SuperDex 75 resin previously 
equilibrated in 20 mM HEPES (pH 7.5), 100 mM KCl, and 1 mM TCEP. The protein was eluted 
with a flow rate of 0.9 mL/min. Both UV (280 nm) and conductance were monitored and 
fractions were collected. Misfolded/aggregated protein was efficiently separated from soluble, 
correctly folded protein and the desired fractions were combined and concentrated using an 
Amicon Ultra-15 Centrifugal Filter Unit. The resulting protein sample was stored at −80 °C. 
Protein concentration was determined using a Bradford Assay Kit (Pierce) and typically yields 
were 100-140 mg His6-ThuS from 3 L of cell culture. 
 
4.4.26. Enzymatic in vitro sugar modification of ThuA and SunA peptides by ThuS or SunS 
 His6-precursor peptide (50 μM) was incubated with His6-glycosyltransferase (2 μM) in a 
reaction buffer containing 50 mM Tris (pH 7.5), 1 mM MgCl2, 1 mM TCEP, and 5 mM uridine-
5′-diphosphate-α-D-glucose (UDP-Glc, CalBiochem). The reactions were incubated at 25 °C for 
various durations of time (1-12 h depending on future use). Reactions were either immediately 
used for subsequent proteolysis studies or quenched with 5% TFA to pH 1-2 for MALDI-TOF 
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MS analysis. For MALDI-TOF MS analysis, samples were desalted using ZipTipC18 and 
analyzed as described above.  
 
4.4.27. Proteolytic digests of multi-sugar modified His6-precursor peptides 
 Modified His6-SunA peptide (taken directly from the glycosyltransferase reaction) was 
digested in 100 mM Tris (pH 7.5), 5 mM TCEP, and 0.1 mg/mL chymotrypsin (Worthington). 
Modified His6-ThuA peptide (taken directly from the glycosyltransferase reaction) was digested 
in 100 mM Tris (pH 7.5), 5 mM TCEP, 1 mM CaCl2, and 0.1 mg/mL trypsin (Worthington). All 
reactions were incubated at 25 °C for 5 h and then quenched with 5% TFA to pH 1-2. Quenched 
samples were desalted with a ZipTipC18 prior to analysis by MALDI-TOF MS or analyzed by 
LC-ESI-Q/TOF MSn without further manipulation. 
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